var title_f11_14_11488="Patient consent form - page 3";
var content_f11_14_11488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 587px\">",
"   <div class=\"ttl\">",
"    Patient consent form - page 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 567px; height: 284px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_14_11488=[""].join("\n");
var outline_f11_14_11488=null;
var title_f11_14_11489="Acquired ichthyosis";
var content_f11_14_11489=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Acquired ichthyosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 217px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe scaling of the skin with hyperkeratosis involving the skin of the upper thigh (panel A) and soles of the feet (panel B) in a patient with Hodgkins disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rizos, E, Milionis, RH, Pavlidis, N Elisaf, MS. Acquired icthyosis: A paraneoplastic skin manifestation of Hodgkin's disease. The Lancet-Oncology 2002; 3:727. Copyright 2002 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_14_11489=[""].join("\n");
var outline_f11_14_11489=null;
var title_f11_14_11490="Stasis dermatitis sclerotic";
var content_f11_14_11490=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lipodermatosclerosis in chronic stasis dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chronic stasis dermatitis with signs of lipodermatosclerosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_14_11490=[""].join("\n");
var outline_f11_14_11490=null;
var title_f11_14_11491="Bacitracin and polymyxin B: Drug information";
var content_f11_14_11491=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bacitracin and polymyxin B: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/37/3669?source=see_link\">",
"    see \"Bacitracin and polymyxin B: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/3/27699?source=see_link\">",
"    see \"Bacitracin and polymyxin B: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AK-Poly-Bac&trade;;",
"     </li>",
"     <li>",
"      Polycin&trade;;",
"     </li>",
"     <li>",
"      Polysporin&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      LID-Pack&reg;;",
"     </li>",
"     <li>",
"      Optimyxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F138738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Ophthalmic;",
"     </li>",
"     <li>",
"      Antibiotic, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F138728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ophthalmic infection:",
"     </b>",
"     Ophthalmic (ointment): Instill",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     &rdquo; ribbon in the affected eye(s) every 3-4 hours for acute infections or 2-3 times/day for mild-to-moderate infections for 7-10 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Superficial dermal infection:",
"     </b>",
"     Topical ointment/powder: Apply to affected area 1-4 times/day; may cover with sterile bandage if needed.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F138734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/3/27699?source=see_link\">",
"      see \"Bacitracin and polymyxin B: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F138729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F138719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic: Bacitracin 500 units and polymyxin B 10,000 units per g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AK-Poly-Bac&trade;: Bacitracin 500 units and polymyxin B 10,000 units per g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Polycin&trade;: Bacitracin 500 units and polymyxin B 10,000 units per g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: Bacitracin 500 units and polymyxin B 10,000 units per g in white petrolatum (15 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Polysporin&reg;: Bacitracin 500 units and polymyxin B 10,000 units per g (0.9 g, 15 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Polysporin&reg;: Bacitracin 500 units and polymyxin B 10,000 units per g (10 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F138721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of superficial infections caused by susceptible organisms",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F138743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Betadine&reg; may be confused with Betagan&reg;, betaine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F138736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1% to 10%: Local: Rash, itching, burning, anaphylactoid reactions, swelling, conjunctival erythema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2558363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bacitracin, polymyxin B, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F138714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Polymyxin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F138715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7413652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F138731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7413655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if bacitracin or polymyxin B are excreted into breast milk. The manufacturer recommends that caution be exercised when administering to nursing women. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Polycin Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-10000 units/g (3.5 g): $26.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Polysporin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-10000 units/g (1): $0.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-10000 units/g (14.2 g): $4.42",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F138724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Glubacida (MX);",
"     </li>",
"     <li>",
"      Miratracina (CO);",
"     </li>",
"     <li>",
"      Nebacetina (MX);",
"     </li>",
"     <li>",
"      Neobacitracine (BE);",
"     </li>",
"     <li>",
"      Neospor&iacute;n D&eacute;rmico (MX);",
"     </li>",
"     <li>",
"      Polisulfade (PT);",
"     </li>",
"     <li>",
"      Polixin Ungena (MX);",
"     </li>",
"     <li>",
"      Polyfax (MY);",
"     </li>",
"     <li>",
"      Polysporin Ophthalmic (ZA);",
"     </li>",
"     <li>",
"      Tribiot (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F138710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F138723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9387 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_14_11491=[""].join("\n");
var outline_f11_14_11491=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138726\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138727\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138738\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138728\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138734\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138729\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138719\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138707\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138721\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138743\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138736\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2558363\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298808\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138714\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138715\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7413652\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138731\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7413655\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524342\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138724\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138710\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138723\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9387\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9387|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/37/3669?source=related_link\">",
"      Bacitracin and polymyxin B: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/3/27699?source=related_link\">",
"      Bacitracin and polymyxin B: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_14_11492="Celiac disease in children";
var content_f11_14_11492=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Celiac disease in children (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?11/14/11492/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/14/11492/contributors\" id=\"au6698\">",
"       Ivor D Hill, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/14/11492/contributors\" id=\"au3113\">",
"       Anne Roland Lee, MSEd, RD, LD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?11/14/11492/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/14/11492/contributors\" id=\"se4415\">",
"       William J Klish, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?11/14/11492/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/14/11492/contributors\" id=\"de1276\">",
"       Alison G Hoppin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?11/14/11492?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      CELIAC DISEASE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Celiac disease is a condition that causes symptoms like diarrhea, weight loss, and a lack of appetite. These symptoms occur because the immune system responds abnormally to a protein found in certain foods, like wheat, rye, barley, and prepared foods (",
"     <a class=\"graphic graphic_table graphicRef56053 \" href=\"UTD.htm?7/4/7245\">",
"      table 1",
"     </a>",
"     ). These proteins are called gluten. Celiac disease is also known as gluten-sensitive enteropathy (pronounced \"enter-AH-pathy\"), celiac sprue, and nontropical sprue.",
"    </p>",
"    <p>",
"     The small intestine is responsible for absorbing food and nutrients. Thus, if the immune system damages the lining of the small intestines, this can lead to problems absorbing important nutrients from foods; this problem is referred to as malabsorption.",
"    </p>",
"    <p>",
"     Although celiac disease cannot be cured, avoiding foods that contain gluten usually reverses the damage to the intestinal lining and stops associated symptoms, like diarrhea.",
"    </p>",
"    <p>",
"     Celiac disease in adults is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=see_link\">",
"      \"Patient information: Celiac disease in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CELIAC DISEASE CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Celiac disease occurs as a result of a child's genetics and exposure to a trigger. A child who develops celiac disease probably inherits the risk from one or both parents and then develops the disease when exposed to the trigger, gluten.",
"    </p>",
"    <p>",
"     Celiac disease is different from wheat allergy. Allergies occur when different parts of the immune system are activated by wheat, causing allergic symptoms such as hives and wheezing. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=see_link\">",
"      \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      CELIAC DISEASE SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The symptoms of celiac disease can vary from mild to severe.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Common symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common symptoms of celiac disease in children include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Diarrhea",
"      </li>",
"      <li>",
"       Poor appetite",
"      </li>",
"      <li>",
"       A bloated or painful belly",
"      </li>",
"      <li>",
"       Weight loss or difficulty gaining weight",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     These symptoms can begin during infancy (between 6 and 24 months), after the child begins to eat gluten-containing foods.",
"    </p>",
"    <p>",
"     In some cases, the child does not have any of the more common symptoms but does have problems with slowed growth, iron deficiency anemia, a skin rash, or changes in his or her teeth.",
"    </p>",
"    <p>",
"     In older children, symptoms can include constipation or diarrhea, oily stools that float, abdominal bloating, and gas. Older children may also be shorter than normal for their age, have difficulty gaining weight, or have other problems (anemia, bone thinning).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Skin symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;A skin problem, known as dermatitis herpetiformis, is common in adults with celiac disease. This condition is uncommon before puberty in children with celiac disease. A person may have skin symptoms with few or no gastrointestinal symptoms.",
"    </p>",
"    <p>",
"     The symptoms of dermatitis herpetiformis include intensely itchy, raised, fluid-filled blisters on the skin, usually located on the elbows, knees, buttocks, lower back, face, neck, trunk, and occasionally within the mouth (",
"     <a class=\"graphic graphic_picture graphicRef87426 \" href=\"UTD.htm?4/61/5075\">",
"      picture 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The most bothersome symptoms are itching and burning. Scratching causes the blister to rupture and dry up, but this leaves an area of darkened skin and scarring. A skin biopsy may be taken to see if the rash is dermatitis herpetiformis. The condition will improve after elimination of gluten from the diet, although it may take several weeks to months see significant improvement.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Dental (tooth) problems",
"     </span>",
"     &nbsp;&mdash;&nbsp;Children with celiac disease commonly develop changes in the permanent (adult) teeth. This can include changes in the enamel covering of the teeth, causing cream-colored, yellow, or brown discoloration, and grooves or pits in the teeth (",
"     <a class=\"graphic graphic_picture graphicRef61446 \" href=\"UTD.htm?24/8/24719\">",
"      picture 2",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Bone thinning",
"     </span>",
"     &nbsp;&mdash;&nbsp;Children with celiac disease are at risk for weakened bones caused by poor absorption of vitamin D. Treatment of celiac disease by eating a gluten-free diet can resolve the problem in most cases. Sometimes, vitamin supplements are also recommended. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/62/15331?source=see_link\">",
"      \"Patient information: Vitamin D deficiency (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Other symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Celiac disease can cause nonspecific symptoms or mild symptoms, such as fatigue, borderline iron deficiency anemia, or being shorter than normal for age. Once a child is confirmed as having celiac disease with a skin or intestinal biopsy, the only treatment is to completely avoid gluten, as discussed below. (See",
"     <a class=\"local\" href=\"#H15\">",
"      'Celiac disease treatment'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      WHICH CHILDREN NEED TESTING FOR CELIAC DISEASE?",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      If the child has symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;All children do not need to be tested for celiac disease. If you are concerned that your child has symptoms that might be caused by celiac disease, ask your child's doctor if the child should be tested.",
"    </p>",
"    <p>",
"     Children who have the following symptoms should be tested:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Shortness or underweight for age, particularly if the child's growth has slowed significantly over time or if the child is significantly smaller than other family members. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?8/18/8486?source=see_link\">",
"        \"Patient information: Poor weight gain in infants and children (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Diarrhea for more than a few weeks",
"      </li>",
"      <li>",
"       Chronic constipation, recurrent abdominal pain, or vomiting",
"      </li>",
"      <li>",
"       Certain tooth problems. (See",
"       <a class=\"local\" href=\"#H6\">",
"        'Dental (tooth) problems'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       If puberty has not begun at the expected time. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"        \"Normal puberty\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Iron deficiency anemia that has not improved with treatment",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      High-risk groups",
"     </span>",
"     &nbsp;&mdash;&nbsp;Testing is recommended for certain children (older than three years) who are at increased risk of developing celiac disease, even if the child has no symptoms.",
"    </p>",
"    <p>",
"     Children with one or more of the following are at increased risk of developing celiac disease and should be tested:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       First-degree relatives (children, siblings) of a person with celiac disease",
"      </li>",
"      <li>",
"       Down syndrome",
"      </li>",
"      <li>",
"       Type 1 diabetes",
"      </li>",
"      <li>",
"       Selective IgA deficiency",
"      </li>",
"      <li>",
"       Turner syndrome",
"      </li>",
"      <li>",
"       Williams syndrome",
"      </li>",
"      <li>",
"       Autoimmune thyroiditis",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      CELIAC DISEASE TESTING",
"     </span>",
"    </p>",
"    <p>",
"     Several tests are done to diagnose celiac disease. The child",
"     <strong>",
"      should",
"     </strong>",
"     &nbsp;",
"     <strong>",
"      continue to eat foods that contain gluten",
"     </strong>",
"     while being tested. Starting a gluten-free diet or avoiding gluten before testing is completed can cause the tests to be inaccurate. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"      \"Clinical manifestations and diagnosis of celiac disease in children\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Blood test",
"     </span>",
"     &nbsp;&mdash;&nbsp;The first step in testing for celiac disease is a blood test. A pediatric or family doctor or nurse can do this test. The blood test tells whether the child has an increased level of antibodies (proteins) called tissue transglutaminase (anti-tTG). The level of these antibodies is usually high in people with celiac disease (as long as their diet contains gluten), but is almost never increased in people without celiac disease. If the test is positive for tTG, a biopsy of the small intestine is recommended to confirm the diagnosis of celiac disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Small intestine biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;If the blood test shows high levels of tTG antibodies, the diagnosis must be confirmed by examining a sample of the lining of the small intestine with a microscope.",
"    </p>",
"    <p>",
"     The sample (called a biopsy) is usually collected during a test called upper endoscopy. This test involves swallowing a small flexible instrument called an endoscope, which has a camera at the end. A pediatric gastroenterologist performs this test while the child is sedated. The camera allows the doctor to look at the upper part of the digestive system and remove a small piece (biopsy) of the inside of the small intestine. The biopsy is not painful. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"      \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Normally, the inside of the small intestine has finger-like structures, which are called villi. Villi allow the small intestine to absorb nutrients. In people with celiac disease who eat gluten, the villi become flattened, which interferes with absorption. Once the child stops eating gluten, the villi heal and can absorb nutrients normally.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      CELIAC DISEASE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The only treatment for children with celiac disease is complete avoidance of all foods and drinks that contain gluten. If the child is malnourished because of the disease, nutritional supplements (high-calorie drinks or vitamins) might also be needed.",
"    </p>",
"    <p>",
"     A gluten-free diet is recommended for children who have an abnormal antibody testing AND:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       An abnormal small intestine biopsy and symptoms of celiac disease",
"      </li>",
"      <li>",
"       An abnormal small intestine biopsy and who are in a high-risk group (even if there are no symptoms)",
"      </li>",
"      <li>",
"       Dermatitis herpetiformis confirmed with a skin biopsy (see",
"       <a class=\"local\" href=\"#H5\">",
"        'Skin symptoms'",
"       </a>",
"       above)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If the results of the antibody testing and biopsy disagree or are equivocal, or if the child does not have symptoms of celiac disease, additional testing may be needed. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"      \"Clinical manifestations and diagnosis of celiac disease in children\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      How do we stop eating gluten?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Strict avoidance of gluten is recommended. Eating even small amounts of gluten can cause intestinal damage, allowing symptoms to come back. Eating a gluten-free diet can be challenging because it requires adjustments for both parents and children. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7929?source=see_link\">",
"      \"Management of celiac disease in children\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Meeting with a dietitian who is experienced in treating celiac disease can help parents and children:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Better understand which foods are safe and which are not",
"      </li>",
"      <li>",
"       How to read food labels to know if a food or medication is safe",
"      </li>",
"      <li>",
"       Where to find gluten-free substitutes for the child's favorite foods",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In addition, a number of helpful resources are available. (See",
"     <a class=\"local\" href=\"#H21\">",
"      'Where to get more information'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     For some people, getting a diagnosis of celiac disease is a relief. For others, finding out that they must avoid gluten for the rest of their life seems overwhelming. In either case, it is important to remember that a gluten-free diet is the key to recovery.",
"    </p>",
"    <p>",
"     Fortunately, life on a gluten-free diet has become easier, due to the increased availability of gluten-free foods. Excellent gluten-free substitute foods are now widely available (",
"     <a class=\"graphic graphic_table graphicRef54353 \" href=\"UTD.htm?26/14/26859\">",
"      table 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Some children with celiac disease have vitamin or nutrient deficiencies. Talk to your doctor, nurse, or dietitian about a multivitamin supplement and how to include gluten-free foods that are nutrient rich.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      What foods contain gluten?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common grains in the Western world (wheat, rye, and barley) contain gluten, and gluten is added to many prepared foods (",
"     <a class=\"graphic graphic_table graphicRef56053 \" href=\"UTD.htm?7/4/7245\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     In general:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Avoid foods containing wheat, rye, and barley",
"      </li>",
"      <li>",
"       Fresh fruits vegetables, corn, and potato are gluten free and safe. Naturally gluten free grains such as tapioca, buckwheat, quinoa, and millet add a good source of nutrients but may be contaminated with wheat. These grains and flours should only be used if they are labeled gluten free [",
"       <a class=\"abstract\" href=\"UTD.htm?11/14/11492/abstract/1\">",
"        1",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       Read labels on prepared foods and condiments carefully, paying close attention to additives, such as stabilizers or emulsifiers, that might contain gluten",
"      </li>",
"      <li>",
"       A child might have a hard time with dairy products in the beginning; many people with celiac disease can have temporary lactose intolerance. If your child's symptoms worsen after eating or drinking foods with lactose, avoid lactose temporarily.",
"      </li>",
"      <li>",
"       \"Wheat free\" does not necessarily mean gluten free. Read the packaging or call the manufacturer if you have questions about a specific product.",
"      </li>",
"      <li>",
"       While pure oats are safe, oats can sometimes be contaminated with wheat during processing. Therefore, parents should be sure the package specifically indicates that the product is gluten free and was processed in a gluten-free facility. Children with newly diagnosed celiac disease should wait until their intestines heal before adding oats to their diet, and those with severe disease should avoid oats altogether. If gluten free oats are added to the diet, it should be done in small portions and gradually increased over time to avoid any reaction to the increased fiber in the diet.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Is a strict gluten-free diet really necessary?",
"     </span>",
"     &nbsp;&mdash;&nbsp;A completely gluten-free diet is the only treatment for celiac disease.",
"    </p>",
"    <p>",
"     Children who do not have bothersome symptoms of celiac disease often find it hard to follow a strict gluten-free diet. Indeed, some doctors have questioned the need for a gluten-free diet in people without symptoms. However, most experts recommend a strict gluten-free diet for all children with celiac disease, whether or not the child has symptoms, for the following reasons:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Some children with celiac disease have vitamin or nutrient deficiencies, even if they feel well. If untreated, these deficiencies can cause problems (such as anemia due to iron deficiency or bone loss due to vitamin D deficiency). People with celiac disease who do not follow a strict gluten-free diet are more likely to have certain health problems as adults, including osteoporosis (thinning of bones) and having babies with lower birth weight.",
"      </li>",
"      <li>",
"       Strictly following a gluten-free diet sometimes helps improve a child's energy and sense of well-being even if the child does not have obvious symptoms.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Monitoring during treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;After starting a gluten-free diet, most children begin to feel better within two weeks.",
"    </p>",
"    <p>",
"     About six months after starting a gluten-free diet, the child's doctor or nurse might perform a blood test to test the antibody levels. The antibody level should be lower, or even disappear, as the child improves and continues to avoid gluten.",
"    </p>",
"    <p>",
"     A repeat biopsy is not usually necessary if the child's symptoms improve and the antibody levels decrease once a gluten-free diet is started. A repeat biopsy or other tests may be recommended if symptoms do not improve or if antibody levels remain elevated.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      LIFE WITH CELIAC DISEASE",
"     </span>",
"    </p>",
"    <p>",
"     Adjusting to a gluten-free life can be challenging for some people. Talking to a healthcare provider or experienced dietitian can help parents and children make the adjustment. In addition, support groups (on the Internet or in the community) are another good source of information and assistance. (See",
"     <a class=\"local\" href=\"#H21\">",
"      'Where to get more information'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Parents of children who are newly diagnosed with celiac disease will need to speak to their child's teacher or day care provider about the condition, what foods are safe, and what to do in case of illness.",
"    </p>",
"    <p>",
"     Other common concerns include what to do when traveling, at parties, at school, and at sleep-away camp. Several of the websites listed below include written information about celiac disease and the gluten-free diet for teachers and school staff. (See",
"     <a class=\"local\" href=\"#H22\">",
"      'Professional level lnformation'",
"     </a>",
"     below.) &nbsp; &nbsp;",
"    </p>",
"    <p>",
"     Celiac disease is a lifelong condition. Currently, there is no cure for celiac disease, although avoiding gluten probably prevents all complications of celiac disease.",
"    </p>",
"    <p>",
"     Because children with celiac disease might have an increased risk of certain infections, a vaccination is recommended to reduce the risk of pneumococcal infections (like pneumonia). The vaccine is given just once. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14225?source=see_link\">",
"      \"Patient information: Pneumonia prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287367515\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9143165\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/6/13410?source=see_link\">",
"      Patient information: Celiac disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/9/25746?source=see_link\">",
"      Patient information: Gluten-free diet (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9143182\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=see_link\">",
"      Patient information: Celiac disease in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=see_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/62/15331?source=see_link\">",
"      Patient information: Vitamin D deficiency (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/18/8486?source=see_link\">",
"      Patient information: Poor weight gain in infants and children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14225?source=see_link\">",
"      Patient information: Pneumonia prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Professional level lnformation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35511?source=see_link\">",
"      Approach to the diagnosis of chronic diarrhea in children in developed countries",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31414?source=see_link\">",
"      Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=see_link\">",
"      Management of celiac disease in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7929?source=see_link\">",
"      Management of celiac disease in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"      Normal puberty",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/celiacdisease.html\">",
"      www.nlm.nih.gov/medlineplus/celiacdisease.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Celiac Disease Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.celiac.org/\">",
"      www.celiac.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Celiac Sprue Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.csaceliacs.org/\">",
"      www.csaceliacs.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       GastroKids (from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.gastrokids.org/content/34/en/About GastroKids &ndash; Who We Are.html\">",
"      www.gastrokids.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Celiac Disease Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://celiacdisease.about.com/forum\">",
"      file://celiacdisease.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?11/14/11492/abstract/2-6\">",
"      2-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?11/14/11492?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11492/abstract/1\">",
"      Thompson T, Lee AR, Grace T. Gluten contamination of grains, seeds, and flours in the United States: a pilot study. J Am Diet Assoc 2010; 110:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11492/abstract/2\">",
"      Hill ID, Dirks MH, Liptak GS, et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11492/abstract/3\">",
"      Fasano A, Araya M, Bhatnagar S, et al. Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition consensus report on celiac disease. J Pediatr Gastroenterol Nutr 2008; 47:214.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Consensus Development Conference Statement. Celiac Disease 2004. Available at: file://consensus.nih.gov/ (Accessed on March 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11492/abstract/5\">",
"      Collin P, Thorell L, Kaukinen K, M&auml;ki M. The safe threshold for gluten contamination in gluten-free products. Can trace amounts be accepted in the treatment of coeliac disease? Aliment Pharmacol Ther 2004; 19:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11492/abstract/6\">",
"      Husby S, Koletzko S, Korponay-Szab&oacute; IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012; 54:136.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f11_14_11492=[""].join("\n");
var outline_f11_14_11492=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           CELIAC DISEASE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CELIAC DISEASE CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           CELIAC DISEASE SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           WHICH CHILDREN NEED TESTING FOR CELIAC DISEASE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           CELIAC DISEASE TESTING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           CELIAC DISEASE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           LIFE WITH CELIAC DISEASE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/61/5075\" title=\"picture 1\">",
"           Dermatitis herpetiformis knees PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/8/24719\" title=\"picture 2\">",
"           Dental celiac PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?7/4/7245\" title=\"table 1\">",
"           Overlooked sources of gluten or potential gluten",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?26/14/26859\" title=\"table 2\">",
"           Gluten free foods PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f11_14_11493="Ephedrine (systemic): Drug information";
var content_f11_14_11493=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ephedrine (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/58/6053?source=see_link\">",
"    see \"Ephedrine (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/10/37029?source=see_link\">",
"    see \"Ephedrine (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9736689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-/Beta- Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8084045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypotension induced by anesthesia:",
"     </b>",
"     I.V.: 5-25 mg/dose slow I.V. push repeated after 5-10 minutes as needed, then every 3-4 hours (maximum: 150 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Idiopathic orthostatic hypotension (unlabeled use):",
"     </b>",
"     Oral: 25-50 mg 3 times/day; maximum: 150 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Not considered first-line for this indication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      PONV refractory to traditional antiemetics (unlabeled use):",
"     </b>",
"     I.M.: 0.5 mg/kg at the end of surgery (Gan, 2007; Hagemann, 2000)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8084044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/10/37029?source=see_link\">",
"      see \"Ephedrine (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Hypotension:",
"     </b>",
"     Slow I.V. push: 0.2-0.3 mg/kg/dose every 4-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8084046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8084062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as sulfate: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [preservative free]: 50 mg/mL (1 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8083937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8084047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection solution: Administer diluted solution as a slow I.V. push. Do not administer unless solution is clear.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8083995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS,  D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      20",
"     </sub>",
"     W, sodium chloride 5%, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Bivalirudin, dexmedetomidine, etomidate, fenoldopam, hetastarch in lactate electrolyte injection (Hextend&reg;), propofol.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Thiopental.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Pentobarbital.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Thiopental.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8083938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of nasal congestion, anesthesia-induced hypotension",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8083968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Postoperative nausea and vomiting (PONV) refractory to traditional antiemetics; idiopathic orthostatic hypotension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8083925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       EPHEDrine may be confused with Epifrin&reg;, EPINEPHrine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8083975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, chest pain, elevation or depression of blood pressure, hypertension, palpitation, tachycardia, unusual pallor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, apprehension, CNS stimulating effects, dizziness, excitation, fear, headache hyperactivity, insomnia, irritability, nervousness, restlessness, tension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, GI upset, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Painful urination",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Trembling, tremor (more common in the elderly), weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8083971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ephedrine or any component of the formulation; angle-closure glaucoma; concurrent use of other sympathomimetic agents",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8083972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: May cause hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disorders: Long-term use may cause anxiety and symptoms of paranoid schizophrenia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease such as coronary artery disease, arrhythmias, and hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vasomotor symptoms: Use with caution in patients with unstable vasomotor symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monoamine oxidase inhibitors (MAO-I): Use with extreme caution in patients taking MAO inhibitors; prolonged hypertension may result from concurrent use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly, since it crosses the blood-brain barrier and may cause confusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injectable: Blood volume depletion should be corrected before I.V./I.M. therapy is instituted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchodilator use: Avoid as a bronchodilator; ephedrine is generally not used as a bronchodilator since other beta",
"     <sub>",
"      2",
"     </sub>",
"     agonists are less toxic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-term use: May cause anxiety and symptoms of paranoid schizophrenia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8083978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: EPHEDrine (Systemic) may enhance the arrhythmogenic effect of Inhalational Anesthetics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8083982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid ephedra, yohimbe (may cause CNS stimulation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8083969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13882193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Ephedrine crosses the placenta (Hughes, 1985). Ephedrine injection is used at delivery for the prevention and/or treatment of maternal hypotension associated with spinal anesthesia in women undergoing cesarean section (ASA, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (ePHEDrine Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $30.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (ePHEDrine Sulfate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (1 mL): $3.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (ePHEDrine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (1000): $39.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8084050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection solution: Monitor blood pressure, pulse",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13276706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Efedrin (BR, DK, NO, SE);",
"     </li>",
"     <li>",
"      Efedrin NAF (NO);",
"     </li>",
"     <li>",
"      Efipres (IN);",
"     </li>",
"     <li>",
"      Ephedrine Hydrochloride (NZ);",
"     </li>",
"     <li>",
"      Ephedrine Sulfate Inj (AU, NZ);",
"     </li>",
"     <li>",
"      Muchan (AR);",
"     </li>",
"     <li>",
"      Sulfato de Efedrina (UY);",
"     </li>",
"     <li>",
"      Sulfato de Efedrina Klinos (VE);",
"     </li>",
"     <li>",
"      Sulfidrin (IN);",
"     </li>",
"     <li>",
"      Tabellae Ephedrini (TW);",
"     </li>",
"     <li>",
"      Unifedrine (BR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8083996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Releases tissue stores of norepinephrine and thereby produces an alpha- and beta-adrenergic stimulation; longer-acting and less potent than epinephrine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8083998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimally hepatic; metabolites include p-hydroxyephedrine, p-hydroxynorephedrine, norephedrine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2.5-3.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60% to 77% as unchanged drug) within 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Society of Anesthesiologists Task Force on Obstetric Anesthesia, \"Practice Guidelines for Obstetric Anesthesia: An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2007, 106(4):843-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/14/11493/abstract-text/17413923/pubmed\" id=\"17413923\" target=\"_blank\">",
"        17413923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gan TJ, Meyer TA, Apfel CC, et al, \"Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 105(6):1615-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/14/11493/abstract-text/18042859/pubmed\" id=\"18042859\" target=\"_blank\">",
"        18042859",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghrist, David G and Brown, GE, \"Postural Hypotension With Syncope: Its Successful Treatment With Ephedrin,\"",
"      <i>",
"       Am J Med Sci",
"      </i>",
"      , 1928, 175(3):336-49.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hagemann E, Halvorsen A, Holgersen O, et al, \"Intramuscular Ephedrine Reduces Emesis During the First Three Hours After Abdominal Hysterectomy,\"",
"      <i>",
"       Acta Anaesthesiol Scand",
"      </i>",
"      , 2000, 44(1):107-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/14/11493/abstract-text/10669281/pubmed\" id=\"10669281\" target=\"_blank\">",
"        10669281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes SC, Ward MG, Levinson G, et al, \"Placental Transfer of Ephedrine Does Not Affect Neonatal Outcome,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1985, 63(2):217-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/14/11493/abstract-text/4025872/pubmed\" id=\"4025872\" target=\"_blank\">",
"        4025872",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9114 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_14_11493=[""].join("\n");
var outline_f11_14_11493=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9736689\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084045\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084044\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084046\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084062\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083937\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084047\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083995\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083938\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083968\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083925\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083975\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083971\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083972\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299267\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083978\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083982\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083969\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13882193\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322637\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084050\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276706\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083996\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083998\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9114\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9114|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/58/6053?source=related_link\">",
"      Ephedrine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/10/37029?source=related_link\">",
"      Ephedrine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_14_11494="Blood cultures for the detection of bacteremia";
var content_f11_14_11494=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Blood cultures for the detection of bacteremia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/14/11494/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/14/11494/contributors\">",
"     L Barth Reller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/14/11494/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/14/11494/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/14/11494/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/14/11494/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/14/11494/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/14/11494/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood is one of the most important specimens received by the microbiology laboratory for culture, and culture of blood is the most sensitive method for detection of bacteremia or fungemia. Issues related to types of bacteremia, indications, and technique for blood cultures will be reviewed here. Issues related to specimen transport and Gram stain interpretation are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35059?source=see_link\">",
"     \"Microbiology specimen collection and transport\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34791?source=see_link\">",
"     \"Approach to Gram stain and culture results in the microbiology laboratory\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR CULTURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood cultures should be obtained (PRIOR to initiation of antimicrobial therapy) for any patient in whom there is suspicion of bacteremia, including hospitalized patients and selected outpatients with fever and leukocytosis or leukopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/1\">",
"     1",
"    </a>",
"    ]. However, a normal white blood count does not rule out bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Circumstances in which blood cultures are especially important include sepsis, meningitis, osteomyelitis, arthritis, endocarditis, pneumonia, and fever of unknown origin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     METHOD FOR OBTAINING CULTURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, patients with bacteremia are likely to have low quantities of bacteria in the blood, even in the setting of severe clinical symptoms. For this reason, multiple blood cultures, each containing large volumes of blood, are required to detect bacteremia. Prior to initiation of antimicrobial therapy, at least two sets of blood cultures taken from separate venipuncture sites should be obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/4\">",
"     4",
"    </a>",
"    ]. The technique, number of cultures, and volume of blood are more important factors for detection of bacteremia than timing of culture collection; these are discussed further in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful technique is important to avoid contamination of the blood culture media by normal skin flora during the process of collection. This is important because normal bacterial skin flora can cause systemic disease such as infective endocarditis, and in some circumstances blood culture contamination can make it difficult to distinguish between false positive results and true infection. Important measures to reduce contamination include effective disinfection of the venipuncture site and avoiding blood culture collection through existing intravenous lines [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/5-9\">",
"     5-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tourniquet should be applied and the vein palpated before disinfection of the venipuncture site. Thereafter the venipuncture site should be cleansed with 70 percent alcohol followed by 1 to 2 percent tincture of iodine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. The disinfectant should be allowed to dry for one to two minutes before blood is aspirated. If further palpation of the vein is necessary after skin preparation, a sterile glove should be worn [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/10\">",
"     10",
"    </a>",
"    ]. Alcohol should be used to disinfect the septum of culture bottles after removal of their flip caps. Blood should be collected directly into culture bottles during the venipuncture procedure, rather than into transport tubes sent to the laboratory for subsequent transfer of blood into the culture bottles.",
"   </p>",
"   <p>",
"    Lower contamination rates have been observed with iodine tincture and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    than with povidone-iodine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. A randomized trial comparing iodine tincture with povidone-iodine in over 3800 blood cultures obtained from adult inpatients reported a lower contamination rate with iodine tincture (2.4 versus 3.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/5\">",
"     5",
"    </a>",
"    ]. A randomized trial comparing chlorhexidine with povidone-iodine in over 2000 blood cultures reported a lower contamination rate with chlorhexidine (1.4 versus 3.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood cultures should not be drawn through an intravenous catheter at the time of catheter insertion. In an observational study of over 4100 blood cultures obtained for evaluation of children with suspected bacteremia, the false positive rate was higher for specimens obtained at the time of catheter insertion than for specimens obtained from a separate site (9.1 versus 2.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drawing blood for cultures through an indwelling intravascular catheter should be avoided whenever possible, since ports are frequently colonized with skin flora, thereby increasing the likelihood of a false positive blood culture. If blood cultures are drawn from an intravenous line, a second specimen should be drawn from a peripheral venipuncture. For circumstances in which intravascular catheter-related infection is suspected, the approach to blood culture specimen and diagnostic criteria are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis of intravascular catheter-related infections\", section on 'Blood cultures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Arterial blood cultures provide the same yield as venous blood cultures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Number of cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal number of blood cultures that should be obtained at initial evaluation varies with the clinical condition, suspicion of underlying infection (eg, the pretest probability), and the urgency of the need for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, the number of cultures obtained depends on the volume of blood drawn for each culture set. Among 134 patients in one study, the yield from two blood cultures (30 mL in each of two bottles) was the same as the yield from three blood cultures (20 mL in each of three bottles) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/13\">",
"     13",
"    </a>",
"    ]. In two other studies evaluating yield for four or more blood cultures (volume 20 mL), the cumulative yield of true pathogens increased with the first (73 to 80 percent), second (80 to 89 percent), third (95 to 98 percent), and fourth (99 to 100 percent) cultures collected [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/12,14\">",
"     12,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One blood culture set is rarely advisable or sufficient. A positive single culture result may be uninterpretable unless an unequivocal pathogen is isolated. If a possible contaminant is reported on a single culture, additional culture data are needed, and in the interim, unnecessary antimicrobial therapy or unnecessary testing may be pursued. Moreover, a single blood culture lacks sensitivity as well as precludes the ability to distinguish contaminants from true bacteremia with bacteria that are common contaminants (ie, specificity), eg, coagulase-negative staphylococci and diphtheroids [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A total of two blood culture sets is usually adequate when bacteremia due to a pathogen not likely to be a contaminant is anticipated (as in intraabdominal sepsis or pneumonia) and when the pretest probability of bacteremia is low to moderate. Samples should be obtained by at least two separate venipunctures.",
"   </p>",
"   <p>",
"    A total of three blood culture sets is usually adequate when a continuous bacteremia is suspected and the pretest probability of bacteremia is high (as in patients with suspected infective endocarditis who have not received prior antimicrobial therapy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=see_link\">",
"     \"Infective endocarditis: Historical and Duke criteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Four blood culture sets is reasonable when the pretest probability of bacteremia is high and the anticipated pathogen is likely to be a common contaminant, such coagulase-negative staphylococci. Clinical examples include prosthetic valve endocarditis or endovascular infections due to infected devices, such as pacemakers or grafts. Four blood culture sets may also be necessary to diagnose endocarditis in patients who have received antimicrobial therapy in the preceding two weeks.",
"   </p>",
"   <p>",
"    Additional blood cultures are rarely useful in patients who have been evaluated by the above criteria unless there has been a significant change in the patient's condition or a new focus of infection is suspected. Furthermore, the chance of obtaining a false-positive test (ie, a positive blood culture due to a contaminant) increases steadily as more blood cultures are obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Volume of blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blood culture yield depends on the volume of blood cultured [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. One study comparing 829 matched pairs of standard volume (mean 8.7 mL) and low volume (mean 2.7 mL) blood cultures demonstrated that bottles inoculated with at least 5 mL of blood had a significantly higher detection rate for blood infection than bottles inoculated with less than 5 mL (92 versus 69 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/18\">",
"     18",
"    </a>",
"    ]. The authors estimated that the yield of blood cultures in adults increases approximately 3 percent per mL of blood cultured.",
"   </p>",
"   <p>",
"    The appropriate volume for adults is a minimum of 10 mL (and preferably 20 mL) of blood; the appropriate volumes for children are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef55558 \" href=\"UTD.htm?39/59/40891\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/16,19-22\">",
"     16,19-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever at the time of blood culture collection is neither sensitive nor specific for the presence of bacteremia. In a retrospective study evaluating the timing of blood culture collection in relation to temperature elevations in over 1400 patients with bacteremia and fungemia, no relationship was observed between timing of specimen collection and likelihood of a positive blood culture [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no difference in yield whether blood samples for culture are drawn simultaneously or at intervals spaced within a 24 hour period. For patients who are acutely ill or have high likelihood of continuous bacteremia, it is appropriate to obtain blood cultures from two separate sites within minutes of one another [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood cultures should be obtained prior to initiation of antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CULTURE MEDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special culture media may be helpful in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cultures containing resins, lytic agents, or other neutralizing substances may be useful for detecting yeast.",
"     </li>",
"     <li>",
"      Dimorphic fungi, especially Histoplasma capsulatum, are best detected from blood with the centrifugation-lysis (Isolator) system, which is also useful in the detection of Mycobacterium avium and M. tuberculosis.",
"     </li>",
"     <li>",
"      Special broth media (BACTEC) are also available for the detection of mycobacteria species.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INTERPRETING POSITIVE CULTURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4828398\">",
"    <span class=\"h2\">",
"     Types of bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two clinical patterns of bacteremia, intermittent and continuous:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intermittent bacteremia implies that bacteria are present in the blood for periods of time followed by nonbacteremic periods; this is the most common pattern of bacteremia. It can occur following manipulation of infected tissues (such as surgical abscess drainage), following instrumentation of contaminated mucosal surfaces (such as dental procedures, cystoscopy, or sigmoidoscopy), or in the setting of bacterial infections such as pneumonia, arthritis, osteomyelitis and meningitis.",
"     </li>",
"     <li>",
"      Continuous bacteremia usually reflects a persistent endovascular infection such as endocarditis or endarteritis, suppurative thrombophlebitis, or an infected aneurysm. It also occurs in the first two weeks of typhoid fever and brucellosis though in these diseases relatively few bacteria per mL of blood are detected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are two major categories of infection associated with bacteremia: extravascular infection and intravascular infection. Extravascular infections originate outside the bloodstream (such as pneumonia or urinary tract infection) and enter the vascular supply via the lymphatic system. Intravascular infections are associated with a primary infectious process within the bloodstream; examples include infective endocarditis, suppurative thrombophlebitis, and endovascular catheter infections.",
"   </p>",
"   <p>",
"    The efficiency of bacterial clearance depends on the infecting microorganism and the host immune status. For example, bacterial capsules and other virulence factors may delay clearance by decreasing opsonization, while the presence of specific antibodies may enhance clearance by promoting opsonization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4828427\">",
"    <span class=\"h2\">",
"     Contamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contamination of blood cultures can occur even when precise techniques for collection and processing are used. Contamination rates of less than 3 percent are desired; higher rates should be investigated and corrected with educational efforts [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Staphylococcus aureus, Streptococcus pneumoniae, group A streptococci, Enterobacteriaceae, Haemophilus influenzae, Pseudomonas aeruginosa, Bacteroidaceae, and Candida species are always important clinical pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/25\">",
"     25",
"    </a>",
"    ]. Viridans streptococci and enterococci may reflect true pathogens or contaminants.",
"   </p>",
"   <p>",
"    Organisms for which it can be difficult to distinguish between pathogenicity and contamination include Propionibacterium acnes, Corynebacterium species, Bacillus species, and coagulase-negative staphylococci; the likelihood of pathogenicity is increased if the organism is observed in multiple blood cultures obtained by independent venipunctures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11494/abstract/4,6,15\">",
"     4,6,15",
"    </a>",
"    ]. In addition, the presence of these organisms in the setting of prosthetic heart valves or devices should prompt consideration of infective endocarditis.",
"   </p>",
"   <p>",
"    False-positive blood cultures may be present when bacterial growth first occurs after 72 hours of incubation; exceptions in which delayed growth of true infection can occur in blood cultures include certain fastidious organisms (such as Eikenella, some Haemophilus species, Kingella, and Cardiobacterium) and bacteria that have been suppressed by prior antimicrobial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=see_link\">",
"       \"Patient information: Sepsis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4828671\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood cultures should be obtained (PRIOR to initiation of antimicrobial therapy) for any patient in whom there is suspicion of bacteremia, including hospitalized patients and selected outpatients with fever and leukocytosis or leukopenia. However, a normal white blood count does not rule out bacteremia. Circumstances in which blood cultures are especially important include sepsis, meningitis, osteomyelitis, arthritis, endocarditis, pneumonia, and fever of unknown origin. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications for cultures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to initiation of antimicrobial therapy, at least two sets of blood cultures taken from separate venipuncture sites should be obtained. The technique, number of cultures, and volume of blood are more important factors for detection of bacteremia than timing of culture collection. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Method for obtaining cultures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important measures to reduce contamination include effective disinfection of the venipuncture site and avoiding blood culture collection through existing intravenous lines. The appropriate volume for adults is a minimum of 10 mL (and preferably 20 mL) of blood; the appropriate volumes for children are summarized in the Table (",
"      <a class=\"graphic graphic_table graphicRef55558 \" href=\"UTD.htm?39/59/40891\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Technique'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Volume of blood'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Timing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two clinical patterns of bacteremia, intermittent and continuous. Intermittent bacteremia implies that bacteria are present in the blood for periods of time followed by nonbacteremic periods; this is the most common pattern. Continuous bacteremia usually reflects a persistent endovascular infection such as endocarditis. (See",
"      <a class=\"local\" href=\"#H4828398\">",
"       'Types of bacteremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Organisms for which it can be difficult to distinguish between pathogenicity and contamination include Propionibacterium acnes, Corynebacterium species, Bacillus species, and coagulase-negative staphylococci; the likelihood of pathogenicity is increased if the organism is observed in multiple blood cultures obtained by independent venipunctures. (See",
"      <a class=\"local\" href=\"#H4828427\">",
"       'Contamination'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/1\">",
"      Coburn B, Morris AM, Tomlinson G, Detsky AS. Does this adult patient with suspected bacteremia require blood cultures? JAMA 2012; 308:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/2\">",
"      Seigel TA, Cocchi MN, Salciccioli J, et al. Inadequacy of temperature and white blood cell count in predicting bacteremia in patients with suspected infection. J Emerg Med 2012; 42:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/3\">",
"      Fu CM, Tseng WP, Chiang WC, et al. Occult Staphylococcus aureus bacteremia in adult emergency department patients: rare but important. Clin Infect Dis 2012; 54:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/4\">",
"      Weinstein MP. Current blood culture methods and systems: clinical concepts, technology, and interpretation of results. Clin Infect Dis 1996; 23:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/5\">",
"      Little JR, Murray PR, Traynor PS, Spitznagel E. A randomized trial of povidone-iodine compared with iodine tincture for venipuncture site disinfection: effects on rates of blood culture contamination. Am J Med 1999; 107:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/6\">",
"      Strand CL, Wajsbort RR, Sturmann K. Effect of iodophor vs iodine tincture skin preparation on blood culture contamination rate. JAMA 1993; 269:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/7\">",
"      Mimoz O, Karim A, Mercat A, et al. Chlorhexidine compared with povidone-iodine as skin preparation before blood culture. A randomized, controlled trial. Ann Intern Med 1999; 131:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/8\">",
"      Schifman RB, Pindur A. The effect of skin disinfection materials on reducing blood culture contamination. Am J Clin Pathol 1993; 99:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/9\">",
"      Tafuro P, Colbourn D, Gurevich I, et al. Comparison of blood cultures obtained simultaneously by venepuncture and from vascular lines. J Hosp Infect 1986; 7:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/10\">",
"      Archibald LK, Pallangyo K, Kazembe P, Reller LB. Blood culture contamination in Tanzania, Malawi, and the United States: a microbiological tale of three cities. J Clin Microbiol 2006; 44:4425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/11\">",
"      Norberg A, Christopher NC, Ramundo ML, et al. Contamination rates of blood cultures obtained by dedicated phlebotomy vs intravenous catheter. JAMA 2003; 289:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/12\">",
"      Lee A, Mirrett S, Reller LB, Weinstein MP. Detection of bloodstream infections in adults: how many blood cultures are needed? J Clin Microbiol 2007; 45:3546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/13\">",
"      Patel R, Vetter EA, Harmsen WS, et al. Optimized pathogen detection with 30- compared to 20-milliliter blood culture draws. J Clin Microbiol 2011; 49:4047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/14\">",
"      Cockerill FR 3rd, Wilson JW, Vetter EA, et al. Optimal testing parameters for blood cultures. Clin Infect Dis 2004; 38:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/15\">",
"      Mirrett S, Weinstein MP, Reimer LG, et al. Relevance of the number of positive bottles in determining clinical significance of coagulase-negative staphylococci in blood cultures. J Clin Microbiol 2001; 39:3279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/16\">",
"      Connell TG, Rele M, Cowley D, et al. How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children's hospital. Pediatrics 2007; 119:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/17\">",
"      Ilstrup DM, Washington JA 2nd. The importance of volume of blood cultured in the detection of bacteremia and fungemia. Diagn Microbiol Infect Dis 1983; 1:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/18\">",
"      Mermel LA, Maki DG. Detection of bacteremia in adults: consequences of culturing an inadequate volume of blood. Ann Intern Med 1993; 119:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/19\">",
"      Schelonka RL, Chai MK, Yoder BA, et al. Volume of blood required to detect common neonatal pathogens. J Pediatr 1996; 129:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/20\">",
"      Isaacman DJ, Karasic RB, Reynolds EA, Kost SI. Effect of number of blood cultures and volume of blood on detection of bacteremia in children. J Pediatr 1996; 128:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/21\">",
"      Brown DR, Kutler D, Rai B, et al. Bacterial concentration and blood volume required for a positive blood culture. J Perinatol 1995; 15:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/22\">",
"      Kaditis AG, O'Marcaigh AS, Rhodes KH, et al. Yield of positive blood cultures in pediatric oncology patients by a new method of blood culture collection. Pediatr Infect Dis J 1996; 15:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/23\">",
"      Riedel S, Bourbeau P, Swartz B, et al. Timing of specimen collection for blood cultures from febrile patients with bacteremia. J Clin Microbiol 2008; 46:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/24\">",
"      Richter SS, Beekmann SE, Croco JL, et al. Minimizing the workup of blood culture contaminants: implementation and evaluation of a laboratory-based algorithm. J Clin Microbiol 2002; 40:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11494/abstract/25\">",
"      Pien BC, Sundaram P, Raoof N, et al. The clinical and prognostic importance of positive blood cultures in adults. Am J Med 2010; 123:819.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2133 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_14_11494=[""].join("\n");
var outline_f11_14_11494=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4828671\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INDICATIONS FOR CULTURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      METHOD FOR OBTAINING CULTURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Number of cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Volume of blood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CULTURE MEDIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INTERPRETING POSITIVE CULTURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4828398\">",
"      Types of bacteremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4828427\">",
"      Contamination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4828671\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2133\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2133|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/59/40891\" title=\"table 1\">",
"      Pediatric blood culture volume",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34791?source=related_link\">",
"      Approach to Gram stain and culture results in the microbiology laboratory",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=related_link\">",
"      Diagnosis of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=related_link\">",
"      Infective endocarditis: Historical and Duke criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35059?source=related_link\">",
"      Microbiology specimen collection and transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=related_link\">",
"      Patient information: Sepsis in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_14_11495="Cardiac anatomy PI";
var content_f11_14_11495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F77576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F77576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Anatomy of the interior of the heart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 544px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_14_11495=[""].join("\n");
var outline_f11_14_11495=null;
var title_f11_14_11496="Yellow fever endemic zones";
var content_f11_14_11496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Yellow fever endemic zones in Africa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 523px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAILAhQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAopk5l8iT7OEM207A5IUtjjJHbNcrpXia8KXk+s29pBawX66aDbyPIzTPLHEhwVGFLSD6UAdbRXP3PiuyjmEFvb3l3dNPLbLDBGNzPGAX5YgAYPUkVQfx3po8mSMPPFdR2r2ix4V5vPSR1HzlVX5YmPLD064BAOvornJ/FMVu16ZbaXbbQW8zRlkjdRLv++XZUXGz+9/TOpoOrWuuaTb6jp7l7acEqTjOQSCOOOCCOCRxwTQBfooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKwrjwxaTabfWfnXKC6vFv/MVl3xzLIkilcqRwyKcEHpzmt2igDm7Lw1Y6TNHfzX11I9tLPdvNcOgBMigOWwoAAAzxjFVoPAtjbaYljbXt9HEtra2RJWGTfHAjKgZXjZTneSeOoGMV0GuWI1PRdQsGAK3VvJAQfRlK/wBap+C75tS8H6HevnfcWUMjg9QxQEg++c0AZS+AtMiS0Frc3tu9otstu6sjGPyEkRTh0ZTlZXByCOhGCAa3tB0qLRdLjsbeWaWNHkffMQXYu7Oc4AHVj2rQooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDMOtW48SroeyX7WbM3u/A2bA4TGc5zk+n41p15nbarqOieNvFN7N4V8RXa3ssMcTWcMLxlIkwHDNKp+bceNoxjvXR6J4yj1HWYtMvNE1nR7ieN5IDqMUaJNsxuVSrtlgDu28HAJ6A0AdTRRRQAUUVyXict4i1WPwxbt/oYC3GrSqCQsYZStse2ZudwOf3YYEDzFNAG14c1m38QaPb6pYxzLZ3ILwNKApljz8sgAJIDDBAOGweQDxWnSIqoioihUUYAAwAKWgAooooAKKRmCqWYgKBkk8ACsEeNPCx6eJdE/8D4v/iqAN+uY+HX7vw7JZng2N9d2oHoqTuE/8c2H8aq6v8TvBWkvbpeeJNOaS4JWJLeT7QzEY4xHuOeRgd+1c74a+Ifhyz1nxNE9zeiCa+W6gxptyfleCMNwI8j50c84zmgD1OisXw34o0jxL9pGj3TzNbFRMkkEkLJuBKkq6g4IBwfauR8bfCvTfEHiM+I4ltptX8nyDDq8P22zkTK4BiY5TbhiPLZPmY5yCQQDdb4ieEm+Wx1201SYdYNJJv5gO7GKAO4Ud2xgZGTyKo3PxN0e2muhPY6zDb21st4889mYf3Jk8tnEblZcK3UbMn+ENVzTPGFil4lhr1q+haocIqXWBDMchf3Uw+VgW4UHa5xnaKh8Hf6T4y8a3sRElnJcwWyv2MkUQWRcdeGOKAOo0q8bULCG6a1ubTzQWENyoWQDPBZQTjIwcHkZwQDkC3RRQAVg6v4nttIvjb32n60UKho57XTZruOT1H7hXKkcffC5zxnnG9Xl174M8Mr8SLhNe8P6Tfw66puLae6tUkdblF/eR7myx3IN4HCrsbHWgDrNB8d+F9duYrTTNdsJL+RnRbGSTyroMhYOpgfEikbWyCo4GelWdC8SW+q39zp0lpe6fq1tGk01leRgOkblgjh0LRuDtb7jtjGDgggcre2Wo+GvEum6D4GtPDGjaZf289z+909+biMxgr+7kQEsj5HfET9R01fDXhHUrHWoNZ1zxJd6rqQtPs0qi2ggibJDdEQMwU7toZm27m7k5AOrvbhbSznuZAzJDG0jBRkkAZ4964zS/iPa6nd6GLXQfEEmm6wivbapDbJcWq5UHEjROzRkMdh3KAGB5wC1dzXm3iz+xfBXj/RvE8ltFbLqiXGmXj21sTJI5RZklfYCz7RbMmMceZnIANAHpNFUNB1ix1/SLbVNIn+0WNwC0UuxlDgEjIDAHGQcHv1HFX6ACiiigAooqK6uILS3kuLqaOCCNSzySMFVAOpJPAFAEtFYJ8Z+FxjPiTRRnkZvouf/AB6sbWfix4E0a5S3v/FGmrKybwIpDKMZI6oCB0PFAHb0VxMHxS8I3EKS2+oXU0LjcskWnXLqw9QRHgiqGv8Axg8M6RYtdiHW76NMtL9m0uf90gBJdi6qAo9c96APRay/E2t23h3RZ9TvUmkt4WjVlhALHe6oMAkDqw79K43QvirBr9gt9o3hLxbd2bY2zLZxIGyAQRvlBIwQcjjnrWF4r8UeLPEmm6poK/C7UHsr9HtY7i8vIVUBhhZHTnGDhsZOMUAex0Vynwv1pdb8FafIY2hurRfsV3AxJaKeL5HUkgZ5Gc46EV1dAFDXtUi0XRrvU7mKWS3tYzNMItu5YxyzckZCrliOuAcAnANu3mjuLeKeFt0Uih0bGMgjINVdd02LWdE1DS7lnWC9t5LaRkOGCupUke+DXKwxeKfCdvFFHjxPpMKBcbUgv0UDttAjl7ALhD6saAO4orF8PeJ9K18yR2Fzi7iz51pMpjniwcHcjc4zxuGVJ6E1tUAFFeaLrGreLPHOpaXoniuy07S9PRJE/s2OG5uLgMoG5nfeiKsgddu0N8uc4IrbHgGwuNrazqWt6rI3/Hwt1qMvkXHqHtlYQ7T0KhAp9KAOluNSsbbULSxub22hvbzf9mt5JVWSfYMtsUnLYHJx0HWrdY/h/wAL6D4c8/8AsDRtP03z9vm/ZLdYt+M4ztAzjJ/M1sUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWfrui6dr+ntY6xaR3dqzBij9iOhBHIP0960KKAOGe91vwfKkN99q8RaXIT5UkSr9st1AwFKDmf+H5h833ieMVJ/wAJZr96d+j+DNQktW+VZr2eO0YN0JaJzvwD37jpWCNCtPiT461LU9YiuW0PQHfTNNVJZbcyXIP+lThlCtgMFhBDkZjk9a1Zvh3LZLdN4V8Va/ozSlXWF5heQK4GMlZgzkHuBIufagCaTTPHupKDc6/pWilBgLp1obkSZ7sZcFcdsevNb/hTQY/D2lC2FzcXt1Iwlur25bdLcy7VXe59dqqoHYKB2rCQfESxuJ1P/CL63bsFMcjST6c6HncpQLOGHTB3DvxXNeH7jxV8T9OuJL7UrbwvpcM8tjd2GlTi5vhNGZI5Y5Jyu2L+BgFViRghhkUAdf4q8faJ4duUspJZL7V5eIdNsUM1xIef4F6DKkZPA71hiz8f+K1me7vYvB+nSIUjtrdVuLwgkfM0n3UOM425xmus8L+FNE8LwSx6Hp8Vu8zF5piS80zEkkySMSznJPUnrW5QBxn/AAgSf9DP4s/8Gjf4VD/wq/w/cXT3OstqWtTFFjVtSvHl8tQScLyMZJ5ruaKAOJPwq8EsCG0C3IPBBkk5/wDHq34PDOhQQRwxaNpyxxqERfsycADAHT0rXooA8+8V6dpcPjbwHZWOlwLdHUJ75zDagBYYrWVCzMBxiSeADPcj0rXZ3s/iJfGKMyPeaOkiRhgN7QSuD14BPnqM/SqVvMNV+Ml2Iry3aLQNHSJoYxucS3kpZg7bvlwlpEQuM4kznpXaGKMzJMY0MqKUVyo3BTgkA+h2rn6D0oA5X4YqsvhkajJL517qE8lxdPtK7ZdxUpg8gLtC46cEjrXW1xPw2M0t74quoo4l0i41R5LSRXLtOdoEkm7AXYWACgZxtbJPbtqAK2o2Fpqdo9rqFtFc27jDRyqGHTH589aoeFfDemeFtOksNEgNvaPPJceXuLAM5y2M9s9q2KKACiiigArJ8S6Da+IdOW0u5bmDZKk8c1rKYpY3U5BVhyPT3BIrWooA85HgrxLbX+jSJ4qOp22nagLmJNRtx5kcZ3q/7xeZH8qSSMbsD5t3VRXo1FeNw+EPiHCJXivoba5uJXnuXtfEEgjlkZiSVSWxl8tRkKEVsAAdTliAeyVW1GzS/s5bd3kiLoyrNE22SIspXcjfwsATg15jDYfGS28uK31DwfJbR4C/bHnlnZf9uRY0Ut7hFHtXpulvfSWETarDbQXpB8yO2maWNTk4w7KpPGP4RQBwlr8J9I0q3gk0C8vrPV7Ur9l1CeU3DwqsflCPax2sgTgKe+D2q9/bXi51/sweHlTU/uHUDMptAvTzh/Eec/u/vdM8c129FAHn9v8ADuazuG1ax8QXkPiebJutQ2AxXOduQ0BOwABQFx90knvVz/hJtf0wfZdc8NXNzev8sE2lZmt5mPYk8xAZUFnAH3iOBXaV5/reu67ceKNW0SSSx8NaRaWy3i6xPKJJLq3xiYxIcLGYyfmkYtszGSjBxgAluZvGmpx7pZ9M8KW0hAQyFbq5V+m0jPlkNyRg5xjvnGD8QvDOn6J4XnvdSOpeKNQd44bCy1KdpoWu5GCoQg6Asee23IqTR/h/D4ivodX1u51mezjkWS3TUJf314FOVkmi2hIsELsVESQBcu2WZBu/Fq5gs9J0K4u5o4II9dsGeSRgqqPPXkk8Ae9AB4C+HGjeGdG8m6srC+1W4YzX14bVV8+VmZiQvYAuQAOgxXTLoOjqMLpVgB7W6f4VpUUAMgijgiSKCNI4kG1URcBR6ACvOfG2jWXiz4l6JoesSzTaZBptxqElkkxVJJFmhRfMUfeUq8gweCCa9JridAiib4t+L5iiGZNP06MPgblUm4JGfQkA49hQB2kaLGipGoVFACqowAB2FOoooA8v1C9uPhr4n1vVLu0vLnwfqrfbZp7cNMdPuAuJGdByI3AByOhB9a9LtLmG8tYbm1lSa3mRZI5EOVdSMgg+hBrjfinI19ZaZ4XjhaX/AISG6+xzEEDZbBS87AkjB2KccHk9K7SGKOGFIoUWOKNQqIgwFA4AA7CgB9FFFAHP+IvBvh7xJdRXOt6Vb3dxEhjSVsq4UnO3IIJGRnFZQ+FngsHI0GDP/XST/wCKrtaKAM7RdD0vQ7VLbR9PtbKFEWMLDGF+UdASOT+NaNFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXjHhdNfXQPAst7e3D6fvspo5jcFpLlp4gzrJzkhD5gAOQQ691oA9norylPGOsf2Q1xb38E94+n/abqFoVI0y582JBCwUgkYeQYY5zETnB41L7XNV07WjZXGqxPeQ3FrFBZ+QiHUI5XUSSAfe+UMw+U4XyyWyDQB6FRXmaeKrttIF1JrkMV7LOkV7amOP/iVIZgrMRjcNoOCZMrk7vujFO1LxPd20zpZ69DdeVbxSWI2RH+1pGmkV0BAwSoRV/d4wTuPBAoA9KorJ1nWJtNmjVNH1O+iZcma0WN1Q56EFw2e/CkVn/wDCa6ZH/wAflrrVme5n0q5Cj/gYQr+tAHTUVzkXjnwrJIIz4h0uKU9I5rlYn/75Yg1uWl7a3ilrS5hnUdTFIHH6UAT1554h8Y3uuX0nhz4dlZ9U814L3WHgL2mlhQN7biNs0w3ALEpPzffwAQaupalr/j7UtV0bw1Ouk+HbSb7He6uDm4ncEebHbYOFwMqXOeTwOM13ugaNp/h/R7XS9HtY7Wxtk2RxIOB6knqSTySeSeTQBD4T0Cx8LeG9O0TSYxHZ2UKwpwAXx1dsAAsxyxOOSSa1qKKACuE8PNPpfxb8Wadc3bvb6vbWusWcJgKqrIv2a4xJj5iPLtiQTxvGB1J7uuD+Id2dD8V+CNc3ziF759FuEjiDqY7tQVZj1XE0EAz/ALRHOcUAd5RRRQAUUUUAFch8VdQ8QaZ4PubjwrAXuwQJpY4xNNbw5+eWKE4ErqMkIWGff7p6+gjIwelAHN/DzSNE0jwnYjw0zzWN4gvvtkrF5r15QGM8rNyzvkEk+wAAAAj+ItrfXehRJZJLNaLco2oW0LYluLQZ8yNOhJPBwCCQCOc4PM6bt+GfihNKZblfBuryIuntnfHp14zNugxjKxyZQp2DbhxmvTqAM3w9qOm6npcUujMv2SP90IxEYjCV42NGwDIQMfKQCOOK0q8c8P6XqXjDxz4k8U6D4hv9F01Z10+3FuEkivGhVlklaN1I+8dqn/ZPtXSwS/EPRpI4bi10jxLbESDz45fsU4+YbC4IKH5SQdoHIoA76ivPl+KWn2KW3/CVaRrXh5pYmdnvLUtCrKBuUOmc4z1wMgE13On31pqNqlzp9zDc27/dlhcOp/EUAWKKKKACis7xDrWn+HtHudU1i5S2srddzyN+gA7kngAck15/pPxE8Q2mmf2h4u8Hajb2MsclzFcaennGKEN8omiJ3I+35jjP0HSgD1GisHw94v8AD/iIkaNq1rcyBzGYt22TcAGI2NhuhB6dK3qACiiigAooooAKqahptjqQtxqNlbXYtpluIPPiWTypVztkXI+Vhk4YcjNW6KACvJPHWvaOZtc17xLAbvw1oMb6bHbLH5hu7uUbJFxwRgN5eGyp3bsjFd5431iTRtAkezK/2jcsLWyViOZn4U88YUZc57Ka8Xtk0Xwv4y0m+186ve+FoIY5NLuGE11aG7fc0txtLERbecDbxuz2FAHqPwd0rWNH8C2dvr07tK7NNb2rlmaxt2wY7ZncBnKDjLAHt0UV02u61pmgadJf63f21jZpnMs8gQZAJwM9TgHgcnFcbqfxHjv7tNL8AW0XiLVpImkLrKUtbZfLDK0suMHO9PlXnntiuY8c+DLq20n/AITLxbdTeINV0e9GpfYY8iyitwQrpHCxx8seX3H5iyDnkggHSHxB4l8ZziDwhbzaDo+G8zW9Ts8yS4PH2eBmB5675VAx0U103hDwpp/ha3ulsmuLm8vJTPeX124e4upOxdgAOBwAAAB0A5rbtpkuLeKeIkxyIHUkY4IyKkoAKKKKAPNZpra0+OIm8RB4mmsFttBlkjTyWYnM6K+MiU4XAJGVzjNelVk+KvD2n+KNEn0vV4fMtpcEEHDxuOVdG6qwPIIrjvDmt+I/DWv2PhzxoIryyu3a10vW42Aa4dVZwlwvRXZAcEfeKN6igD0eiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBk0UcyFJo0kQ/wALqCK5TxZ4e8M2mh6lqtz4a0i5lsraW5G61jDHYhbAbbkZ2gZrrq4b4yTSP4PXSLaO4kudbvIdNjWGQRkh23SBm3DCmNJAcHPOO9AGb8NvAGn2vgXRfPa7t76S3WeV9P1G5gQs/wA/RXAPUdRzjmurs/DclndxTQa/rhiRgTBNOkyOP7pLoWx9GB9627aCO1toreBdkMSCNFznCgYAqWgAqlrdzLZaLf3VuqtNBbySordCyqSAfxFcj4g+KPh/TNcXQ9OW98Qa7v2yafosIuJIRuKlpGyEjCsAG3MCMgkY5qpdaH4y8a2csPiLUF8K6RcRlG0/SXWa8ZWUZElyylV5zxGp4ON5oAo+CvBth4t8NaPr3iTW9S8QzXloJsG8MdvE74ZhGsRGNpG3kkjBHrXR2vw08KW11BcRabL5sMqTJvvJ3AdGDKcFyDhlB5HUCt3wxoVh4Z0Cx0bSY2jsbOMRRKzFjjqSSepJJP41qUAFFFFABRRRQAUUUUAcx8UNLOs/DrxHYx273NxJYytbxR53GdVLRFcc7g6qR7gVzni/xcbj4eaMnhq43at4mjitdNLEK43rl5drEH5EyT6HaO9elV5F8DvDE9rPf6jq08F5LpbyeHtNkSIJ5dtbSMjEggkO7hifmIIx0xigD0rw1otr4d0Cw0jT122tnCsKZyScdSc9yck/WtOiigBsiLIjJIoZGBDKwyCD2NeW2V3pnw2+Ieo2N6LTSfDmvql1ZTEmKCO6UbZIuRsUuMOMEZ54zXqlQX1nbahZzWl/bw3VrMpSWGZA6Op6hlPBH1oAmBDDIII9RS1wTfDtdIaKbwLrN94fkiJxaM73dg6mQOyG3kbCA4YDymjI3n6U+LxB43sLdodV8Fx6leLbIyXGjanEYJZsMGVhceU8QyFPAkwG6kjkAg1fTINe+L9pBqpe4s9J0yO/trVm/dC4eaRPNZf4mCoNuemSevNeg1x/gnw5qlnqeoeIPFF1bXOvajHFE6WiyLBaRIvEMYd2yNxZi2FyWPArsKAOf8QeDPDviCUTatpNtNcBw4uFBjmyFKj94hDfdJGM9K5ifwl4h8M2bzeGfGMn2O3gQfZdeUTxKqHJPnDDINvBJDdAa9HrhfjPqEtr4LOn2q3RutauodKjNtGHdRK2JDg5/wCWYk5wccHHcAFLwv4+13UfDun6vfeErmSxuo/tDXOmTrcKkZJxiM4ldsDoqHORjNdDpHjvw5ql7DYRanDBqsgJ/s66/cXSYG4homwynHOCOmD3rfsbaOysre1h3eVBGsSbjk4UYGfyqPVdNsdXsZLLVrK2vrKTG+3uYlljfBBGVYEHBAP1FAFlHWRQyMrKe4ORWHr3irTNGuI7SR5LrUpV3RWNohmncZxu2LkhQeCx4Hcisa8+HGmiQt4f1LWPDUbxPA8Gj3CxwFXxnbC6vHG3Gd0ao2WY5JOa6TQdC03QbVoNLtUh8wh5pT80s74xvkc/NI5xyzEk+tAHEeKvHfirRvDt5qY8B3US2sfnStc6jbbEReXJ2OzEgZxgHmu71bWdM0eymvNUv7W0tYcCSWaUKqZIUZJ6ckD8afrGm2ms6TeabqUXnWV3E0E0e4ruRhgjIII4PUEGsbQfAnhbQbqO70vQrCO/jZ3F9JEJbos+7ezTvmRidzZJYnBx0oA8/wDFPiXSvHV94htdGvor6w8P6JNeb4CJI5bmaKVFwcdY0B5BIzIQeVr03wkAfCmjxtgkWMAZT2/djqKxPGQOleKfDevoSsPmtpt5j5F8uUZSSR+m1HTAB4zNwQTyz4Zjzbjxdcy/PctrlzC0rcuUTARSeuFBIA6DtQBT8TX+saHq1r4e8GaNoum295byyxaheN5Nv9oGP3apGCWkCgvg4yqHB+U4kT4f3eqXd2/jbxFc69YzKoTTkh+yW0ZAwWwjFmyOxbHLZByMafxHvvDieHbvTfE9sNTjvYH2aTDGZrm92gEiGJfmZhwdwxs4YlQNwb8LLHxDp3gyzt/Ftx51+CxRHkEs0EJP7uKWUYEsirgNIFUE+v3iAYzeDdf8LuZvAOsbrPJZtF1Z2kgPJJEUvLx+nO4fSpdP+KGmW8/2HxrBL4U1UKT5epELDLjZkxT52SDLgYBz6gV6DUN5a299aTWt7BFcWsyGOWGVA6SKRgqynggjsaAJUZXUMjBlPQg5FLXnsvgC60BpLn4casdFY7mOk3Sm402Vj5jYEeQ0GXkBzEwUbfuGup8F603iPwlo+svALdr+1juDEH3BCyg4zgZ6+lAGzXPeP/Dp8T+FrvT4JhbX6lbixusDNvdRsHik6Ho6jOOoyO9dDRQBzfw58UReM/BWk69DH5Ru4syxYI8uVSVkTkAkB1YZ74rpK8M0rxTfW3ijxDpvw5t5tWsNanN3p+oTWdw+m2l4WYXSvPnBjZkLgx5G+Rh0r1Pw/wCJY9Rv30q+tbrT9bhgE81pPHwUJ2+YjqWRlJ9GJH8QB4oA6CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK4b4j+N7zw0I7LQNBvte1uaF5kt7ZCViUcB5COg3EDA5POOlAHZX15bWFrJc31xDbW0eC8szhEXJxyTwOSK85sL8/EPxnoeqWFlejwtpAnuIrydjFFe3JIjjeJAcuqqJCGbA+fgVzdqBqmrpqvj7S/EuvXEP8Ax6WkehzR2dr+835VDy7cINzjPy13kXju2hjWOLwx4qSNBtVV0eQAD0AoA1/HPiOPwr4budUe3a6mUrFb2qEhriZyFSMEA4LMQM4OK5y98G654pmlHjTXnXR3XA0fRy1rE6srqyzTA+ZKMOBgFFO3JTnFZPiDxA3inxh4M0aOx1nTLZr9r6Zr6waHzTboZERWb/aAzjnAr1egClo+k6fothHZaRY21jZx52Q28YjRckk4A45JJq7RRQAUUVw/xN1zUdOjsLTQmuBqEnm3ZEFs85aOFc7CFVioeRolLY4BbnOKAO4orz4eKbifxJs0qZHg1SOxWzefLRQiSK5lLlQRnKxAYBGSV5qAeONauUgh07TIrm/WCe4kRFJWXy53iCrlxsyUyWO7buHBzQB6RRXC3niXVJGvpFht4bG11aysFZJCZnMk9sDkYKhdszA4JJ9utT+G/Fd3qniSKyeKOTTru1nu7S6WLytyxSRpjBdmYHzQdxVOnAOeADs6KKKACuH+EE8d54a1C8tyWtbrWdRuIJCpAkje6kKsM9iCCK7iuM+DH/JKPCf/AGDof/QRQB2dFFFAFDXNTj0jTzeTo7oJYotqYzl5FQdfdhVDxV4kh8P280ksRlaOynvdocLlYjGCPX/loOcYHfqKs+KNKfWtGlsobhbaRpIpVlaPzADHIrjK5GQduOo61i694TvtdjZr/VLYXB0+7sA0NmyoBM0DBtpkJ+Xyemed3bHIBtWXiDS72dYILoee0jQiKRGjfeqhypVgCDtIYeo5GRUaeJtJd7UJdMyXJURTCGQxMWO1R5m3YCx4AJ5yMdRXO+IfCWoXmmXjpeeZrd5eW8i3dqggFqq4jLKrMx4jMueSTvI4HR+peAkudRtZbe6t47O2lspIIZbUyvbrbyIwSF94CKwTB+Unk8kcUAdHp/iHS9Rvms7O6Es4DkAIwVtjBX2sRhirEAgE4yM1q1zWkeF/7Ou9Mm+2eZ9i+2/L5WN/2iUSevG3GO+fauloAK4b4vLNBoWlatavGJdJ1e1uhHIpKyBn8grwRjiYkH1Arua4z4v/APIhXf8A19WX/pXDQB2dFFFABRRRQAVzK6zPpnjIaRq8heHV2aXSZFjwqeXEpkt2IH3vleVWJ+YM442DPTVy3xK8NnxP4WltrfeNRtZEvbF45fKdZ4zlQsg+5uG5C3YOTQBH8WL2z0/4fazc6gkkqxQmWKOIZdpk+ePaMjOGUNjphTnjNcb4NsfiN4e8F+HI9NfQtajeFZbqC8LQSoXy5CSp8pGWGMpnryapXcWu/Evw/ZWjwTLHp6pqMd3LD5SX8okzAFP8LGNX8xf4WlA/hNeteHNWttc0W11CzVkilX/VuMNGQcFSOxBBFAGJ4B8NX2kR3mp+Ir9tQ8R6oUe9lBIhiChtkMKdFjTe2D1YsSSc8dbRRQAUUUUAFeb2Oha38PS6eGo7nXfDbeZI2nT3LNdWhwBHFbM52+UMY2Ngjk7j0PpFFAHiVv8AHGdtOu7vUNB0/SHtZPKmtdS1ZobgMfu4jEBLBucEZHBzir9r4un8TfZ4/HllL4S0K6j3ixvV4vQBnEtxnasRDKGiZULHCksrMld7qXgvw3qniCDXNR0azudWg2+XdSR5ddpyuPpmty6t4buBobqGOaFsbo5FDKcHIyD7igCRVCqFUAAdAK5rx5pk91pceoaWgOsaXJ9rtDyC+PvxEgbtrrkFRjPFYcmkJ8Ovs99o9zeHw+915d7ZTzNLHbJIx2yQg5KhZGAIHG1iT90V6EDkZHSgCppGo2+raXa39mxa3uIxImeoyOhHYjoR2IIq3XAx39t4F8Vx6XdM8Gg6y5exfYfKtrrJaSNm6KJM7lHTIfnkCu8jdZEV42DIwBVlOQQe4oAdRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBDeXMVnaT3Ny2yCFGkkbBO1QMk4HPQVzHw8t5rizu/EV8my91txOFyD5duMiBMjgjaS2cA/OQelQeNl/4SDWdO8JpzbTAX2p/wDXsjfKnY/O4xlTldnTBrtKACivPdK0ODxD4n8ZSanfa5/ouqpbwJbazd20ccf2K1faEilVR8zuc4zk1sf8IHpH/P54k/8ACj1H/wCP0Ac98V4NXuPFfgdfDd1bWuqpcXcsL3SFon227ExvjkK3QsMkdQMitrwz43S91YaD4hsZdE8SFpfLtJQzQ3SR4Je3mKhZRtYEgYYYbKjFXNO8E6NYata6nH/ak95a7/Ie91a7uhHuXaxCyysoJHGcVf8AEvh3S/E1jHaazbefHFMlzC6SNFJDKhyskciEMjA91IPJHQmgDWory4eIdZ+GdvHb+NpJdV8LRu0cPiJd0lxbpgeWt5Gq5JzuTzlJ3ELuUFsn0nT7221GxgvLC4iubSdBJFNEwZHUjIII6igCxUX2eH7T9o8qP7Rs8vzdo3bc52564zzipaKAMTU/DOm3unPZxQQ2cb+WGMNtC2VQkqpV0ZSAScccZ4xTbXwnokOj2emz6da3lta7vLF1CkmCxJZuRgEkknAA9ABxW7RQBVOn2RR0NnblHlWdl8pcNIpUq545YFFIPUbR6CobPRdKsbx7uy0yyt7uTcHmigRHbcQWywGTkgE+pArQooAKKKKACuM+DH/JKPCf/YOh/wDQRXZ15X4auJvhprjeHNcllPhfULk/2FfMxaK03dLKQtllIOdjMxDDgYxtoA9UoorL1PV/sGr6TZSW0rpqMzW6Tqy7UcRSS4IznlYm5HfFAGpXm/xA1XUovEUc+mRX0tpoEKXt39mdAh3uNyyAsC2IElIADcyKccCutHinRxHcvLdmBbcK0nnwyRHazbVYBlG5S3G4ZGe9Fl4p0e9u4ba3umM8rtEqPDIhEgBJRtyja+FLbTgkDIGOaAOa1PxDqEMnia7bURHp1lewWNusEUYK+ZDbP5ryvlQoMzclcAZPzcCueh8Rz3l7pM+qeILbTzCdSt1v45I3WQKYShBZFRzg9kGQDgDOa7vUPGemW2nyXURlk8qe1ikjkieFlSeZYlkw6glfmJBAwdpANWD4r0oRJObgLa+VcSyySAxmEQY8zejYYEZ5GOMe4oAu+HLu6v8Aw9pd5qMAt724tYpZ4QP9XIyAsv4EkVo1hW3irSbm6SKG7jaOQR+XMG+V2d2RQO/JQ4PQ9ialvPEulWcbyTXLGKN5I5JI4ZJEjMZAcuyqQoXPJOAOeeDQBsVyPxatp7n4d6ybTyvOto0vQJCQrCCRZiuQDjIjI6d664EMAQcg9CKwPiD/AMiF4l/7Blz/AOimoA1tLu/t+mWl4E2C4hSXZnO3coOM/jRqV/a6ZZvdahcR29upVTJIcAFmCqPqSQB7mqvhb/kWNI/684f/AEAVn/ECwutS8Nm3sYJp5lvbOfy4ZFjkKR3UUjlWYgBgqsRyORQBtadf2uowGexnSeIMV3L0z6VZrynxoy2dpby6rbXZtWtbuOK11G9gaYXBEZjlUGUhsAMBtJdS3C/Nmr1jYag/ifS9N81xZS2lrqeoRs7b45Yl2Kp9BIyxnH/TCT+9QB6Jc3ENrbyT3U0cMEY3PJIwVVHqSeAKkrxix8P3+v8Aha4ay06SMzadeQTSzTJ/p8plUxDhifl2MAz7duQBwTj13SkSPT4EjtHs0C4Fu5UmP2O0kfkTQBy9ix8LeLpNOkH/ABKdcnkubRxwtvckBpYmJ6mRi0i8kk+YMAKCU1xV8Iavc+JIgV0SdP8AiawRf8s3yMXQX+IgfKwXBI5+YqBWx4x0Ztc0Ka2t3EN/GRPZz52mKdeUbcASoP3WI52swHWneF9VTxD4eguZodkzqYrq3kXBjlHDoyknHOeDzgjNAGzRXH6Hv8K6wmg3JZtJvpW/sd92RBiPe1oQfmAASR0OSNu5PlCIG7CgAooooAKKKKACiiigBk8MVxBJDcRpLDIpR43UMrKRggg9QRXJeCJ5NJuZvCd+ztcWKGaykJL+dZltqFm/vqflYEDoMAjmuwrlvH+nTyacmtaV5Y1vRlkubQysRG+VxJG/B+VlBGQMjjBFAF261vRLvW5/DF5JHLeSwAyWs0JMcqOG+TJGxiVRzsyTtVjjANZb6Dqvh6Zrjwrdedpwbe2h3CrsC91tpOPKPLMFfcpO1R5ajI8uvfEXh7VP2d/EWvx6oWv7lm1GWSOQpPb35kAtgwiY+WytHCoPyg7AxAya98triG7tori1ljmt5kEkcsbBldSMhgRwQQc5FAHKHWPGV6Q+neFbOzjHDJrGprFIT6r9nWdSuPVgc54xyUe08d3wMjaroGjEjaLeKzkv8f7Xms8PX02cY6muvkkSKN5JXVI0BZmY4CgdSTXlXinW77VdLXxjpl/cW/hbSZY7lFgnKtfxRzKZpcLjKGNXRUc4bduIXCkgHVeFbnUdENr4f8U3r39+wb7LqrIEW/6sUKjhJVAPyc7kXcpOJAnW0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUF/d2+n2NxeXsqw2tvG00srnARFBLMfYAE1PXJeL92taxp3hqEkwyEX2pFT923RvkQ46GSQAAEYZIphQA/wDZ3DWl3rmpRtHqOsS/aXjcYMMQGIojg4yqAZI6nJrqqQAKAFAAHAA7VxvjHxbe6b4j0rw5oenwXes6jG08bXVwsMKRoyhyf4nIDZ2qCcAnoKAJvBH/IwePP+w2n/pvs662uf8GeHZPD1nffbNRl1PUNQu2vbu6kQRh5CqoAqDhVCRooGT92ugoAKzvEelprnh7VNJllkgjv7WW1aWP7yB0Klh7jOa0aKAPL/AfgDwfrngXw9qmo+GNIkur/AE22uZ8WyhWd41ZsL0Ayenal1DwfrXguX7d8MfLktGZjceH7uZhbEE7t0H/PJs54HynPTit34QNcJ8PNKsbxYhcaV5ukO0RJVzaytb7xkA/N5WfxrsqAOZ8E+NNK8XWzmweSG/gVftdhcIUntmORtZT7gjI4OK6auO8c+ArLxRcW+owXd1pOv2ikW2o2bbXXuqyDpIgbDbT6e5rK0zx9daHrdn4d+I0Ntp2q3ZRbK+tdzWd8do3YdgPLcPwUb+8mCc5oA9GopAQwBUgg8gjvS0AFFFFABRRRQAVjeL/Den+K9Cn0rVo2aCTDJIjbZIZBysiMOVZTyDWzWZ4i1/SvDelyajrt/b2FknBlncKCcEhR6k4OAOTQByvw/wDEGoxavf8AhDxXcwza7pyJLBdL8p1C2bOJdvZxjDgcZwe9dHquj3Gpazpt1JeJHaWEjTxRRwkSGVopIsmQtjbtlY425yBz2rzi70TW/ilrei63cRXfhXRdMYXNjLhRf3LNwT1PlRlf4WBJzyK6S28I+KtPvLptO8eXUtpMV2Q6lYJdNFgc4cMnUknp6enIBFZ/Dl4Q5m1O3eZooImmjsiskvlTpLvlYyMXdtuCeOucdq2bnwkZp5ZF1B4i+qHUgUjwy5t/J2g56j727HtjvWXFbfEqxvrkLfeGdXs2CiFrhJbORT/FkIJAeeOvasrT9b+IviO1vxpNv4X0+Wyv5LOSWWeeXcYmw2F8scN65yPSgDS0/wCHj27M8uoWplY2BZ4bIxmQ21yJ9zkyMWd8bSxPHXnpVnV/AX9oRaon9peX9th1CLPkZ2fakRc/e527M9s57VUt/iOukXSWPxC05/Ddy7bY7yR/MsJz85+S4HyqdqZ2vtbkcV6CCGAKkEHkEd6AOU8X+HZb+PWry1LTXdxpyW1vAuEKzRu8kcgcnAIdlPTjbnnpWdq/w+N/otrp66hEY0spbaYXVqZ1eWQ7nuFXeoEpYscnP3uMd+9ooAjtYvItoYd27y0CZxjOBisvxlaT3/hDXLO0QyXFxYzxRIP4maNgB+ZrYooA5/4fajBq3gfQr21DiKSzjADrhgQoUgj1BBroK4r4Lf8AJL9B/wCuT/8Aoxq7WgAooooAKKKKACuLkA8PfEKxitPlsfEAm823X7q3Ma7zN7blBBA6nBOa7SvOPEGqS3Hjq01K1s31DRPD0cq3UttuMkVxJ8jbAAfN2IW3qvIz3I20Adxrmk2mt6dJZX6MY2IdXRijxOpyrow5VlIBBHIIrM8Jatc3CyaRreBr+nxR/aiAAlwrZC3CY6I5RuP4SGXnGTu2lzBeWsNzaTRz28yCSOWNgyupGQQRwQR3rk/ER/snx94c1NTti1MSaPcKg+aR9rTQMc/wpsuBxzmXv2AOxooooAKKKKACiiigAoIyMHpRRQByfiX4f+H9caW6bTra31fytlvqMUSia3YZ2Ohxwyk5HvXD+D/BepQWH9reD/EN7pOomVk1HSryRry0a7WXFwW3nf8ANswrAgldrD73PslYGp6fd6ZFrep+GreK41a8Ecv2W4mMcMsqKE3ZAJVmQKuenyJ05NAHKX2k+K/F3laF4w0+yttEWVpLy60+7ZReorDy4vLPzKjfxgk9Md66bxnJpul+Dbq2udOiu7KSMWUWnKAouC/yJCoPA3EgD0rN/wCEy1ezUS634L1u0tsfNJbGO9bd2AjgZnI684wO9OWUeIviBFGyyJZ6Fbx3XlSKUaSedWCEr6KgfggEMQe1AEngJH0e+1jwvJPNNFphgmsTLIZXWzlQqgZzySJYrgc9FC9sV2FclpX/ACVbxL/2B9M/9HX1dbQAUUUUAFFFFABRRRQAUUVzHxLme38DarLFKYWVF/eeYU2/OufmHIGO9AHT0V5bofiCTS5ZyL61fSTqsKSXaXbT2sUTwNlFkc/KRIik84zIOhJrT8Pa/q2uanpEcN9bxW0sd5cSlYA5lSK6Eaqpz8uVPJ5oA7+ivGfBviO/k8EaNBdyC2mgTQ4oLNv9ZJA81uhuC4PzBtzAAcDGG5JFbP8AwleqWlv9uvbuSWCe31JvKhgTMBt5giMuevBJbcSOM8AHIB6bRXIfDvWrvVl1iK8u7e9WzuljhuIZUlDo0SPy6IikgsRwo9OcZPX0ARXdzBZ2s1zdzRwW0KGSWWVgqIoGSzE8AAc5Nc/4Htp5bW513UYZYdQ1hxcGGZSr20AGIICp5RlTDOmSBK8pHBrT8S6RD4g8O6po91JJHb6hayWsjx43KrqVJGcjODXnngTwT4O1bTruLV/CGntrthceRqj30IuXe5ZEld1lkLvIh80FWZs4IzigDt9X8ZeGNGvWs9Y8R6NYXagMYLq+iicA9CVZgea4nWPFHhfX/ij4Ci0LVtK1PUop7t3ezmSZkh+ySgguucAsU+UnnGcccd/oXhzRfD9vJBoek2GnQSvveO1gWMM2MZIA5OK0xGgOQqg+oFADqKKKACiiigDjPhlK6W3iLTbiCWG6sNdvhIHKkMJpjdRspUngxXEZ5wQcgjiuzrjPBtzEvjjx9YsWW6+3212EZCN0L2VvGrgkYILwyLx3Q12dABVHXNJsNd0m60zV7WK7sLpDHNDIMhh/QjqCOQQCOavUUAeU/YvEnwvJGg2cviHwNGcrpsW+XUrEH+GDJxLED0UncA3Bwteg+GPEGneJ9Fg1TR5xNay5HIw0bDhkdeqsDwQelatcD4s8ANPqR17wTeQ+HvE5J826SAPFeITllnj6P6huoPegDvqK4Twh49kvNQOieMNPHh7xEADHBLMGivVyFLwP3+fjZ94Ar613dABRUF/d29hZT3d7NHBawIZJZZGwqKBkkmvMZvE2s/EiU6d4JF1pnhqU4n8TfceVB99LVSMhySAJDwPmIGVFAHQeM/HsWj3yaL4esv8AhI/FcnK6RbXCRtEgAZpJ3ORCm1lwW+8WUAHJIq6J4Dk1C8tNb+IVxHrmtRqTFatGpsbBi27EEZGSw+UeY5ZjtGMdK6Lwd4X07wlpAsNMWRmZ2muLmdt811M3LyyueWdj1P0AwABW7QAUUUUAFcL8K5on/wCEthSVGmi8QXnmRhgWTLAjI7ZHIruq828fRy+Ddcj8badcypazywWutWTEMk8RIRZkBYYlTIHy/eHGOKAPQ7y2gvbSa1vIY57aZDHLFKoZXUjBUg8EEdq4OLwXrPhXafh/rOLBdo/sTWXee2Cjy1xDNzLDhUbAPmLluFFehUUAcD4Y+Jun6lrkfh7X7C98OeJnyFsL9Dsn29WgmA2SpkEA8E4OBXfVm+INC0vxFpsmn65YW19ZydYp4wwzggEZ6EZOCORXB6honi/wSY5/BV1Lr+jKSZtF1S4LyxIMYFtOcvnAICyFgM8YoA9Oork/CHjzSfEbrZMz6drqL+/0q8Hlzxt8wIAOPMAKN8y5GBnitnVdf0bSJki1XVtPsZXG5EublImYeoDEZHBoA85+FNl4tl+H2jvpmu6JbWRR/Kin0eWaRR5jcM4uVDH3Cj6V1n9neOf+hl8O/wDghm/+TKq/BRg/wt8PspDK0LEEHIILtg129AHB61Z/E2G0VtE1nwheXO8Ax3el3FsgXBydyzyHOccbfXnjmXR7n4kQ2KJrGkeEbu8BO6W21W5t0IzxhGtnI4/2vyrt6KAOV+3eOP8AoXvDf/g+n/8AkOj7d44/6F7w3/4Pp/8A5DrqqKAOSksfEmvFbbXlstI00fNKmk6jNLNc+i+b5UTRKOpKZZuBlQDu6TTbG10yxhs9Pgjt7WFdscUYwqirNFAHH6bjQ/iC2jWg26bqljNqKW68JbTRSxrKVHP+t+0IxAwA0bNgmRjUvxSgLeCNRvY38u40oDVIZFHzBoD5hVW6rvVWjJHQOeCMgx6uDb/FPw3dTfJbz6bfWMbno07PbyhPqY4JW9PkPtXX0AQWFx9rsbe427POjWTbnOMgHGanrhfhoZvDtjD4O1qRP7QsVcWkqqVS8tgx2uuSfnAIDr2Ptg13VABRRRQAUUUUAFFFFABRRRQAVyWrW1zJ8SdAnsYJYxFaXH225aMmOSA4CwhuQH83y3xwdqHnsetrmfCWrXWsav4kkllxZ2d99ggt9o+Ro1Bd9w5O7eOD02+9AEGlf8lW8S/9gfTP/R19XW1yPhgi+8d+MNRXKC3NppBjPOTFG0/mZ9CLwLj/AGCc84HXUAFFFFABRRRQAUUUUAFFFFAGb4j1aPQ9Ilv5YnmWN402IQCS7qg5JAHLDrVR/EltaWSXOrRy2atvOVUzqqLjc7PGGVFGeSxAFWfE2kLrujyWEkgjR5YpGLJvBCSK+0jI67cfjWD4u8EJrkP2e1ntLS0NrLbG2ls/NiUvj96iB1AkHPzEH2xzkA3D4j0pbm5ha7Cm2VmmlKMIk2ruYGTGzIU5IzkCrGk6tZaqkjWMrP5TBXR42jdCRkZVgCMggjjkciuUvPARvLm8Mmorb21zbyQSJaQtE0paPYGk/eFHK9QdgOQMkjIPQ6JpNxZ3t9fajdxXV9diNGaGEwxqiA7QFLMc5ZiTnv7UAas7SLBI0CLJKFJRGbaGbHAJwcD3wa5qHxla28y23iO1n0K5Y7VN5gwSH/YnXKH6EhueldRTJ4Y7iF4Z40licFXR1DKwPUEHqKAHghgCDkHoRXlz+JG8MeJPFEn2Xz0u/EMMcuX2mKAaVDI8oGPmwIH474IzxXTN4PGnEyeE9Qm0Vs5+zBfOs2PvCx+Uf9cylcTZXjv471fU/GGn3Al0i6gtBd6ZGZrQKto7ASpgyDI1CVidu0fKCflJYA6/T/HCXI1udrMmxsZkSCSOZB50bA/vCXKqqkgkHdggg98VctvG+jXOmTX8UsrW8VmL1yEziPe6EcHBIaNhxkccEiqsPh7QtcjTUtF1DEXnQzW8tg8TxxNFG0ahFKsuNjkYIOOCMEDDZfh9YPYvapqWpxpLBJbzsrRbp0eV5cMTGcYaR8bccHnNAFy88XWsV1c20ENwz2t5b2c0skLLCHllhQKHxgtiYEAenOKrWvjeJ9AOq3emXVvELiWAhpYlHyO67tzuo/g6dc8DPWtObw1Zyw3cbSXAW61GHU3wwyJYnidQOPu5hXI68nkcYpL4Mto5Ld7fUtRha2uJ54CvlN5XnMWkQbozwSepyw6BgMggCjxvpTm2eBLue2mitZjcJGPLjS4O2JmyQeT2AJHU4HNQ33jrT9M0s3+pIyWq3F1C8qOgVBDM8RJDsrMfkzhAx9M8Zks/A+m2umLYxz3hhW3srYFnXdttWzGfu9T/ABevbFV9Q+HunXdvewrfajbreRXcFwYmiJeO4lkldcsh24aV8bcHGM7sCgB1h/yV7Xf+wFp//pRe12FcVqcEcPxi0C5iDJNdaLfRTkMcSLFNbGMEdDtM0uD/ALZrtaACiua+IlxfW/hg/wBk3Zs72a9srZJwobYJbqKMnB4PDmuYt/FOtRate3WrK+nRPYxi3sJod+yYzLCDhcMxaRiB8wBXYeMk0AemUV5ZfeLdVkhaS4V7S5sRqMU0cZCCRo7ZZEYqGcA/MONzYI/CvTbKQy2UEjZy8asc+4oA5L4u+GrbxJ4D1iN9OW+1K2s7ibTsLmSO5ETeWYyOQ27GPfFZWufE+S3aCy0jwr4iu9Zu932a2uLJrdSBgNIzNxsVmTd6bhXpFcfrX/JVfCn/AGDNS/8AQ7SgDnLPwR4j8WXsF/8AEfUo/sKOJU8P2R/0fIO5RM3/AC0Kt+BwK9QhijgjWOCNI416KigAfhT6a7rGu52Cr0yTgUAOoppkQNguucgYz3PSnUAFFFFABXCfE0Nfap4N0eK3Ez3OsR3TFiNqx24Mjk569Bgetd3Xn91Imp/HCxtjdl00fSJLoQRsuEmlfy8uOvKdBx60AegUUUUAFFFFAGF4r8JaJ4qszb63YRXBAIjmHyyxHDDKOOVIDN+def8Agjwvcaf8S9Z07xNqA8SeTo9o9pc3sCmRYzPc5VuME7s4PptHavXa4yz/AOSyat/2ALL/ANKLqgDsIIo4IkigjSOJBtVEXAUegAp9FFABRRRQAUUUUAFFFFAHF/EG7t7DXfAtzeSrDbprTq0jnCqXsrpFye2WZR9SK7SqmrNYppV42rm2GnCF/tJudvleVtO/fu424znPGK8v8CeLjH4qaw06S+1DwRdTGx07VruQODeIGLQQMBulgCIQJGz80b/O2RQB6N4j0S312xEE7PDNGwlt7mI4kt5B0dD6/oRkHg1T8IavdXy32nauI11jTZBFPs4EyEZSZV6hXGfxVgM4zXQ1578RtUTwvqkGu6e8T6mtrItzaSFxG9opDPPIUBK+VjIYq2dzRqN0goA5zwfq01r8P7G/07WNLuNXksrFX/fvcSo0jwqzSoZDz8xzjbz6Vqa7f6jZ635Nxrb2kdtqFolxegCNCjW8v3wTtC7tox0zjvivTbZZUt4luJFknCASOibAzY5IXJwCe2T9akoA801LxDr0FjcXv22BLR9Ym08v5axCzhRpAJGkbcuSURMsu0bxx3rO1nxvqlnpNvKmp2RvYbZrolJ4vs94gmdFCHYWkfbGNwj2BSwOQCK9cooAKQkKCWIAHJJ7VV1XUbTSdPmvtQmWG1hGWcgk8nAAA5ZiSAFAJJIABJArDuNGh8Y6PCfE+m3FqPMd4raO9licIcgeZ5TL8xU8rlgM9TQBPN4z8ORaxb6U+s2f9oXG0RQq+4vuOFxjjkisWD4iQay0q+DNJvvEIiYBriECG2YbQTtmfCsw3L8o55Poa6rRNF0zQtOSw0awtrGyTpDbxhFzgDJA6ngcnk1i+Bz/AGXJqHhdxgaQUaz97GXd5A46bCkkOCSxEAY/fFAFmys9c1PRby18SzW1nPMdscujzSI6JgfxMMhs56cYq/4d0a18P6Pb6bYea0EIPzzOXkckklmY8kknrWlVDW9WtNF097y/kKxghFVVLPK5OFRFHLOx4CjkmgDnvAf/ACHvHv8A2HR/6Q2ldhXL+A9J1DT7fV77WCi3+sX76g9ugH+jKY440iJBIZgkSbiCRuLYyME9RQAUUUUAFFFFABRRRQAU2R0ijZ5GVEUZZmOAB6k06sDxxZw33h6WG4N2qCWKQNbW5uGDI6spMQB3rlRkYPH5gA2ra4huoRLbTRzRHo8bBlP4ipa8plfXjAix2rW2mveyGe6stOuLWS5/dJsd4UPnL8wZSw67FJAU1bZPELIZ2utVuJrWHTDCywyQrMzTETs0WOcpjcrD5c5wDQB6XRXlCy+LFGqS/aL9dS2XIe3FpMyEbvkaJ2/cghPuheWz8wJBxJ/aF1KNVtLE61LYLqUUImlF40tqhtVkJZFxOwLnpkfeHIFAHqAmiM5hEiecFDmPcNwUkgHHpkHn2p9cF8P49Wk1SK71mK689tHgheaeFoyzrPPwc/xbSpI68g960dT1rxZb6hPFYeEYby0RsRznVUjMi+u0ocfTNAHWV5v4d8WaDoya9qGtarbW+o6jq92xs0O+Zlt5TZoY4VzI2UtkZsA87zwOBmeLPHPjKNl0Sw8M29prN1GXV11SOY28QPzSEbAFJ6KWyC2OCAa53wdoj6FdRR2ngmx0yJwEmvV1KOeXCg4J+QFiSeTkfeJNAG9qPiHw9d6i2o2+h+JdG3kM2vWcUdupTtJLHv3uvtJESB1A612MN/4k0uFJbiC38R6awDJdafiK42nGGMROx/XKMM9lrJ/AH6iqOl6o3gmUkh5PC8hLSRKCzacx5LoOphPUr/D1HGRQB3eh+JNK1xpI7C6Buov9bayqYp4v9+JgGX8RWvXjXjpI/iprun6T4R1BYF0uI6hca1DCSYZWT/R7dX4ILeYXcDBAQDIJqh4e+IOu6fa6fZww6nres7St9otzZuJ7R0IEhW5AwyZ+7uDFhj5qAPdKK83k+LNlb3MFrqPhvxNY3kx2xxXFoieY3ohL4f8ACr1t4o8YXcQnt/AjJC7NsW61SOKXaCQCybTtJAzjJ60AS+No3tvGfgXU7eeSOY30+myIApWSCa3eVgcjIO+2iIII6Ec5rta811VfGniDWPDZk8OWWlQ6dqa3ss8uoi4BjEUsbKEVVO4iQ4OcA4zkV6VQBHcW8NzGI7mGOVA6yBZFDAMrBlbB7hgCD2IBqG806xvfM+2WdtcebH5L+bEr70znacjlc846VaooAzYdB0iGAww6VYRwnd+7S2QL8yhW4x3UAH1AxWiqhFCoAqgYAAwAKr3t/Z2AQ313b2wfhTNIE3fTJrkl+KfgxyfL1pZFDFd8dvM6kg44YJgj3BoA7auP1r/kqvhT/sGal/6HaVWtPiNBfQ/aNP8ADfii7tWZhHPHYAJIAxG5dzA4OOMgU3wXpGsanrbeLvFge1vXhe30/Slb5bC3cqTvI+9K+xCx6DAA6UAd3XMfEfTf7X8MCxa2e6im1CwEsSKWzELyEuTjsFDEnsATXT0UAeV2Ntr0eq3guLS5kuYdSsoftDwkpcRpGw87OMYIKliPusSO1VIL/X2tZYLCXVzqp0q3mvY7lJNyymdRO0StxnZ5m0R/KSBt5r1+qWm6Tp2liUaZYWlmJTuk+zwrHvPqcAZ60AcLpNvrN3PptsdS1dbBrqcu6280DJGIkKozTguRv3EMeTnaDgV6PRRQBBf3cFhY3F5eSCK2t42mlkPRUUEk/gAa5D4bRXV9JrHii6Aii16WOa1tzEyPHbom2MyAn77D5iBwMisnxc//AAnni5fB1q6PoenGO612RJiPNJ3bLT5fXAdwT02jvXpUcaRRpHEipGgCqqjAUDoAKAMfxXqVxpthbCyEYuru6itI5JQWSMu2CxAIzgZwMjJwMisrWLrXdGu9Cgju4tSa+1EwbZI1gJT7LcSEMwBAG6NWyFzgEc5rpdTsLXU7J7S+hE0DkEqSRgggqQRyCCAQRyCARVK28O6bbzW0oS4lmt5vtEUlxdyzMr+W8ecuxJGyRxg8fNnGeaAOcuPiDFDZWF2LLfHNHG9zEkrPLb7pDHnaqEbQwPzMyA4454qzbeJb2/8AEulRW0CRaRcS3kIkMm6SUw5Ukrt+UblOMMSR1Aq9J4K0F0CGzlVAioyJdTIrhXLqHAYB8MzEbs4zVu18NaVa6muoQW8iXKvJIv7+QojScuVjLbVLEknA5Jz1oA2K4yz/AOSyat/2ALL/ANKLqjxnqGq3HifQfDfh6/XT7i6Se+vLpVjkeK2iCoAI3BBLSSx8+ivVvw14WutL1691jVNcudXvbm2itA0sEUQSONnYACMAHmRuTQB1FFFNkdIo2eRlRFGWZjgAe5oAdRUVtcQ3UIltZo5oj0eNgyn8RTp5ooImknkSKNeruwUD8TQA+iiigAooooA878XWdr4u+I2l+GdRNxc6NY2L6rf2IQi3ml82NbZZ2xh1OJ2EecExgsCBit/xhoQufCD2miWqRXmnIs+lxQBYhHNEMxop4CKwHlnGPkdhkA1n+DhPe+PvHGpzGJY4pbXSYo0BzthiMxdjnqTdkYHQKK3PFOq3Gl2Vuun232nULycWtsjZ8tXKs26QjogCsT64A6kUAZQ8YJfaRpR0FYtQ1fU7cT28IJWNF6NLIeqRg8epPAya1dA0GPS4bh7iZ73UrzBvLyQYaYjOFAH3EXJCoOBk9SWY8f4Ght/B/izUtC1SSJ9S1eQ6jDfeVsN2T99CQNqlG4VOu3nnmvSaAOT8G/8AEjvbjwlI37iwhjl0ot1aywECE8bmidShIHCNAWJZyTej12e+11rHR7JLqztnMd9eyTGNIn/55xgK3muP4h8oXON24FQvi/SrjULCK50zYNZ05zdWBc4RpQjLsf8A2HDMp9M5HIBFb4brZJ4Qs0sHlkZGdbp51CzNchyJjKB/y08zdu980ANi/wCEzXxsyzHQJPCRQlWRJkvVbHCnLFCM9+MjsKki8c+G5P7ZUatAs2jLLJfwSBkmgSIAu5jIDlACMMAQcjBNdJWZqmg6Tq0sEmpada3MkEy3EbSRglZF+62fUUAUodOi1rWbHXpZ3nsEtY5LC0mgaPyJW37pirYO8oyKAy5QBsY3sK6Cio7iaK2hea4lSKFBlndgqqPUk9KAJK5fx34jvPDraAbHTpdSN/qP2OS3hC+ayfZ5pMx73RQQYl+8cY3d8VWufiBpc13Pp/hsPr2qxtsaCy5jjbAwZJfuquSoJG4jcOKt+GNH1Bpota8VNby680PliK3yYLJTjckWeckgFnPLYA+6AAAUB4l8WX100el+CJLeGNAzSazqUVsWYn7qCET545JJWremaRqeqazaaz4pitLaew3/AGGys52mSJmUq8rSlELsVJULtCqCfvHBXqqKACiiigAooooAKKKKACiiigAoornfFV3OmoaHp8d09nBf3Lxy3CYDHbGzCNSRgFiOvXCnGDggA6KiuAj8RXNvFNp2mHUG1VLx4vsupRxzyKFhikIDJKq7cSodzSEguRzwBBH461O806DULO0so4DZ6bdPFKWLMbttu0MMBdvXODnpgdaAPQriCK5t5YLmJJoJVKSRyKGV1IwQQeCCO1RafYWem2wt9OtLe0gBLCOCMRrk9TgcVwz61rl5r9jYw3NpDd293dWsr+W/kShYUkVjHvz/ABgY3dcn2qOz8a3d8kckCeVdX1tYva25jM4aSVJpGVBlM/LETuZgMDPHQgHo1FYXhbVbrXvC0N8Y47W9kEsZDDeiSI7JkgNyMrnAb23d6yo/DXie6uJptU8c3kRbaI4dI0+3t4kAHORMs7Ek853Ae1AGb4p8MyaPrWoeJ9Dtpbo3wj/tWzjBeWQRghJYR3ZQxBjH3h0+YANVttQs7q3iuLe7glglQPG6SAhlIyCD6EUvxA8GXTeBvENw+u+J9Y1SDT7hrFRdeQySCNiAI7VYhISQvDh+mBjJz4L4e8GeDY1nvVudUljvNkkQs/C80luse0Y2faIJ255YsHwcjjAFAH0Ak0TttSVGPoGBqQEg5HWvH7LQPh9p8v2u10fxGNQCndNa6fqNtJKccgCJERc9MKFX2FdR4c+IekalpENwun+IbWMZjRJtKuZmIX5c741cHkEfezkHNAF7wfAmi+IvFGl2peFZ7pNXAikYL+/QRsDz97fbux7Ydceldcbi4KgG5uSB285v8a831Pxbo7+OPCphmuoL24eex2X9lPaq0ToHJUyooL+ZFAowT98jBJBHoiqWYKoLMegHNAEV7Cl/ayW17uubeQYeKZi6sPcHg1if2LfacAfDmr3VnGvSzuHea3+gBYMn/AWwPQ1f0nW9M1iW8j0q9gvDZsqTtA29EZgSF3DgnAOQDx3xWhQBg/8ACUXWn/L4it7ywUdbqKZ5rY+5ccp/wNVHua3be9+0wJNbXsk0LjKyRzllYeoIPNLXEeOLS18PaRcatoyXFnqskiQ28VkSq3M7nCq8YVlOeSSVzgHkUAdnf6kmn2kt1fX729vEpd5JJyqqAMkkk1x58Za14gV4/A1lNcQHco1e/meK0U/vFyn8U2GQfdBHPJFZp0G/guobnxvZt4qELF4pYgkkVsSCDi12qGHPDHzG4BG3mu50zWLHWEaWxu47gg/OM/Oh9GU/Mp9iAaAOF+InhGO78I32oayb3xFrNsI50km3P5IEqNIIYVOFTaGO07jjjJFd/omp213pNrcaDdY0uRA1uLZykYTsFVeBj07VZUlWBUkEcgjtXnuqyR/D7xAdSgtph4X1NidQSBWdLGfr9oCAfLGw4fB64OOxAPRTPOxybi4J9TK3+NIZ5VUlricAckmVuP1qKKRJoUmhdZIXUMkiEMrKRkEEcEEcg1yvjpJtZFv4YsZvKe//AHt7IAx8u0VhuXKkFWkPyLnggS91oA6uK8MpxFeSOQM/LOT/AFqTzZv+e8//AH9b/GuUm8A+GS++z0xdNk8ryt+mTSWRK9Ru8pl3kHnLZqOHw9r+nvF/ZfiyeaJYvKaPVrOO5HGNrKYjEQcAg7i2c560Adf5s3/Pef8A7+t/jR5s3/Pef/v63+Nct/aXiaxz9v0KDUIl+RX0y6HmyHs5jlCKinHIEjEEgfMMkVP+Ej8R6jmPRvCdxbODKjzavcxwRoy8DaIzIz5OewBA4bnNAHaebN/z3n/7+t/jXL+PvGVv4Y0G/lfWIoNUFrNJZwz3BzLKqZVQueeSvHvVX/hF9W1Ng/iTxHcyRlo2NnpSfY4flHzKXy0pye6unHb03NG0DStFkMum2MMV0y7HuyN9xIuc4eZsu46feY9B6CgDnvAl5/wjljb6LrM01rqt5M9x9pecFdUnclpJUZcZJOflbDqu3IwRXb+bN/z3n/7+t/jXmXia9Twr4f1Dw1cRs9ldxrBovyGQJGTHGVc4ODA7hlLYBXyxvL5I9C06yXTbC2skkklFvGI/MkdnZyOrEsSSScnkmgC35s3/AD3n/wC/rf40ebN/z3n/AO/rf40yigB/mzf895/+/rf40ebN/wA95/8Av63+NMqK7LrazNDnzAjFcDJzjjigCP4TKNU8T+MtekuUuilzFo8DBc7I4IxIwD9STJO4I9Yx6V6bXnnwOvLJPhZoP+mM1w6SSXf2n924umldpwVIXGJTIOnbv1ru/t1p/wA/UH/fwUAWKwPHFnDfeHpYbk3aoJYpA1rbm4YMkispMQB3rlRkYPH51r/brT/n6g/7+Cj7daf8/UH/AH8FAHA6Pe6pY31tPPYyrprXsyyzWWlywNdZgTbJJBhnXDKU3Hg7QeARWLqCa5qHhiwi1mHWpLp9H094o4opsNc5zcecEGNwwnEnA7c5x6x9utP+fqD/AL+Cj7daf8/UH/fwUAecXl34gPia4ktItUgUtewvB5NxIm1YnMMgdj5Q3MqEBFyN2Cc5FdD4Mi1K31S5ivXv5Ld9NsrjfdFm/wBJYziYAnocLFlBgLkcDNdN9utP+fqD/v4KPt1p/wA/UH/fwUAWKZNIkMTyyHbGilmPXAHJqL7daf8AP1B/38Fcd8V/FiaH4PuF0wwXes6ifsGn2wdT5s8nCggsvAzknPAoA8/+F/jm7/4Ry4Phvwtf3j399dXkmpXkgtoJGknlEb5c75AsaxA7FOAMdRg9jaeOfEGnf8jH4dW6h+811ocpnEa9MGF9srNnH3Fbg57HFDwtay2HhfRbK4UrNbWFvA6kglWSJVIyOOCO1adAGpDr3hTxzaXGlLfQy3CgPLZyMYbq2YHhijYeN1OOwINOsNU1TQby30/xQ0M1lM4t7TVYyRvc8Kk64AR2zgEZViMcFlWuT1/w5pHiCILq+n21zIqbIp2jXzoec5jcjKHPPH45ro/Burf23Z6h4b8TrFdX9upjcTIANQtSABNs+7g5Ksozg9cbgKAO3rjNHc2HxS1zTLfi0urCDVHU/wAMzO8TbewBESkjuxJ71n6jr9p8OvEOhaPf3VzNo2uTNbWbXE5nntbn5cIS7GWWJy33ju8tuC210CWNWTVtL+JM2s2nh/UNWsZ9Jhs91lLbKySJNK5DCaWPjDjkZoA7ukJCgliABySe1cfZ+NZtUgWPR/DeuNqR4e31C1ayjtznGZJnG0rn/nl5pxyFIpLvwfceJLeWPxrqUt1azKVOmafI9rbKCMYZ1IllOCykllRgQfLBFAFvWPGVnaX0mm6Vb3Gt6wmN9lYAMYsgMPNckJEGXJUuVDYIBzWe3g+68RjzPHN59rt3IYaPb/LapyCFkP3pSpHX5Qe6mus0rTbHSLGOy0mytrGyjzst7aJYo0ySThVAAyST9TVugCtp9hZ6bb+Rp1pb2kGS3lwRiNcnqcAYqzRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUF7aW19bPb31vDc27/eimQOp+oPFT1h+N5byHwtqEmnGYTqgy0AJkWPcPMKAc7gm4jHOQMc0AWP+Ed0T7LHa/2Ppv2aOTzki+ypsV8Y3BcYBxxnrU0ekabHAIY9Ps0hCRxhFgULtjOY1xjop+6O3bFeez6/YaVc3jeHBZvFFDFK93b6g1woj8+JXM6HhX2s53Ek4VjnrV1/FE19fWslrcQz2y67NawyRHKtGumyyjkHDfOO+R+QNAHY3ug6Pfgi+0nT7nMhlPnWyPlyApbkdSABn0Ap93oul3kbpd6bZTo4QMssCsGCZ2Agjnbk49MnFecN4r1+10uKR7pZ2utP0+9eZ40jW0EzushBC4CgKMFw205JyOKi1rxpqdpoKtHq1l9tihuriKdLiEwXIjI2IzeWd8nOCkYXPqvFAHqtnaW9jbLb2UEVvAmSscSBFGTk4A45JJ/Gpqx9R8RabpNjaXGq3KW5uVBjjCs7ucAkKqgs2M9hWY3ijUL1SNC8M6rcZ+7NeqtlF7ZEh8z8koA6uvn/AOJt1e+Hk1uP4f6rbz7Glv7u3isvtUlh+8L3LiQsIwB8zeU4Z8vgYXbt9JXwhf6+m/x1qAvI2wf7Lsi0doh44Y8NLghWBbGDnFdVpulWGmWC2VhaQW9oF2+UiAKRgDn14AGTQB876N4q8Q3emXukWckOua/Kf3V5bFPs9jDL9xp5Y9qmQKdwWNQemTmvQPDmkxaFoVjpcDtIlrEEMjEkyNnLOSecsxY/jVDV7LT/AIZ38sMNuLXwzfu09uYoixjumJLQgLyQw5XPTlRgCrOivqt1NJeaki2du67YbHALoM/ekb+9/sjgepPQAs63pNjrml3GnatbR3NncJskjcdR7HqCCAQRyCARXPWPgS0ERi17UNR8QQgKqQ6nL5kKhV2g+UMIWx/GQWyTzzXRalq+naXJbR6jfW9tLdSrDBHI+Gkdvuqo6nOKu0AcZqluNA8eaNqlraRix1KJdGufKj+ZHLZgY8jjI2dDgV2dc/4/0f8At3whqdlGUW5Mfm28jZxHMnzI3HOQRXOeHLjxh408NafqUmtaZo1te2hZm06AzzM5+Ukl8KhGG+70bjtQB6HXIy3EmufEKOzgKPpegJ5t1kbg95IP3a8HGY1+bkZBYikm8PeIdMuhdeHNfub7p5mna1IZkmwG+7KBujJJUcDHHJqH4Rzx3fhMXr3ME+p3txNd36xoEaKdnO5Co7KeBmgDr7y6t7K2e4vbiG2t0xulmkCIuTgZY4A5wKyRrvhgXRuRrGhC5K7DL9sh3lfTO7OPasvx5DbSav4Rk1K0a509NUCSAx70WR4nSEsOmPNaPk8ZxS+KJbPSp7aG00PRHMg3SSXMaRoi70TPCHPMgye340AWx468KHVX00eItL+1onmMPPAQLgH/AFn3M8jjdmoPEfiq3R7XStFtk13VdRj3xWsM4WNYDkGaSUAhY/TqW6D1GHfLHNqngLVotH0r7NcXE9jcIkaFUaZAVZeBu/1Tc47+9X/COn6d4f8AH/iXS7CwFit3bWt7AEjwjooZJCrezsuVHHtQBmaL8LLY+HrSPX9Qv7nWYYttvcJdyldNOVZVtdzHYE2IA3U4IPBxWp8LdPnSz1PVtVulv9YvbuSOe9WJI1mjhYwxFAoxsKoGHXO8nvmut1bULfSdLvNQvWZbW0heeVlXcQigk4HfgVQ8FWFxpfg7Q9PvQq3NrZQwShWDAMqAHBHBHFAGzRVG81azs9TsbC4kKXN6HMI2kg7Nu7J6D7y9euaba6xZXMIljl2wmMy73G1QoYqSSenINAGhRVNtU09bRbpr61FqxCrMZl2E+gbOM0671C1tUdppkyiliinLEAZ4HU8UAWqUAk4HWq0V9aS3clrFdQPdRjLwrIC6j3XqOtc98R5p20CPSrKSaO71m4j05Hhi3siOczMOw2wrK2e22gDnPE9w3jTxLa2PhUQX0dpaX1vd3cisIIZJAgi8uTo0iywq2RuAxnOenc+GNQTVvDmmX0TSMs1uh3SfeYgYJPJ6kE1asLW00jTYLW0SK0srZAqKuESMdPwrkfhTcW0tjr8OmQbdJh1i5+xzIT5UsbNn93n+FTkemTQB29FFFABRRXMeMfFsGgvb2Fsq3Wt3mRa2nJLf7TBecZ4wOSeBzQBV8KqdF8X67oBlJtJwNWsUcOSokZhOgYkjasgV8DGDNXY15hd6Vqug6npPi/XLyS41SS8S0voobgJbWtrP+7WFAeGCzNCxbqcE+9enggjI6UAFFFFABRRRQAUUUUAQaheW+nafdX17IIrW1iaaVyQNqqMnqQM9hz1xXHeB4b3xBfv4v1YvFb3aD+zNNdi4tIsY80g8LK467ccHHNJ4/wBMj8Q+KPCeiXd1KmnO1zfXFvGw/fmERGNWH93LHse9dfqmoQ6baG5ut/lh44gI0LEs7hFAA9WYCgC1RWbHrdkbi2gmd7a4ud3kxXCGNn27c4z/ALw+vajS9b0/U7IXNtcxbBGJXVnUNEpGRvGfl49aANKsPxS76VaSeI7GaO11PS4JJY5pCRG8YG54pcAkxttGRjIIDDBANaJ1KxW0W7a9that0mMq7D9GzimXOoWCrMl3LCsCxJI7zECIq5YDk8HO08fT1oA8wuNX1fxBaazr97pJFv4mjgtV1fTJEv3srKby4005Ed1EUzM+WYZG6TJXoV+jvD+r6drFiJdJu47iOPEbqD88TYB2SL1RgCMqQCPSvD/F3gOx1ez/ALW8JiCz12KSO8tJYpdltNKjIymRB8jcRgA8AZya6nwdqS+PvC0PijwnPHpHiiIGHUII4wUkmXloZVPBy3R+oDZ7mgD1qiuCtm+IWtxMLiPSfDETNwyN9tuEAA7Y8sgnPfIHvVj/AIV3p16v/FRX+qa2D87Q3l0xgEnd0jGNvVgADgBiKAL2r+PPDOkzSQ3WrRPNEzJLHao9y0JXqJBEGKf8Cx0Poa5+5+IeqXYKaB4Svy3UzarKlrFt7Mm0uX9duF4711Mun6f4e0Z00mzt7PKLCpiiGSBwMnqcDPJNczQBp/DXxBqetW2sW+vvYtqWnXzW7GzjaJHj2KyOEZmYA7mAOedprsa8w+Hb3P8Aws3xYPJLWbWNiDPvBCyKZvkx1zhs+2B6ivT6ACis/V9XttLFuJhLLPcP5cEEKF5JGwScDsAASScAdzTYtbsTbQS3cv2BppDEkV7+5dnz90Bup9MZB7ZoA0qKqNqdgt59ka9tRdbS3kmVd+ByTtznAqvpmv6VqenWl9ZahbyWt0iyQvvC7gduODgg/OvBGQWANAGnRWRceJNKisp7qG8hu44Jo4JRbSLIUd3CKCAeOW7+9a9ABRRRQAUUUUAFFFFAHGaf4+tLqxlunsbiGJdOl1NS0sRBijxkMQ3yN8wxuxnnng1tS+JtIilu0kvNotAxmkMb+WpXG5Q+NpYZAKgk54xXJRfDVv7Fl0+XUbNP+JZcabHNbWHlO3nJtLynzD5mOuPl55rUuvBkk+q6hdi8s0huklVrYWjGKUuRzMnm7ZCMdQqMc9euQDZm8TaZBZLdyvdJASwYmzm3R7eWLrsygA5ywAqyus6czMq3kTFZ0tjg5/esiuq/Uq6n6EVx9z8Pri405bSbWI7iPE6tDdWzzwIJNuDGjSkhk2naWZ8bmwBwBbtvBVxbXcJj1SP7Gt3b30kRtTvaWKCOHh9+ApWNTjaSDnk9KAO1ooooAKwPEPiNNOuY9P0+3bUtbmXdFZRMFwvTzJG6Rxj+8evQAniqN9r17rV5NpnhHYfKYx3erSLugtj3SMf8tZR6D5V/iOflOhp9hpHhDSrm4nuY4IyfNvNQvpgGlbpvkkbA7gDoBwAAOKAKFn4PhvfOu/Fxh1jUriNomDJ+4t0Ycxwofuj1Y/M3c9APPdX03XdP8Vjw3FrgtdLW0N1BctD5l5LEHVWUOTtUx7lHmMCTuX5Wwxr0A+MJtVZk8G6W2sKvW9mlNrZH2WXazSZHIZEZD/eFcT8R/BGv6zJZavqW7Wsq1lf6TpzC1X7HJhiI2Y73dXVC2ZFDquNq5IoAz9Q+HegXmmahELctqF5CF/tOd2muEkGSsqsWG0hzvwm1SeMY4rQ8Favcajoca6vELTWLQ/Z763JA2SgckAE/KwwynPKkEcVKmvaRb+Gp9SsSTp1gpi8iGExOjKAFhEThSrnKqqEAncuOCK5rW/B1pqeka/reu6TYXevXdhII0+zrJ9n2xN5aISuWccZc8k9NqhVAB6BnbznGOc+lcr8OPOg0nUtOuREZNO1S6g8yNiwkDsJw3IGDicAj1WuY8Q+IrLWfBWneHLKS7jvNTNnpkxudMuUWNX2q53OiqSMcDdz716NpmmafpNu1vpNha2FszmTybaJY03HqcKAM8D8hQBbrmLrwF4audUu9Sk010v7tzJcTw3k8LSMeSTscflXT0UAeW+L/AAhpGjax4d1Gzv8AVIZm1iwiisZNQeWCQ+eu47JCzFgu4/e4xnFdd4sa9M9tDE+pJZSRyeb9gt4pWLZXAbzFYbSC3QdqPEf/ACNng7/r8uP/AEjnqh8QLe1mmszdvHK6IXitZEkdXYPGSSEViAVBUtg43DryCAJ41spbr4cSvDHdTXlisd9CZisEytEwZm+XaobZvGMAc9KtXVyjeNPDOqQAmLV7Ga0VGGDGu0XIb3Pyhce+c9qv6Bp8U/hCDTpWCwz2zQMUVk2q4IIAcA8A4yRzjJFcFok/2jwF4SupnvUvdB1qKxuJ7h2Ro0EuyUuc/cMbKCW4wegoA7T4h4k8JXlk3C6k0WmF/wDnmLiRYd+O+3zN2OM4xkda6NF2oq9cDFefXF/danr0WnX0nmWsfig24j2hcJDYrdRjIGeJlDZ6nGDkcV6FQBha9oj6pqdvOJFjjitJ4Q4++krSQPG6jp8piJ+uOvNc7J4b1C00u1luXt5JbWGLzI4VkkWR1uRKVwqlipHGcEjrg4rv6KAOAtdC1HUFTUfJWGQ3N0/2WSaSAMkpT5t2zcD8h4KDIY9KuN4Qb+ztUijis0nuLKG1t2Zi5jCR7SC5Xdj36nvXZ0UAcpb6FqZ8SW1/dywvFBcTyBhcPkxurBUEW0KCMqC2STjOe1QWwGu/Eq5nZney8PQLDCvluqfa5gTId2cMyRbBjBwJj0rpdb1CHSNGvtRunEcFrC8zuVLAADPQc/lWN8N9LfS/B9j9phjiv7zdf3YSIx4mmYyMpBJOV3BOTnCD6UAZPxZsoGttH1XUovtWi6fdAajaM5VGhkKgSN8yhtjqnyncCGYkYFdxaxwRW0UdmkMdsqjylhULGF6jaBwB6YqPUbdbvTru2khS4jnheJoXcosgZSCpYcqCDjI6V5h8OfHqQ6C2jXllrV9q2mXX2BYobNmklj/5Zuzs2xcL1LOvABAxQB6vWb4j1ZND0ebUJIJbgRvFGIoioZ2kkWNQCxA+846kCsddd8SXdxINP8JmGBAvzapqCW7uTnO1YllGBgclgeelU5PD/iTXBpS+KNR0r7Jbzx3c9rp9tNGZHQEqhcyncgcq3K8lF6dKAJ4NS8bXv2sxeHdK09Fdlg/tDUyXcdmKwpIB7jd247GtDwh4cTQYZ7m5na+1y9w19fuMNIf7ij+GNegUfU89N+igDM8TaRFr/h3UtJuCqx3tu8G9ow/llgQHCnqVOCOnIHSsbwX4n+3xwaRrUMmn+JYIM3FpLEYw+0lWkiJ+WRCRwVJ6jNdZWX4g8P6V4htUg1iyiuVjbdE5yskTZByjjDIflHKkHigDUorj9I1O/wBH8U/8I/4hvUuobxTLpV7IuySUg4Nu+AFaQDkHgsOoJNdhQAUUUUAFFFFAHnd9/wAnB6R/2Lsv/o5663xXpsuraMbW3WF3+0W82yZyqOscySMpIBIyFI6HrWD4/hk03WvDvim3U7dPnNpfeXErSSW05C4ySOFfbwOfnJHfPbMCrEHqDigDmIdFuI9Q0u7jsdPgFs0qyQpOzDa+z51YoPmGz7uB9RWcvhG7XT9OhV7QPa2ixOuTtkkWeKXB+X7h8tgT1+boa7eigDirnS9St9UsbpLO2muJtRlunhEjeTCDbeXy+wkZK5zt5ZjSQeF9Ts41FpcwHFtaQMokaLd5bzs6qwUlF/ertIycKRx1rtqKAMjwpps2k6KtpclDIJ55fkkaQBXmd1G5hkkBgCT3rmtS0rxT4b8d3fivwMLK5hvIFGoaRczGIXco+XehC7VbGCWZuTu9a7yigDO0f4zabBstvHmm33hW/Mot991Gz2krnP8Aq7hQUIA5JJA5716Xpeo2WrWMV7pd5b3tnLny57eQSRvgkHDAkHkEfhXCsAylWAKkYIPcV5z4u0Hw34Os5/EekJPoWrRokNsdHlNu9zIHDpAI1DJJvZQCGRgRyRgcAHsniu43TxW6nhBubB7npkfT+dcprWpQ6RpV1f3HMcCbtvPzHOFXj1JAz2zmsrwE/imbw5BN46uoLjWpfncxxKhRT0V9uFLAcfKAPr1OvoNh/wAJL4tJmBbSNDlSQFePNvhyMMM5WNTyAQQ+QwIoA6r4faHLoXhyNL7nVLt2vL5uMmZ8ZHBIO0BUyOCEB710tFFAGF4g0y9m1TS9U0v7M91ZebGYbhyiSRyAbhuCsVIKqQdp6Ed8jnvEfhbVtbvBeXcVnJ51m9lNZJfywoqFiciQRktuBwwKjouDxW7481SXSvDshtHlS9upEtIGiiMro0jBS6oASxRdz4wfu9DXIW2t6rqy+GEN06NFHdtfowkt3lltmRMkAqyhslgp4+YZB6UAbkHhO5j1Fbkta/8AIZGoMcsWMX2Xyducctknjpg9e1VvDvgy5s/+EYXUYNMYaJpk1ijrmTdIfswSYBkG04hfPORuABOSRUuPGeq2mmaLqV9bWqvf2clzHBDM3lKG+zhPMYrngykkjoM9aveKfEusaDaSKpsb7ULa3mvZooLZlDQoF5JaUCPqRnLnoQp5FAGZB4J12Rnlvp7RrhoLWGST7XLKJWiuElZwpQLGCA2EUYBP416bXFL4qv31qRVhtRp0epw6cVIYyt5ttHMH3ZwMGQDGDkdx37WgAooooAKKKKACiiigAqC3u7a5eRLe4hleM4dY3DFD6HHSs3xlbXl54V1S30zcbuSBlRUfYz+qhuxIyAeME9RXGajcXgluD4b0dreCHTnMbppEttcW5WSD9yrNxJuHmHai/wDLMDnjIB6WWClQSAWOBnuev9KWvPJLvVr/AFcXENvqH2RNdfyPOtHQpB/ZLfMAygqvnkjPHzHHfFZ+3xRbaMRbPqsks+m6fPctMJHdJDKwudg6hvL6omCMDaNxGQD0+4mjt4JJ53WOGNS7uxwFUDJJrj/+Jl40PP2nSvDB7fNFdX4/Rooj+DsP7o68rrE/iBNFeG0l1iSRI7ma0uUs73cHATZCUyGY5zh5iVxxhsGvWbRne1haYESMilgRjBxzxQA2xtLews4bSygjt7aFQkcUShVQDsAOlcglpb+NPEVzcX0S3Og6VIbe2ikGY7i6VgZJSOhCFQi/7Qk9q0/GupXMFrbaXpMmzWNVc29u+M+SoGZJvoi5PuxUd619H0620jS7XT7FNltbRiOME5OAOpPcnqT3NAFqNFjQJGoVFGAqjAAp1FFAHI+MPAmmeIrqPUoglh4ggx5GqRwo8kYGRgqwKuMM3DA4OCOQCOC1zXNV0YNpV1YxR+IXcRW0kvy2NwSf9YG3bgu3kqeQxCgtya9e1nU7XR9Olvb+QpDHgYVSzOxOFRFHLMxIAUckkAcmub0jwtFq+n3F94ysYLrUtUiQXNtKqulsi7ikCHvsLt8/UszHjIAAPPfHtrqrnQLy0sZtTh0y6N3d2VtceS0zqn7sqD97a/zBT1rW8NeJtK8SJcf2XNIZrVtlzbTRGOa3YlgFdT0J2noTVnVdM1XweWklN5rehH5Y2htzJc2YH3Q4XJlT1fGRgZGMmsLw9JbyePPE9zbPC0E9hpswmixtkB+1YfI68Ac+goA62iuJ/wCEg0yTU21zVdUtbTSLVza2PmzBRLIch5TzznBVfYMf4hVz/hPvD81zDbaXdSavdyhiLfS4WupAqgZYqgJA5HNABrUklz8QfDFnDDkWsd1qM0pcDCeUYAoXud06nr0BqvrMM0uo3t3Z3OrG4t5ks1igliRcusbnG5DgDKnJJ79KoXniGGz8Z2utanpmu6bpSafJYyXd9pk0EUcsk8JTczKMLhT8x46etaGs3OnSTwzaVrF6L/U0Bgs9NeN3viFGCqurY+UrlxtwoyThcgA6Hw/MbnR7SQtM7lcN5xBfcDgglQASCCMgV4n4wnmv/EWs6BoL3OsvdXd3LBBaR5zLLaETLv4VgjqmeSRnpXt2i+BNY1Gzhh1q7bRdKRAqadYS7p2Xjiac55wWVgmQeoatXW9Os9K8YfD+0021htbaO6u9scSBVH+iSc8d/egDyLw7eardeOdZ1KXwr4he1jv7iWS2S3SRra6e3swufnHzBBMN392Qf3jjsZfGen2d01vrVlq+jzeWJUW+sX/eKSRlfL39Cp4OO1dx4UH2Hx54y01fnWdrXVzIeCGmjaApj0Aswc/7ZHbnsaAPM9NvrXU7C3vrCZZ7S4QSRSrnDqe4zVistrMeFvE8mhL8mlXKG40sE8Jj/WwAnqQfmA7Ka02YKpZiAoGSScAUAMuZ4bW2mubmRYreFGllkboiKMsx9gATXCeHoPFHiHSpdcj8R3OkjUi09rYm0gnSCLpECWXIO0AsO5JPWofGGvaX4o1TTfB+m6lazfbLlhqQjlUlIYfmaEjcDudgFwMnaJDjivRFUIiqvRQAPoKAOC1fRPFeuSaVpmvJ4eu9GWeG5vZoFlRm8pg2zYzEHeRg4GBk135JJyetJRQA6NS7qo6scVy3w6CzeH5tSQbU1a9n1BUJyyB3OEY9yMHmrfjm5+yeD9XcF1aSA26OhwUeUiJXz6Kzhj7A1qabaix061tFWNfIiSM+WMKSAASPqeaALFFFKAScDrQAlFcRL8RLO1v4v7R02+tNEmkZINccK1nJhiqsXH3VbHylsZHPQ5rs7eeK5gSa3kSWJwGV0IIIPcEUASVmahPrSXJGnWGnTwYGHnvnibPf5RCw/WtOqV9q2n2FnLd3t7bQW0Qy8ryAKozjk/U4oA5fxbpOu+JdCuNOutJ0ZGcBoZ/7SkZoJBysi/6P1Bp2h+IPE13LPp1/pejjWbML9oDag8XnqRxOiCFsIxB78FTwOBVxfHOi3BB0przWI/45NKtJLtYj6OYwQp74Paua1qfxNqOo6f4g8NeFb+01CANCft09vEt1bFhujlQsJF5QMpxkHtzmgDsPtXiX/oEaN/4NJf8A5Ho+1eJf+gRo3/g0l/8Akesrw38QdJ1e9Om3iXGj6yuA2n6inlS8gsMZ4b5QG47EV2IIIyOlAGH9q8S/9AjRv/BpL/8AI9H2rxL/ANAjRv8AwaS//I9blFAHHeKtP1/xF4b1LR7nSdJEV5C0WV1WQFW6qebcDhgDgkZx1qp4D8ReIdc8LWtxHo+mBrctYy+bfyRN5kWEb5fJbH/fRrvK4iSWPwt8R/nlSPS/FALYZgPLvoxyeST+8X0AG4CgDb+1eJf+gRo3/g0l/wDkej7V4l/6BGjf+DSX/wCR63FIZQVIIPII70UAYf2rxL/0CNG/8Gkv/wAj0favEv8A0CNG/wDBpL/8j1uUUAYf2rxL/wBAjRv/AAaS/wDyPR9q8S/9AjRv/BpL/wDI9blYnibxXovhmyNzrN/FAvOxM7nkIxkKo5JGRxQBT1bWta0jTLjUNSsNDtrO3TfJK+qygAf+A/JPQDvXLeGLTxNrmpp4r1nSLCSVl/4llrdXrwiyiPVggif53GCXJBxxhRxWvpdo/jPXv7Z1i0vYtC091/sqxvIfKE8uMtcyRn5iBkbAwx35rumJZiWJJPJJ70Actq2s+I9NsjcNo+kPIXSKKNdSkdnkdgqgL5AzyQSMjgE5GM11/hLT/Fnh7Qrewj0bQ55BmSe4k1mUPPKxy8j4tOWJ+tUfDNp/b3jVp3ydP0A4HpJeyIDn/tnE4wRwTOw6rXpdAHNfbPGP/QC8P/8Ag6m/+RKtaZc+I5LxF1TStItrXB3SW2pyTODjjCNboDz/ALQ/GtuigDnpPEOjT61HZTpIbm3u/s8U0lsxjS4MedqyYwGKORnIyGI74q3GdDa+vGjOmG8gLG5K+WZI9wUEv3GQig56hR6Cudbwfdx69PrEE8b3H9qfa0tpZ5DA8RiSM5TBCyjDFWAPYE88c9qfgnUdP8MatGYFv5orC6gt5Uu5ZJJvMYNjyNmAWIBOGbkcDngA9Etl0O+t4BbLptzAiPawiMI6quAGjXHAGFGVHYe1YssPgxb+DR59O0VcRLNbrJbwiNvNYriPPViY+QBzgVU/4RvWF1pNbji01LwXonNktw4i2C2MOfM8vJfkH7mMADtmsz/hBtYGkjT/APiWOtxokekzzmZw0DBnLSRjyzuxvBGSvKigDrrG70W6vJoYrOJZUupC7NAoHmwqil8+oUoATzgY6CtawvrTUYPP0+6guoMlfMgkDrkdRkcZrhdW8D6hfyX225tY0uDfFclm/wBd5JQMMcj92wYZ6HjNdrpC3YgkN/aWdpMz52WkplUjaACWKJzxjp0AoAvUUUUAFFFFABRRRQAUUUUAFV9QvbbTrSS6vp44LePG6RzgDJAA+pJAA7k1YrH8W2Qv9FeFrO6uyJI5FS1mWKZWVgyujMygEEA8kA4x7UAT2GtadfojWt3G++Y24XlW8wIXKFTyG2jdg9ua0a88k0vxXd21oonuo2j1CZ4Zbt4fPhhNjNGrS+V8jYndcBcnG0nkHGbp3hPU/wCzhbtaanbmWey+1RtPDGjhJcyurRPuLFSdzNhmAXqegB6BbaMkfiO81iaZpp5YUtoVK4EEQ5ZV92bknvhR/DWrXnl54Xu4U8Ry2mn/AGhpbuCK0ilm8xfsYgtkk2Ru4TdlJOHxkqM5GM7nw80690rRbi2v4p4VF3K9vHM0RZImOVGIvkXqflXgUAdClzA93LarKhuYkSV4wfmVGLBWI9CUcD/dNQWmqWV3dG3trhJZhEJtq5PyFmUHPTqrD8KxJEv7Hx1f30elXV3Z3en2dus0EkICPHLclgwd1PSVDwD3ri7jwtrckDrLpU01/JpYtra98+I/YrgTzMspJfd8odGyoJ4I9RQB6ndWNtdz2c1xEsktnKZ4GOf3blHjLD/gMjj/AIFUpniFytuZF89kMgTPJUEAn6ZI/OvNv+Ea1ka5qVxLHfPcySXjRXcLwLFLFIkghidiwlwoaMBcbQyA5xUl14a1WysbSPS7Izg6Z5V1HcTiXfM0sHmfffDPsWTGTtyACQDQB6TXkXjP4feGtY8TjS9MsZ4NQ1DbcanLb3s8ccVqGOQYlcR7pGLqAVx80jYznPQeHpZvBnhXVp9Vt7pIlvSbG0byTLIHVAkSLF8gLSFgFGBk5963/CGkTabZTXOpMkms6g/2i9kU5UPjAjU/3EXCr7DPUmgBumeC/C+lXkN3pnhvRrS7hz5dxDZRpImQQSHC5yQSM57mugorkbfxHqMF/rC6xDp8FhpMay3M0MkjsVMZf5V289On5UAddWfpuiaVpd1d3OmaZY2dzePvuZbe3SN52yTucqAWOWJyfU+tZn/CW2obyGsr9NSMqwrYMiCZyyM4IO7Zt2o5yWAG0g4PFQnxxpf2RbpIrx4Ft/tdw6xD/RYdzLvk56ZR/u5OFY4wCaANfxBrVnoNh9rvmchmEcUUSF5JpD0RFHLMfT6ngAmsjQ9Gvb3VItf8TKg1CNWFlZIcpYIwwef45SOGfp2XjJatLZnQ7bVPF/iZ/t2o2VrNMkcGfLtYVUsY4Q2PmIXlzgsfQYAv2Xiy0lW/+3RSWbWbRo4JWYOZB8qp5Zbcx/ugbuRxyMgFLR/+SseKf+wTpn/o29rsK44at4c0/W7zxA+pP5mo2ccTp5bMEjtpJdzFQu5drTMH3fdwM45rXuPEunWtxPFdS7GjnW2QKDI0sjReaFVVyxO0E4xk44oAZ4z0Wx1zRvI1Gaa3EMqXMNxAwEkMqHKuuQQSD2II56V5mng6wmZZdWutT1WXPP2y7Ox1/uPFHsideudyHOTnI4rq7rUI9TlN1bXBntZfnhbJxtPoD0+lQ0AZlzoWny6RHptvbpZW0LeZbCzUQ/ZpMkh4wowpyT2wcsCCGIOd4a1C7GoeINP1O7S4j0qaNI7l0EbtG0KSZkx8pYb8EgKDjOB0rc1C9ttOs5bu+mSC3jGWdzwP/r+1eY3F/Yv41v5PEqy6dpd5awX62LBpJLuRWMKvJGilsBUGYxlRhS3JIoA9PsLyDULOK6s5PMt5RlHwQGHqM9vQ9+vSp64t/iX4Yi1K2sFmvmMsTS+YmnT7I1BAG4FA3JOAQpGepFW2+IPhaP8A1+rfZxtZt1zazwqdqliAzoATgE46nHANAHUOiSI8csaSROpR43UMrqRgqQeCCOCPSuc8PSPo1/F4au5HmVYGmsLpzzLEp5ibPWRBz8vBXBwvStzTb6z1SFptLu7a9iU7We2lWVQcZwSpODgg4965/wCJaGTwjcRQFl1GWWKKwaM7ZBclxs8tuqv97ByMeooAtaz4hew1RNPstJv9VuvJ8+VbQxAQrkBd5kdQC2TtHfa2PunGLrfi3WEt4bS18N6tYX+oyiytLmeS1ZIpWVm3kLK2diK74xg7NvGa6zStKtNIgkgsBJseQyPJNI0kkrHjc7tlmbAAyTnAA7Vh63Ilz488N2ErI6RQXWoCMMAyyp5caOcc42zTDHQ577eADb0rTbbTNIt9NtY1W0hhEATkgrjBByT156+tYP8Awg9jaXUk3h++1HQFlz5kGnPGIGJIORFIjoh+UcoF9811dFAHM/8ACHWs5V9U1PW9QuF4WZ9QktyF7LttzGnXJyV3c8nAGL1h4X8P6ddxXWn6DpFrdxHMc8FlEkiHpkMFyD75rYooAVmLHLEk+5pKKKAKes6XY63pz2Gr2cF7ZvyYp0DqDgjcM9GAJwwwRng1zB8P674eJk8K6j9tsgSx0rVZGYAZJIiuOXXjCgSBx7iuzooA4aH4gPLqC6YnhfxBJq6D/SbZIo9tuduQTKXEZDYbaQ3O08A8Vpf2z4ju/wDkH+GPs+37/wDat9HDuz02eSJc9Dndt6jGecVkuobP4tS2yXYLanpIklt8BiskDgIeBlco8nUgHHHOK7CgDzya68Y3vjCz0fU7m00OyuomuYJNMUXUj+UAJI2klAC/eRgfKYEEDPBrUT4deG5LZ49UtJdXmkhMElzqVw88pUnJKknERz3jCU3xL4UvZ7QTaJq2oi/tJReWkEzLOjTKDhRvBbkFlA3YywJHFT6Tquv3OlWl/HbaZqcE8YfNvI9s4PQrscMCQQRyw6UAUJvCGs6MQ/grxBLbW0auy6XqaG7t2bYFRFkJEsaDHTc2D0GODYbxheaRNNH4t0K6sIUVpEvbAPfWxRVUtuKIJEI3H7yAfKcE1pHxPDb8app+p6ef70tsZE/77i3KPxIrS07VdO1RC2n31rdr38mVXx9cHigDmZviJpT6dFd6TY67qyzFfKW00qcB1J+8HkRU2++6uc8YeM/iBbTQQ6H4LjtxPcrBBJfXcUrzZHQRRvwRyxIZgFBJwMkeqqoVQqgKo6AcVydlZw3fxQ1m7uVaWbTrC0S03sSIBN53mlAeAW2KCRzgY6UAZtj4W8Waq7SeL/FRjtpcF9N0aIQRqVYEATn97tIXkDacsQDgc9HpPhHw/pNwlxYaPZreLIZRdyJ51xvJJLec+6Qnk8lu9blVdSskv7byZJbmIbgwe3maJgR7qQce3SgC1Wfq1zd/LYaNGk+uXaOLSJwSikAZllx92JCVLH3CrlmVTi39jqlpcQWWia1f3WqXJP2eyuFikTHQyO2wMsa92yfQAk4PXeHPDfijw2bqWG40PWLy6YNPcTxy2sjgZ2R7gZAEXcwACgDJOCzMSAdb4b0W28P6RFp9k0rxozyPJKQXlkdy8jtgAZZ2ZiAABngAYFadcwdd162x9u8J3MgyAW0+8hmA9/3hjYj8M+1H/Ca6bEP+Jja6vp57m506YIP+2iqU/wDHqAOnorF03xX4f1N9mn65plxJnBSO6QsD6Fc5FbVABRWfrGrW+lLbiZJpZrmTyoIYU3vI20sQB2ACkknA4psOtWLW1rNcS/YjcuY4orz9zIzgkFQrYJOR2zkYIyCDQBpUVSuNW062uDBcX9pFOFZjG8yqwCjcTgnOACCfY5pr61pca2rPqVkq3f8Ax7kzoBN/uc/N1HSgC/RWVb69ZTXdzbhpEe3neB2dcKGSNZGOegG1xyfermn39nqVv5+nXdvdwZK+ZBIJFyO2QcZoAs0UUUAFFFFABRRRQAUUUUAFY/i3UZ9K0Vru1CGUT28fzjIw8yIf0Y1sVT1fTbXV7CSyv0aS3cqxCyNGcqwZSGUggggHg9qAMHxX4wTQr8WcVjLezrbm7lSPdkR5IAQKrbnJVsA7Rxyw4pB4wBu1P2Fhp0lzLZR3BkAczRo7MDHjhf3bKDnOR0A5q9J4V0uQxswv/NQMonGo3Al2tjKmQPuK5AO0nAPIFSr4Z0ldQa8Fs/nEs2POk8sMybC4j3bQ5UkbgM4J55NAHPL8QFj09rm8014WktrS6tY0l8wyLcOUQNhflIIycbuOmTxXR+GdYOtae872slrJHK0LqwbaxGDuQsqllII5KjuMcVG/hbRntxA1kDELaK0UeY+VjiYtGAc5BUnIYfNnBzwK0NNsIdOgMNu07KWLkz3EkzE/7zsT26ZoAtUUUUAFFFcp4wu57+6g8MaVK0V3eoZLueM4a1tc4ZgezsfkX3y38JoAh0sHxT4kOsSc6NpbvDpy54nn5WS49wPmjT/gZ7rXY1hT6nYaB9m0izs7mUwW6sltZwl/JhX5VJ9BxgDqcHAODV+LVtPkvI7Nb23F7IgkW2Zws20jOdh+Yce1AF6se68O2N3/AG0LjzXTVolhuE3YAUIV+XAyDg9c9emKv2l/aXjzJZ3UE7QNslEUgcxt6Ng8H2NZn/CS2n9t/wBlfZtQ+19f+PV9u3dt37sY2570AZWp+E51CXlhd3F3razrKLy5uI4XCrG6bcrAyYw7cGP+InOcGo7DwHAuiwWl7fXPmPZizvhAUCXce522NuUnGZJBldpwx9eOph1SwnjmkhvrWSOF/LlZJlIjb+6xB4Psaba6xpl3LDHa6jZzyTqXiWOdWMig4JUA8gEEEj0oAj8T6X/bnhvVtJ87yPt9pLa+bt3bN6Fd2MjOM5xkVytz8PhdvNPPdWMd0XgeNLWx8q3BiMmN8XmEuSJWBO4HGMYxz2dnf2d8ZhZXdvcGF/LlEUgfY391sHg+xqw7KiM7sFRRkknAAoA40eCP9Fni+1WsBm067sSLW0McYM7K3mBS5ORt5BPJJOR0qzD4S8vW7fUPtufJvkvfL8rrtsntdud3+3vzjtjHeo2+IGiXAxoZvNedvljbSLWS6haQ9IzcKDCjcjO91CggsQOab/aHjDVvlsNFttBhI2tPqs6zzRt13LDAzI69BzKhzk4wBuAPN9fi1fStTn8P6Nqy2rWOnS6ibj7GsxnPmMoj2McKOM5BJOa0NN8VWkvg/R9YnmW4lvraNkjtl3NPMVG5I17kNuHoMHOAM0/xZ4Tkj1mK7/4SDU5fHF9CYQmjKlsk0StlGkSTzREiHGXB5PQFjir3hn4d3Hhu2SW4P9oX4QgzqSRGGYsyRqeQCxJJAyScnsAAUdP0m5vr2LVPEIQ3EZ3W1kh3RWvox/vyf7XQdFxyTyet6zeJ8QdXbSrC/a6toINN/tCz0/7YtshHnk7QeZC0m3YcDC5PUVteN9cuYNGvrmzmms7K2d7dbmPAmvLwZC2tsCrfNvGHcqwBBQAtu2VvBVhHoT3GpapqNvbJNDHaeRJZGxAcEuXdnkfzpCGwXzk4xnjAAH+DLa+m8VPqn9napZ2EVjLai41N9txeTPMjtIYz8yAhcc8cDFdB4302TXfCOs6dHHFPc3FnNFbibBAkaNlU5P3Tk9e1WRrNj/aj6e06JcqqMquwHmb92AvPJ+U/pVhb60aSeMXUBkgG6ZRIMxj1YdvxoA871CHSpda0Sy8R+A7e1k1B2tYHW9ib7ql2JjiIyABy3bcPWt1/BT/2pp0yeIdYksLSeO5NjdyC4VnjYlNrNgxgA44zkVLe3cF1488ONaXEUyra6jGxicMAwNrlTjv7V1VABXK6MDd/ELxHefZ1WK0t7XThKxUs0ih52wOoG24jHuQfSuqJAGT0rkfhq0d3pep6sl0bttR1S6lMwZWR1jlMMezAHy+XFH65655oA66iisjSfEWnamsbQPJGJIFuY/PiaMPE2MOpIwRyPzHqKANeio3uIUzvljXBIOWAwQMn9Oarx6pp8lobqO+tXtgSDMsylMgZIznHSgC5RWZqmu6dpmnfbbm6h8lkLx7ZFJlGM/Jz834VbS+tHvHtEuoGu0G5oRIC4HqV60AWKg1C6jsbC5u5v9XBE0rAHBIUZwPc4xU9ch8TH+0aVpmipcxwSazqMFmSV3N5e7e7KuRkjav0zQBY8AWV2NI/tjWQG1rVsXEzFVDRQnmKDI/hVSD9WNdPSXUwRZZ3zgAue59awPD8ni7xXZ219pOiWul6Rd28U0N3qd2rSOkgyHSKLfnapU7XZCSccckAFT4j6pcWujQ6VpbhdY1uT7BaHIygI/ey88YRM/iy1v6Nptto+k2em2KBLa1iWKNQMcAdfx6/jXI61o+t+G/ix4Zm1m9t9aj1GzuLOF7W0e3a1KkO7snmMu0hlBbOeFGBjm9H4gu7jxXeaHD5UTRXIxNIhx5IhhcqvZpCZG6fdUZPbIB1lZ2paFpWpuHv9OtZ5R0keMF1+jdR+BrCPjaIQ39wLGZrW3guJ0kXd8wiBJDZUBd2Dt5Pvg8VdXxJ5N21vqFoLYpcJA7iUMiCRCyMTgdSNpHYkckc0AO/4Rxrc50vWNUswOkZm+0J9MShiB7AisDTDr9p468SBBp+pSC1sPNJLWpK4n27R84z97OcA8dK07nxikNvZ3H2MtDOiSugdjLHG77UcqFIAI5+Yr6ckVPpP/JQ/FX/AF56b/K4oAl/4SNrc41TR9UswOsgh+0J9cxFiB7kCl/4SeyvXitPD81vqmrXDeXDaRygFTjJaXuiKOSSM9hya0b+8ljmhstOtzearc5+z2wO0YGN0jt/BGuRub3AAZmVT0OkeAdIjs5Dr1raa1qVyQ9zdXVurZYdFjU58tF6KoPHUkkkkAv+EfDMWhRTTzy/a9XusG6vGGC5HRFH8KL2UfXqTXQ1y48G29rk6LqmsaUeoWG7M0Y+kc29APoBQIPGFgv7m80jWEHRLmJ7OQ/WRN6n/vgUAdRRXMx+Jb63ZU1jw3qttk4821C3kX/kMmT80Fa+vanHo2jXmpTo8kVrGZWVMbiB6ZoAdqOk6dqabNSsLS8Q8bbiFZB+oNZln4N0Gwu4bnTrD7C8Tb1W0lkgjz7ojBSPYgirOoeILLTtSktL1miCWwuTKRlcGQIFAHJYsQAAOcgDmmHxRpQsftYluGhDtG2y0mZo2X7wdAu5cd9wGKAG+LdLfVbOCJLCyvvLlEm25uHtzGcEb0kRWZWGSOB0J5FcrN4M1ptOuIXns7yS8sZrB/tlxJIbRHkdl2OylpdquFO7aW8tTkV1z+JtHS8itftyNLKYwpRWZR5mPLywG1d2QFyRk8DNVJPF+njXE0+HzJV8q4llnWN9ieSVDKp24c5YghScEY60AZ03hGeTUbu4ZrWQS61baiGkyXMUVtFFhvl+9uRyB0weoyRWJrngfXrzQtR0y3uLNoLpNREafa5YBE89xLJGxKITIAsiAocKCp+9mvQtK1S01SOV7ORyYn8uRJImieNsA4ZHAYHBB5HQg1doA4PUfCWryahf3dhd2kE0s91NC7ZbZ5ltHEmQVwcMhJ6jGOvStPwXoV7pN7q9zf8Alr9taJlRbyS6IKptJLyKp544AAHTtXU0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYV5rs41S6sdK02W/ltFVrlhKkaoWGQiljy+OccDBGTzW7XP3Oi38Wr3t9o2pQWpvVT7RHcWpnG9V2h0w64O3AOcj5R05yATS+JtKiuZbZ7gi4iVi0exj8ypvaMNjaXCgkqCTjnGKrW3jTRJtKstQa4khhuofPVZIX3RpgEs4AO1RkZc/KPWqyeEZDer52oh9OS7lvlgEGJfOkR1bMm7G3MjsBtznAzgYOY/w/ke309Zr3T7ma1sV05vtOns8UkS/cOwSghuWyd2DnoMCgDrvEGsW2h6PPqF3uaOMALGgy8rk4RFHdmYgAepqj4Q0iewtbi91Ta2tai4uLxlOQhxhYlP8AcRflHryerGrl3otreXelz3O9zpzF4Ys4j8wrtDle5Ubsem498Y06AOU8Y6Dc6vcxyWljZvKsJjjvDfzWk8LE9miUll6HGRyPfjJuPCWvXWr2Ut7fxXUVtdQzrc/aXhcKsQRx5KpsLFtzb2YnnHAqLx/rOo2HiJWtLq4jsNOtYb29MWMQxmZsuUwTKrLE6kDGz73OeNrxXrFwfAKapYGa2muPsjqIirSKJJYwVBOVJwxGelADPB3hy+0q4snvhZRrY6cmnR/ZGY/aApB8xwVG0/LwoLY3Nya0rzRp7nxFPeiYRwS6c1nlCfMVi+dw4xwPfrWBpuqeJLbUrTTZIFdbya4kgfUnAmS3jWH7wiBUsWeTA4+XbnkEGhH401SPSpLiGO3eOzsBqExnyzyjzpUKKVwAcR8MQfoetAE6+C9Sn07yLlNMgaO1srJUgdmjmSCcSM75QYyAQqfMBk/Mc1dufB9zLdXEkUtvAZdYa/8AMjJDrGbUw8cff3EnHTHftTNb8R6n/wAI/wCKtTtmtYbTTIryJIxn7QXhiY792SoyRkLtPy4bJzikvvGV9Yzz3E1tby6fHfXFiIYg3nsYoHl3g5wc+WQVx3znjFAFrwJ4YutBkU3kUHmR2kdoJo7ySXzFQ8fu2QCMdTgFsbsZ7nQ1XwV4c1jW11bWNIttRvljESNegzpGoOfkjclEOe6gE+tQeDNb1XV97apYpDA8EdxBMgCq+7OUA3sW2jad/Abd0GOeooAK5nWtfuJdRfRfDMcdzqygGeaQEwWKn+KQjGXxyIwQT1O0c1Vu9XvfEt3NpvheYwWUTGO81gAEIQeY4Ach5OxY/Kv+0eB0Oh6RZaJp6WWmwiKBSWOSWZ2PJdmPLMTySSSaAKnh/QrTw/bXErTPPez/ALy8v7kjzJyB1Y9AoHAUYCjpWTH9o8aMZPNurLwwP9UYJnt59QP9/ehDxwjtghpDzwnEi/FTT7TVPCsNrqFvHc20mqacjxyLlWVryFWBHurMPoa6u2gitreK3t41igiQJGiDAVQMAAdgBQBxXxF8DjxD4esrHRhZ2cun4+xxuhWGIqv7sgL02OsbAYIOzaRhjXnGnadrNwLu2mm/eWt/LFcWct/LvQCNEBExXzNjFWkAwu5ZB2HP0BXnnxD086Lef8JTZqRa4CatFGPmlXhUmA6bk6HoSuOcKBQBwdn4U1OGzgs5DYsjWVhbTTiVt6NbnLFBs5yehJGDzjtUN9ojTCfQjf6TFfyWd9FaobnFxc+fuIZ49uQowSSN2SueMYrstf1a10LRLvVb5ibS2j8xvLIJcdgvYk9vWuO0rwHba7aXGqeOrFrjXL/OUlcFtPiy3lwxFcBSqtksOS5J7UAWbDTI4/i5qU0i4MWlQPbqrELGHd0f5emT5Cj6KK7euZ8L+DrXw3qdzdWd/qFxDJbxWsNvdzGUW8ce4hUY84yzHHbNX/GGoDSvCuq3rRtIIrdvlVsHLfKMH2LA0AQapfXN9fTaPo0gjmjwt7eYDC0BGdqg5DTEdFPCg7mB+VX1tMsrfTNOtbCyTy7W1iSCJMk7UUBVGTyeAOtVvDejxeH9A0/SYREFs4EhZo12h3AAZ8erEE/jWjQAVxGl+DJ7TSI7GSZJUn0ldPuS8zuYXCY3Qluik9V+XGFIxjFdvTPNjMpjEieYP4d3P5UAcZb+FdThkmuEvLdbqW0mZmwWUXsuN0gBH3AFCjI6dqfY+GL1dQW5ufs4X7bDdMjXMlwcJE6H5mUc5ZSBgAY9q7OigDhJvCepLY3sEJsZDd2z237yRlEI8+WRSuFOciQAjjBQdal1G1ksPEdhqWtapp1raR38kkctzfGEMrQSIsaxkBNwLA5ySQpPHSu2qhq0WmXlrPbasLSS38smVLgrtCHIyc9B1GaANLypP7jflXmfxHXXr7XGl8Ny/Zn8O2pnmulRS6PKAXiKyKVOYQrggcepJ2izdeHPh1Dazyxad4fupI42dbeO4iDykAkIpLcEkYH1rjvBvhiTUNFWfTrbwGNXuoZXjZJJJbhS6soI2OAuA2ANoC+lAHV+NLHUYfAmqapZeMdZuYPsTXEWYrVBIhXcOVhVxkEdCDz2r6FtbeGztYba0hjgt4UEcUUShURQMBVA4AAGABXivhqG38T/AAz0+zvoZIobix+xTxiT5gUzE2GAHdCQa0bXx9qlpaSeEjaX0/imK32W2pNDm3kjwFW6kY9wSdy/xOpA4YUAUPHL6z4h8eT33h+7gjbw24s4IJ1BguzIqtcbpACyn7qcZ2tEfUgGh3GjeIbnU7c2c1pq1tdJcXlpOxWeOQIqLKpVuUKqAGU4I6gbiDreHdNk0vTBFczLPeyyPcXUyjass8jF5HA/hBYkgds4qr4s8NW3iGzjBke01C3cTWl9BxLbyjowPceo6EUATSeHNMeO6iaGXyLpJElhFxIIyJAQ+EDbVJyeQAeT60mt6Ba6pZ3sDAJ9taIXLEFt6ow4AzgHAIBHTOecVm2Hiaex1KLR/FscNpfNEHi1CI7bS8I+/jP+qYcfKx5zx2FdWQQcHrQBlX/h/Tb+Yy3MDlmREYRzPGrqpJUMqkBsEnGQcVhXr6npnxFX7BYC9XxDbR2sHzCMRXNuHYeY5PEZjaViQjN8gwD0PXXE8VtBJNcypFDGpZ3c4Cgd6vfDrSpp3l8S6nE0V1eR+VaW8g5tbcMfXkNJ8rN06IMZByAbnhXw7FoVvK8kv2vVLra13eMm0ykZ2qq5OyNcnamTjJJLMzM27RRQAUUUUAFUNe0yPWdFvtNndo47qFoS6dVyMZHuOtX6hvLmCytJ7q7lSG2gjaWWRzhURRksT2AAJoA47W/DOo3Sz6ld3a3uqRC3+ypZ2oiVTFMJeVklw2SBnLrwOMHmqFr4N1PU7AyarPbwTTXN1NLaXFt50TCUqFZo1l2iRQnB3OBvbqeR6AbmAXa2plQXLIZVjz8xQEAtj0BI/Oi4uYLZohPKkZlYom443EKWI/75Vj9AaAOStPA/2fTha/2huw+mPu8nH/Hm8bdN38fl4/2c98VBL4FumiWCPW/Jt4ILqG1MVuVljE7q3zOH+bG3HAUkHqDzXbwTR3EEc1vIksMih0kRgyspGQQR1BHeorm9t7We0hnlCSXcphgUg/O4RnI/75Rz+FAGL4Q8N/8ACPtqb+ZaMb6ZZilra/Z40IjVOF3NnO3JJPU10VFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5prt3pq+JfE6ajq01rfRQwGxSG7dJdxjJ/dxA/OS2Pl2nPQg9Km1qKKxl8K3Gq3P2XUtT1SGW7j+0mNWk+ybGVQCMrujj45GfrXotFAHnFz4o11P7ZtYo0a70SGd7uTyCVfcwNuyjv+63OwB6rt700eIbp7+wS31BNUsk1Roob9duJR/Z9xKVzHhG2uo5AxzjG5c16TRQB5RdeJfEcGl6JJc6rYwNqFh9uF3MI7aHzCqbYSXDAgZZiMhmB4ICmvUbKVprOCWTZveNWbYcrkjJx7VNRQBTvdK0++uILi9sLS5ntzmGSaFXaPkH5SRkcgdPSnJp1ilktmlnbLaKQywCJQgIbcCFxjO7n681aooAie3he4jneKNp4gypIVBZA2NwB6gHAz9BVYaRpoikiGn2flSR+S6eQuGTJO0jHK5Zjjpkn1q9RQBnXGhaRc3M9xc6VYTXE8Zillkt0ZpEK7SrEjJBHGD24qDSvDel6bqN5qEFrE1/dTPM9y8amQbsZUMBnbwOK2Kpaxqllo2nS32p3CQWsWNzt6k4AAHJJJAAHJJ4oAitdN0jQ47m6tbOw05Cu+eWOJIQQMnLkAcDJOT6muM1TXIvEjRR3l6dI8Lz7tjuTHcaqoxnZ0KQ8jJ+84PG1TltO30y98WTx3viS3e10hGD2ujvjc5B4kuccE9xHyo75P3X+MdNvLjX9Eu7Wz1C4t7aK5SX7BcRwyKX8rbyzpkfK3Q9hQB02mR2kWnWqaakUdksSiBIlCoEx8u0DoMVZry/WrG7tNWt7u8sLpjNqmnfZbyWaN3tof3SPAx3ltxcSFtuVbeOTinppnidII4E013a00zUbUtcTxtFcySTQmPAD5OUSTG7bjocZoA7LxZaDULGzsxcwQTPqFpNGJWx5hhnSdkX1bZE5wPTPQE1t15RZ+E9QjmtpJ9HuZrC11kXcdnI1sjiJrN4m2LGwjUCVg23IOATyTy++8N68+m6xFaWU0WpyWGpRSXguEH2+SXPkbfnyCOMFwuz7o4NAHqAniNy1uJF89UEhTPIUkgH6ZB/KoZ7q1N7Hp0zIZ7iGSVYWXO+NCiufTAMiD/gVcRr3h2/gubuLR7A3OmS21tG0UsqzFiLiR5SBK+GfBU5c4PvjFHgnQdW0/VdJlvreZLa2g1OEedJEWjWW5t3hUiM7R8kbcKNq7cccCgDhNX8Ky2Hj/RtD1NUl8LWUct7pnnIG+03GSRCxzyYlLOARyF6YWtjTbufWtbe7t5Xj0ezLQx7eBdy9Gb3ReVHq2T2FdP8RbGPxZd2nhi0JjvVIu57+IkSafDnGUYdHk5QDoV3kggYPlfhDwhc6vp0Fzr+v6nLHaXd5bQ2OnyGytkjjmeELiPEjYMe4EvxkDnksAemkgDJ6Vyutyt4luI9JsIGn0uO6j/tG7LAQMinL2+M7nJ4BK8KeCRSyeAtCljeOX+1pI3BVkbWbwhgRggjzeQRXSWVpDZWkFpZwJBbQoI4oo12qqjgAAUATMSxJPU80lFFABXnd/Y3B8V6hNHbSvL/AGtbTRA2L4kQQwKzC4xhQMPxnqpHOcH0SigDhFvtae2MKpqIuYNMv/MY27gG4Dx+TtYjDHG/GM5GadqkmraZbXcUMuq3Uk2nKYHELSkXG5t2dq4U4K9cD0ruaKAONuV1ldTmubc3rSDUmhjjYt5XkfZyQSvTb5mPm9eM9qxxaXNyly5tdRuHmtLGO4F7A7B5PtBMqhXGMAEkhRtA5FelUUAZ0Ph3Q/NT/iR6SfmHWyi/+JryH4eyzaxoeleHNDsbPSNRisxLqOsQxRiaK0dvk8sjkyyLjOeFHXnivVvGsskHgvxDNBI8U0em3Lo6HayMImIII6EHvWR4Hjitdb1+2REgDxWE0MSqEBjFoillX+7uBGRxnI60AdLpGm2mj6Xa6dpsRhs7VBHEhYsQPUk8kkkkn1NXMnGMnHXFJRQAUUUUAVtTsLTVNPnsNSt47mznXZLDIMqw/wA9D1HUVywfUPBf2G1KXeq+GseW125Mt1YYHHm4HzwgA/PjKjg8AE9lVbU9Rh0fTbvU7kOYLKF7lwmNxVFLELkgZ445HNAFDSY7fx3q8dpZzJc+HbTZPfyIw2XTMA8MakclejN26DqCK9crzj4c6n4b8HeANE0vUNc0G2uYrdTMEuo18yRuWbBwSxJ54yTXQ/8ACc6C3/HtPeXnp9j0+4uM/Ty0NAHTUVzSeKpJ3VbTw74gnBONxtkgA9/3rp/kfSsn4g+Kb3QdSiitp44I/sE11l7N7gPIrxqisVI2KS+CxIHTkUAd3RXHXXjQ22sppzabLJLEYI7vyizGJ5dvCgKQwUMCxLLx0z0qD/hPhHbR3V1pjx21xDJLbMswZn8uVI3DDHyn5wRycgHODwQDuKyPGGmy6z4S1vS7dlWa9sZ7ZGboGeNlBPtk1ja34lu11CO10qFTNBrKabKsrhVlDWnn/ewSo+decE/KfWs5fGtzPfsyoYIVNnbvAVDmOdtRe0lG7jIypAPoM47UAL4j0/W9e/tG6g0y5sJhpMtnDHLcRB5JZHRvlZHIAGzqSDz04pJvDF/HqzQWNqIdIbVDMEWQKghbTpImO3OcGZlyMZJO7HU103hzWbjW4VvFsRDpsyl7aYzbnkXOAWTHy5HI5PHXB4rObxc/nZSw/wBEmuLqytZjMMyXECyl1ZMfKp8mUBsn7vIGRkA40+EdVOkaNbNpl/Db2+mi2aC1e2aWG6GN06l32gnja6ncu3oM1tW3h/Uv+Et0u8u9MaW4t9WmuZNTaSI5tmtZ0RB82/5WdFKhcZyR1Jrc8IzazqngyyvLu7EWo3kaXHmNGkioGVWwqqF45OASSO5NZeleKNTh8KaVqV89pfXupIHjtkV4iPlJYKqLIz9ui8dyKBneUVxMXj1LiG2urXTpHsZLexuZZZJQrIl221MLg7iDyRkcdCTxVufxXNb32rQTWEMcdhGrPcNdgR73YCONjtyHYHOAGIyvHzLkEdXRXF2Pjaa/EFvaaSx1KS4mtjDLK0SK0aK5O50D4KsMZQHPbHNRweOUubb7XbRIUntLK5toZ2KFvtCyMFBRXZmwn3VUng++ADuKKy/DOsJr2iW2oxwyQCXcrRSAgoysUYcgHqp6gH2HStSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOf8bX9xY6XbfZp/sv2m8gtZLkAEwpJIFLDIIyc7QSMAsDz0qjq1zPoCw2WmahPeX93L+6t7pftLKFRi2PnjwDgHLvgc49K6q4giuYJIbmJJYZAVeORQysPQg9RWaPDOhC0+yjRNMFtvEvki0j2bwMbsYxnBxmgDjV8d6pc6aL+1s7OOOLTLHUJopWYs5nllQxqw4XHlZDYPpjnInuvGGrw6hJo6W1vNqaXslt58ULGNlW3hnyIzIDuxMBjf8Aws3tXZpo+mpC0SadZrE0aQlBAoUxoSUTGPuqWYgdAScdaLzR9MvY5o7zTrO4SaUTSrLArh5AoUOwI5YKqjJ5wAO1AHHT+MdZiivZ5dLtIEsNPhurmKWcl0lkEg2ZUEbVZBlvTPFSz63qM+sxaHPBpkmpR3gWO8eBjAuIDKCELZEmCRjf0+bP8NdfBplhbxPHBZWsUbxLCypEqho1BCoQByoBOB0GTVb/AIR7Rf7O/s/+yNO+wb/M+zfZk8rd/e24xn3oA4//AITnUprdruC1tI4Lexsr2dH3M0nnTSxsqNkADEW4MQc5HHOR6JVNtMsGV1axtSrxpCwMS4ZEJKKeOVUsxA6DJx1q5QBzeu6nd/25FpdlN9lRbOS9nnWAzSFVYKEjQdTkkng9AAMtkZ8fjWG10a+uJXbUDY6fc38kyQG3LiGR0aMxvyrgoVOe4PA6V0mq6PZao8El3HJ50G7ypoZnhkQNjcA6EMAcDIzg4HpWXd+CdAu7L7JNaTGAxTQuFu5kMqTMWkDsHBfcxJ+Ynkk96AK03ii4j1m8062tBdXP9pfYYVd/KRcWcdwSzYY4+Y8gZ7Y4zVCH4iwXDWRtdNuZUkht5pwu4vF5vRVCqQxXq2SvHTJ4rql0LTl1I34t/wDSzcG7Mm9v9aYRCWxnH+rULjpxnrzVOLwlo0P2f7Nbz2/kRJAvkXc0e6NSSqvtYbwMn72ep9TQBU0rxal94mbSfs67HWZoLmF3kR/KdVYElAob5hwrNjBBwcZ0fFOtjQ9NEscJub6dxb2dqpwZ5m+6uew6knsoJ7VDB4f0TRJ31VUa3+zRzNvkuZDFAjnfJtRmKoOM8ADis/wtbza5qZ8U6lE0auhi0u2kGDBAcZkYdpJMAn0UKOu6gDU8KaK2jWEhu5hdapdyG4vrrGPNlIAOB2RQAqjsqgV4/Y6BrFtquv6ZB4p1CxWz1Kd1hS0tWUpO32gOu+Jn25mZckkFkbB4wPeq868b2507xzpWogYg1a3bTpTwSZot00AHcDYbsk9CQoPagDl7bwXBFbxpPrfie4lVQHlbW7pS57khXAGfQACmJ8O/CpWb7Xo1vfzTMzyXN9m4nct1JkfLH254rrKKAOP8ETz6XqmpeE76eec2KrcadNM295LJsKFLY5MbfLyScOg7V2Fcz4+sr6XSotS0VXfV9KlF5bxIWBnA+/AdoyRIm5cepB7U2fxiscEjx+G/FUsiqSsY0txvOOFz2z0zQBNqHjfw5YapcabcampvrfHnQwQSztHkZw3lqwB9u1XNC8R6Rr0lzFpN6s81sFM0TRvFIgboSrqDg+uMVS8B2F3YWF/cahZLY3t9f3N40YdJHVJJC6qzr1wCOO1Z/wAT7EQ6RL4osZntNd0aJp4LmMA+YgGWhkB+8jDselAHZ1nXOt6ba3P2e4vYYpt6x7WbB3MQAPqSR+daci7XYDoDiuXmW/uvEwlvdLu3sLRgLTY8JQuRzMwLg5GSAMZAyepGADo55o7eF5ZnVI0GWZugFPrzhtE1x5L+SOye3muLG5jlETQxxvMZIzGV2tvPAk+Zzkf7OcVf1Hw9fSwX80ccrTy6gXePzQxltuPkVWOwc4O04BwQetAHY39pBqFhc2V4hktrmJ4JUDFdyMpVhkcjIJ5rhvDFxPbeM4bfVnDXcVgdHaUKFDyxyGVHIwAokiZWVRk9vU11fhe0kstISCVbhNruVS4KblBYkD5CVAGeADwMD2rkvina6XpNk2vrMLPVRNC5MchEt1tyqBV53Op5U44G4d6APQqKwvBPiCHxL4btdQifMuPLuEK7WSUcHK/w5+8B6EVu0AFZ2p6bLfSoy6nf2kajBjt2RQ3uSVLZ7cEVo0UAYX/CLWL/APHzcarcn/prqM+D/wABDhf0rF8ZeFtEtvDV5exaTZmSzMd48kkYd/KhlSWUBmycmNHXHfODxXb0EAjDBWB6hhkH6igDttIttPjtIZtNtLe3ilQOvlRKnykAjp+FXq4X4TXJi0rUNBkYl9Fumt41J3FbZhvgy3c+WVz39a7qgAqlc6XZXV39pubdZZjbvanfkqYnILKV6EHaOoq7RQBhw+FdJhlhkgiuYniRI8x3ky71T7okw/7zHT588cdOKoaP4G0uy0t7S8Et88kUkDySTScI772CKXPl8hfuY5VT2GOjv7y3sLZri8lWGFcAu3QZ6VU07XtK1Jttjf287eYYcI2SHC7yuPXbz9KAKf8AwiGjeQ8Xk3Xz3QvWk+2z+aZhGIg/mb92dgC4zipE8KaKixqtlgJ5OP3r5/dTedGSc8kSfMSeSTzmtuq9le298kr2sgkWOV4XIBGHRirD8CCKAKml6HYaVNJJYRzRb937v7RI0a7juOyMsVTJ5+UCo08N6UmoSXi27+dIzuQZpCgZxh2VN21WIJywAJyeeTV+8vbez8j7TKI/PlWGPIJ3O3QfpVigCCxtIbCxt7O0Ty7e3jWKJMk7VUYAyeTwO9ZjeGNJaz0+2W3ljisFKWxiuJI3jUjBXerBiDgZBJBwM9BW1RQBh2/hTRbeyW0hs9tuIbaAJ5rn5Lc5hGc5+U9+p75qNfB+jLHeR+TdGO7kM0qNfTsvmGQSb1BfCuHUEMuCMcEV0FFAGPp/hrStPuEntreTz0leYSSTySMXdFRmJZiSSqqOfSqyeDdCS3t4YrOSJbaOCKFormVHjWFGSPa4YMCFd1yDkhiDmuhooAqaTptrpNglnYRmO3QsyqXZzlmLMcsSTkknrVuiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKK5TxzNHHc6IupTNBob3Di9k3mNP9WxjEjAjCFuuSATtB64ODrGvWulxiLw/rEFlpgtri4gmDCeO4uVK4gQsSMc/cTBOflIwaAOl8SaTda9qdnYXCKvh+PFxdfNk3Tg/JCR/cBG5s9cKOm6ukrz+LX9ZfWpJJpxDBFrFvpzWXlqRtks4ZW3NjduDyHGCBxyD2xrfxpqjQQSLqUUk89ilxewGND/Zbm4hjkBAAP7pJJCQ5JJTPTigD1muN+LUGPBlxqiYE2iOuqq/8QSLJmC9izQGZBnjL9uo0fBupTajb6jvu1v7a3uzDbXqhcXMflo275flJDs6ZAAOzpXQ0AedIwdFZehGRS1z3gONbXQW02LPkaVd3OmQljlmjt5nhRmPQsVQE4AGScADiuhoAKKKKACuY+KH/JO/EX/XjL/6DXT1n+IbODUNB1C0vE8y3mgdHTJGQQe45oA05v8AXP8A7xplU/BvjDwZe+EdCuda8S6CNVnsYJbtZNRijbzmjUvlNw2ncTxgYpdC+I/wx13VE07Tdfs3u34RJTLCHOQNqs4AJJIwAcntQBbors/7F0//AJ9//H2/xo/sXT/+ff8A8fb/ABoA8z8TXWpxHSLLQzaJqGp6glkk10paOEeXJKzlRyx2xMAuRkkciuq8J/D7TdGng1LVG/trxGkYR9Uuoxv4z/q05WIDJwF5x1J61zvxAlTTvid8MNMtYI1hu7+7uZHJYsGitmVQOcYImbPHYdOc+q0Aea/FfwVd3iP4n8HDyfF9oIyu+dkhu4kzmGVD8pBVnweCCR8wFc4fFZ03SLLUvEdlJZ6beJFJb6nbq81nIkm0qxfaGiGHQHzlj5JxkAmvba43wJK+n634n8NSQSotld/2jbSvg+dBePJKTkHqJxcrjAwqp1OSQDD0zUrLVbRbrTLy3vLZshZYJA6nBweRx1Bq1UXxE02DRvEWm+JrSBIzeSpp2qOqAB0IPlSyP0XYw25xlvMVc8AVMQQcHrQAlFFFAFC1ujonjvSL1SI7TVc6ddk9GkxugIUclydy7jkBQBx1r1OvDvH+pIdPv9M06C4vvEFtb/2hFb2jBJLYJyJmkPyxYwepDMCQoOa9f8NX76r4c0rUJggku7SKdggIXLoGOAckDnvQBpVT1fVLLR7CS91O5jtraPq7nuegA6knoAOSeBWZr3iRLC7XTdMtn1PW5F3JZxNjy1PR5X6Rp7nk/wAIY8VBo/hqQ38er+JLhNR1deYgq4t7PPUQoe/YucsfYcUAS6rquqT+FftugaXdNqFwAIYLgJG8QJx5jK7AcD5tpIJ4BxzjnpdF1H+y9Nt9M06/tjA101w91PD5s7yW8g81ikhBLSMPoewAr0KigDzCXwbexxXTWthtnWw097ciZci9SWQzyA7uH2+Vl/4hxk8iiPw/rMN/dz6dpCwX63mo3H2ueVPKu4pFl8qFtjl9pdomOQMbD3Nen0UAeRweF9VjSYNot3Lp5vLK5+wubSPdtEgm2ojiMDlOpJPcmrreE9emtrO2tpZtOtrkXccyrMC1lH53nWyjBwSv3CFyAGwDgDPp9FAHlN94Z1++tbCbU7e7k85LqW4traSCSS2nll3qVMrBfkTCK6nK7eOpNeoWSulnbpMXaRY1DFyCxOOckcZ+lTUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVm6follp95LdwLO1zIuwyT3EkxVc52rvY7Vz2XA4HoK0qKACq2pX1tpmnXV/fyrDZ2sTzzStnCIoLMxx6AE1Zri/i3OW8J/2PHky65cJpmBgZicFrjk8A/Z0nIPPIGMnFAHJ+C7e5i0COfUImgvr6WW/uYCMeTNPI0roPZWcgewrb3LuC5G7GcZ5xQoCqAOgGK4i/t9Ufxf/AG1HZFra1uIrNfmbzGgIIkKx7eV3yBic8iEcHuAdxRXBN/b8Ns9xbG/e8mt7/Ky5KqyyDyMKflU7c46bu+aSK6uHu7qG2l1d9LiuoBOGE32hYzC5OMjzBmTy845wTjAoA7zzE83yt6+bt3bM846Zx6U4gEYPSvPW/taP/SZbW+mZrUwrJiRZFiN0dhbYN24RbWKj5uvTrW/4VnvYtCvHvzPI0E0vlNPE8bPGOV4clsf7xJoA2P7MsP8Anytf+/S/4VmWuj6XP8Q7axvtOtLuz1vS5YLiCWJSgFtIsinHck3Bzn+4tZmi6r4w1bRtP1KCx8MJDe20dyivdXO5VdAwBxH1wa09Ah19fGmlaxrsejx2tjb3MOywllkdjL5XOHUDA8v170AbP/CHeI/CK7/AWsG40+NeNE1Z2liwBwsUv34/pyo9K0dG+I+mzaiuleIra48Oayc7bbUMKko+fmOX7rjCE9j7V2sMqTRLJEwdGGQw6EVS13RdM1/TpbDWrG3vbSQENFMgYcgjI9DgnkcigDhvidoGs3njbwP4j0iyS9t9Aku5LqAShJGWREUeWCPmbhjjjOAMjOa6vwd4s0nxdp73WjyyExMEngmiaOWByAdjqeQcEVzEnhPxJ4V3S+BdVF3YAlzouruzp1kbEU/LJksow24cdRUvwym1O+1/xjqOraLe6O9xeQIkN0BlvLt0RmVhlXXcDhgSD+lAHoFcp4yP9l6x4e15flWK6GnXZHJaC5IRQB3P2j7Mc9l3+pB6uuT+Kq7Ph/q96PvaYiasq9pGtZFuQh9AxiCk9s5oA2/EWmWusaHe6ffkLbTxFWfjMfcOM8AqQGB7ECvIdE0T4geJvDml31jrmjaTFIM5axeaeRASoLl2KknG7IA5PpXpvjt/M+HniF8Y3aXcNj0zC1XPCH/Ip6J/14wf+i1oA5I+Adczx44v8f8AYOtP/jdMl+H2uSRun/Cdakm5Su5LC1VhkdQQmQfcdK9GrK8Qa9Y6FBG967tNM2y3toVLzXD/AN2NByT+g6kgc0Ac9/wiWi+DfAGuWui2qW6tYStPOxzJOwjb55GPLN15NZPgnUNW8QeDNBsdAWTTtPi0+CKfVpo/mYrGoZbdG+8c5HmMNo7Bu1jxLo+p6/4b1W+8Un7Nax2kslvo8EmUUhCVadx/rGBAO0fID/eODXS/D7/kQvDX/YMtv/RS0AXdA0Ow0Kza306ErvbzJpXYvLO56vI55Zj6n+VaVFFABRRRQBT1bVLLSLM3ep3MdtbhlTe5wMscAfmf61bBDAFSCDyCO9eUa9rejeK9d1C0vGudQsrNZ7K202wTzLh7jEsE8zAfcUAtGjOVGfMbkFTVzwLP4q8R+HIbe7vLTRFsWawuvsiedcmSL5WAZh5adOoEmeoI6UAdj4z1m40HQJL6ytBe3Pn28EcBfZvaWZIhzg4+/msKz+IVndaldeVCz6VHbRSw3KEs88ruqCNUx13Oi9fvbgcYroZ9Bt59GttNmuLySKCeC5EskpeVnimWZdzNnILIAfbgY4xW1Hwlpt7M8mJLYmJUUW+1BGyzCZZFGPviQBsnIz1BoAgvPGVpaafPdz2OogW0pguYhGrSQSYQhCA3JYSJt2lt24Y61LP4u0+21+PSLpJobmUMYtzRneVjMhAUMXHyqxyVA4xnpmvN4LikmgnGr6olzHcteSSgQEzTFFjV3UxFcqiBVwBj3OCFHgqzGpLd/br/AGrdy3ogzHs82SF4mYnZuPEjHBbAOMYAxQBCvj3TmgM5stSWEW8d4XaJQBbSEhZj833cg8fe4ztxzT7LxeGvry2vrWWIJezWdvcBR5TsiFwpOSwYqrHONvGM54qZ/BmnPp0lmZrvypNMi0oncufKj3Yb7v3vmOT09qVfCFp/aElzJe30sTXMl4tsxj8uOZ0KFhhAxwrNgFiBnOMgYAIrLxrZXEdkfIuHWY20cs8SgxRSzqjIhJIYkh1PCnAYZxmrEnjHR4rSK5mmkjgltZ7xWZD/AKuF0R/x3SKAO+azJ/Ay20Vimj31xHFDdWU00EzKUm+z+Wm84TdvMcSjghSVHA5qceAtNbelxdX89t9muLWO3d0CQxzSJIwUqobIaNcEkke9AGt4c8Q2evJc/ZA6S2zhJYnZGKEgMOUZlIIPYn0OCCK2KztF0s6XHIjXtxdlyDumSJSMDoBGiD8wTWjQAUUUUAFFFFABRRRQAUUUUAFFFFABRVPVNU0/SYFm1W+tbKFm2LJczLGpbBOAWI5wDx7Vmf8ACaeFv+hl0T/wPi/+KoA36KwP+E08Lf8AQy6J/wCB8X/xVH/CaeFv+hl0T/wPi/8AiqAN+iqGlazpmriQ6TqVlfCLAc206y7M9M7ScZwav0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXm/jGf7d8RrG1UsY9K017iVH+6ZLiQLE6D+8qwXCk8ECTAyGbHo5IUEsQAOST2ryLw3L9vuNd1gLsj1TUpZo064SNUt1Oe4YQeYD0w469SAbVFFFADZY0lieOVFeNwVZWGQwPUEVDY2VrYQ+TY20FtDndshjCLn1wKsUUAFV9S/5B11/wBcn/kasVX1L/kHXX/XJ/5GgDE8Chz8OPDXlyLE/wDY9ph2XIX9wnJFVbDW79bG61Gea2uLF5Fisd6GFp+Tl+NxIP8ACApJAz3qbwdZQaj8MfDtndqz28+jWiSKrlCymBMjIINaB8O6eYBCwu2RWV03XszGMr0KEvleCRxjIOOlAEvh34gSpp0hh0t5Vjtrq9kR5fKMawSFJVGVyWJyQCB77a3NS8W6iZoba1skgvBeWi+W0wZZYZg+3LbflPyHOAcY4Jqp4X8K6abiSNbUm1NvcQShpZCWWdt0g3E5yWJOc5HaurvfDGk3rs89vIJD5J3xXEkbDyt3l4KsCMb26dc85oAw18bZkJliit3jgufNhmlwgmiuEhwJMcgs3GFycjgH5a09D8V2l9ot9qOpbNLjsJmhumuXMccZAVt26RUIXDLyyrWR4wtfDvh7TtOS40a/vnupjY2sFk7NO8jMbksGaRfm3QmTeW3blznNcH4h8L654nh06fSvA1taix1b+0Iv7d1V5HnwAjebFtf76quPmbGAe5yAd1dfEmxvRJD4K06/8VXgd4lNhGUtA6pu+a7cCEDkD5WY5I+U9Kq+IPDXjbxhpepadrGuaVoGm3aywG20u3a7leJoSmHnl2DBdiSFiU4UAOCSRYsPiZptvKtp4tsbzwxqJdUKXkZa3ZmJAK3CjYQSOrbTyOK7uCWOeGOaCRJIpFDo6MCrKRkEEdQaAOOTX7nTL7TvD3jDTUb+0d1rb39qhktLkhfuSK3zQuyhjsO9cAjexBAf4anl8Pa63he+kkktple50qd2OBECM22W5LoORyxKcnbgCqHxG1S103xd4PfW5fI0ON7m5kmZG8uO4RFEJZwPl4eUAEgEnHJxWL4huL7x54r0DR3gudP0Es+oSoWMN5LHGPkl6Bok8wqoAIc5JIXFAHZan4knur6bSvCkEd9qMR2XFzIT9lsz/wBNGH3n5/1a8+pUc1b8P+G4NLuJL66mk1DWZl2zX84G8j+4gHEaf7K8euTzWnpmn2mlWMNlp1tFbWkI2pFEu1VH0/XNWqAMnxf/AMinrf8A14z/APotqrfD7/kQvDX/AGDLb/0UtVfHmrx2+l3Gk29vc32qahbyRQ2tqoZwrDaZGyQFQE8kn6ZPFPsb6x8HeE9Fstev7aCe3tIbbaGLGV0QKRGuNz9OgGfagDpqjuJoreF5riRIoUG53dgqqPUk9K5g6t4h1n5dD0tdMtj/AMvurKQ+PVLdSGP/AANk6dDTJfC+lW8Z1LxbfvqrQfvGm1ORVt4eeqxcRrjjBILe9AD/APhMBqRMfhTTp9ZPT7UD5NmP+2zD5h/1zD1T1XTbptPlv/G+uvHYpjdY6WHhiJJ2qm5czTMxIUKpG4kAISQKkufiDpbNJD4fstS1+aIfMmm2+UC44YSOVRlzgZRm/Q4s+HdHvb2e01zxNNJLqGzzbewZVEOms64IQDlpAp2l2LHl9u1XK0AR/CPTF0n4aeGbZrEWNz/Z1u1zF5PlP5xjXeXXAO/Oc55z1qDSc6L8StV085Wz1mBdQgz8kazJ8kqIOjOwAkYjB55B612teT6pL4i1X4mifToIrrTdH1O2gSUYVreOSE/aSD92QfdUj7ynkelAHrFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnfxbhin1HwTHcRRTRNq0uUlQOp/0G56g8VR/sfSv+gVp3/gLH/hWj8Vf+Qt4H/7C0v8A6Q3NMoAo/wBj6V/0CtO/8BY/8KP7H0r/AKBWnf8AgLH/AIVeooAr/De2t7X4heKktbeGBDpumsVhjCAnzLznAHWt7xxdazp9zYyaPOmy/P8AZxjkxtglc5juBxztwwK/xZXpisf4f/8AJRfFP/YM03/0ZeV3GqT6bALc6rLZxgyr5JuWUfvO23d/F6Y5oA5e38R6qfEcum2li9zY2F1FY3EzgbzujRjKX3ADG8fLsO7kgjIFc74P8S6s1vokJufPutR07SkWa7LOkUj208skjAEElvKx1GWK816BcweH5tega5i0qTWl4iMixm4G0bvlz83AbPHTOe9Z8c3hS5vLnRY7fSpUt7VGnRY4miijiO1UfsNnOFI4HpQBi3fjy/t7WDbpaXF5OlysMUTHE0ttceXLtP8AdKAyL6gGtWbxBc3vgDWtbsDFE8cV49nIPmDLEXVJPfds3D2IrUS78PQafZ3qXGlR2MAItpw8YjjH3TsboB24+lL9q0SLTZ7GD7FJZ24S2ltLdVdY1chVRo16A56EYxmgDj9P1/W9Pni0q1s21B7SGCa7dnd2kErMSQ8kmUCqCckMCQQAoFTXPj65gs7xvsET3Wmwv/aEYcgRTGYRRAH+62HfJ6KB68dTNa+HtU1IQTwaVeahZAYjdI5JbcZBHByVGcelSrJorXV9Cj6cbmfP2tAU3ybV2nzB1OFAHPYYoA5lfEniPzLKyfTbWO+urt7eOS53RI8YgMnmbFZyDlWXBJzjORnjuqwLBfC1jYR3mnroltZJIzpPAIkjV9pDEMOM7QQT1wD2rTfVLCNrQPfWqm7x9mBmUednGNnPzdR09aALlFFFABRRRQAUUUUAct8UfEUPhXwBrerzmL9xbMI1kbAeRhtVfxJArzPw3e6pdaTpWkeCtFvdQt7W3jtU1bU4zbWpjiKxeZnq+QCQF9K9b8ZaDa+JvDGo6Rex+ZFcxFR0yrdVZSQQCDgg9jSeCtXl1zwtp1/dCMXrx+XdpECES5QlJkXOeFkV1ByQcZBI5oA84muvGVjYLPqHgieUoF877DfxTHkgMUj+8wGc464FQ3vi+109El1XSfEGnWrOsZubzTXjiQngbm5wK9oooA8f03xd4e1OZorHWLOR1XcQzGPj6sAK17e5guQxtbiCcL94xSK+364PFd3q2kabrECQ6vp9nfwo29UuoVlVWwRkBgcHBIz71zV/8L/Bt7dfaG0OG2l2CM/YZZLQMASRlYmUE/MeSM80AZ5B/OorqLzraWIHBdCufTIqQ/CjTYLiVtI17xJpVvIQTa294skYIGMjzkdhnv8ANXm8NxrWpWkmneFfEmr+IGWWa1NxbeGjE0ZQnO65mmjh3DgZGcnHymgDU8Eas2k6bpvhrxHCNO1OzRLC2LZ8m/WOMBXhc9flALKeQePavQtP0u5vXG1CkWRud+OOvHr/APXryDV/BGtaXe2niLx7ph1bwwgiN7bf2jNeXmnALIftCeUkCYRnXftV2AUlTjONy/07RdfabTfhZa6nqN1b7Adbi1+dLGxcqWUeYzyCR1whKLG4w2GK0Ae36dYxWFuI4hknlnPVj6mqvibX9O8M6LcaprNwILSEcnGWdjwEVRyzE8ADk15SNP8AE2i+LtL0fxT441xrXVYVjtL+1ktIlN2q5kiZHhJAbqmCemDzXc2PgG1TW7LVNY1jWNduLHc1ompSRNHBIcfvFSONAXxwCc4ycYoAzdHstY8YeKrXxBrcFzpWiaVM7aVpkq7JppdrRm5mHVflZgqehJPUV6HRSMwVSzEAAZJPagCK8tbe9t3t7yCKeBxho5FDKfqDXkF7b6X8MfiJpUPhW1lmXXLeW1fR4r5VVJlCNbuqOcIuEnBI/vHAOMV2suuX/iWR7bwiVisQSkutSpuj9CLdT/rW/wBs/IP9rkVjeJPCOj2mo+BrM27T+Z4hF1PPPIXmnmjsruRJJH6sQyqQOgxgDHFAGs3gw69G8/jWZb+6dSIreElbey94h1Mg/wCejc+gUcVW8JaTrC+OdRvNeZpf7Psk0+0uwu0XkTsJC7ejqVCnHHf2HeVg6vrOox3zWGi6JcXtyAC1xO4t7VM+shBZvoit74oA3q4bxl43FrcnRfDEUmq+IJDtdLRBMLNT/HJyFU+isVBPUgc1gXVpqnje8k01fEbXNvG5TUJtK/dWdpg4MKnJaafjGGbYg+Z05VH9B8LeG9I8K6UNO0CySztAxcqGZizHuzMSzHAA5JwAAOABQBx/hnwv4naOafVdSj065uyGuriBVmvJ8dAXI8uJR2RFbHZs8112h+GdK0WV57O13XsgxJeTuZriT/elcliPbOPQVs0UAFef6zpVj438eG01K2S60rw6oEsUhJWS7lVJAGXoQieWwPIy5HavQK4fwTbx2Hjrx3bHdHJc3sF7GkjktJG1tEpkXJyU3q68cAqQMYxQB2sEMVvCkUEaRRIMKiKFVR6ACn0UUAIzBVLMQFAySeABXH/ChTL4RTU3Vo5dXuJtSkiP/LJpXJ2j1A9an+Kc6Q/D3XY3DZvLc2CEDo9wRChP+yGkUnvgHAPSug0q2az0uztpCGeGFI2K9CQoHH5UAWqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPN/jHe2un3ngu61C6t7S1j1aTfNcSrGi5srkDLMQBkkD6msT/AITXwp/0NPh//wAGUH/xVevzwRXCBJ4o5VByA6hhn15qD+zLD/nytf8Av0v+FAHk/wDwmvhT/oafD/8A4MoP/iqP+E18Kf8AQ0+H/wDwZQf/ABVesf2ZYf8APla/9+l/wo/syw/58rX/AL9L/hQB5x8LNT0/VvHviu40q/s76BdO05DLazrKobzLw4ypIzgjj3FdD4z8L3WsarBeW/lzwi0ls5baS7e2BVypJDordcYKkc8HPGD1lvbQW277PBFFu67EC5+uKloA4ZfB10J7iRZLaNpdWtr1XV2LrFHaRQkbiM7tyOR7Hk5JFZZ8CatPpcdnPJp8H2bTbexjeCVz55hmSTLjYNivsIIBYjcetem0UAcRpHhO4h1WyvbqC2jMdzPcTqbyS6Ls8KRhgzovPycjAH1JNZ9t4E1CHRdIs1lslktNLsbOYqzANJDPHI7D5eQdr4J5yeQMmvR6KAOb8J6TfaOGtLqCwe3jad47uORjNL5ku/50KAA8/MQxyQDx2xtX8Kanq+oa7LeQaYouYHtrKZZmYxRnBIaPywCZGHznd90ADpk97RQBxMPhe/n1yz1S9SwgKaot9LbQyNIiqtnLApVii7nLOp5AwFHORzjR/D/UIlRJDbXcUlolrLF9tlt1jCSyOpUqh3j94ODtwV4PPHp9FABRRRQAUUUUAFFFFABXmHxCkk8LxeKpLd3htdf0u6mjkRiGi1CG1Y5B5bMkEYI6Kv2U/wAUlen1h+MtMuNS0YvpuwatZSLeWDMdo89M4Qt1CupaNiOdkjDvQBw0+t3mha1qdjeXN5nTdOSNJdwO6N7hVimJfK8K213bOPLdjxVjQPEOs6xPa6cNUhXde3Nub228ucuiQxyKQ2wITl8EhACB07132g6rb63o1nqVnvEFzGsiq4w6ZHKsOzDoR2IIq/QB5RD4m1efQ9Puby5WY6jp2najsCCNYHkuI1ZUK4JXD/xEnI9Diqtvrt1aabrMFjqaXbCbXWuLLKlrRUnuGjkJXDrlgq8nkOMYxmvYaKAPNYPFt43jHTrOC7XyJLpbOeznkjDgfZy/mIgTft3AfOz4OcBTkGqX7Nv/ACJWsf8AYdvv/QxXq9eUfs2/8iVrH/Ydvv8A0MUAer1DZ2tvY2kNrZQRW9rCgjihiQIkagYCqo4AA7CpqKAOe8e+FrTxj4YutIvi6h8SQyI+0xyqco3Qg4IHBBHtWT8LPFV3rum3emeINieKtFkFtqsca4TeclJEIJBV1Ge3OeBwK7evO/iRbSeGtTg8faWq7rCIW+sQrFuNzYl1Lvxg74gC49tw70AeiUyaKOeF4pkWSKRSro4yrA8EEHqKi069t9S0+1vrGVZ7S5iWaGVejowBVh7EEGrFADY0SKNY4lVEUBVVRgADoAK5PxpPCvivwDbtLGJ31eaRIyw3Mq6fdhmA6kAsuT23D1rrq4Lw7M/ib4latrKn/iVaFE+i2fAIluGZHupAcZwpSKMckZWSgDtdQvrTTbKW81G6gtLSEbpJ55BGiD1ZjwB9a5Uyal4yASKOTTfDEhO6fzGS6vkHZVwDDG39/O9l6BMhqtfE+zjvfh/rqTZ2Q2xusDHzGEiUKfYlAD7E1t6JdnUNFsLxkVGuLeOYovRSyg4H50AWLa3htLaK3tYo4beFBHHFGoVUUDAUAcAADGBUtFFABRRRQAVw2tTR6T8W9AmG9n1qxmsZBsLhRAwlQjaPlyZX3M3HC9D17muO8Hr/AMJDqVz4quf3kDs8GkAnIjteAZF7fvSu/OM7dg7UAdjVa+v7PT4vNv7u3tYv780gQfmTVmqV3pOm3l5Hd3en2k91ENqTSwqzoM5wGIyBmgDzrxt4w0PV9Z8MaZp17/akP21r26jsYnu45YoUYbCIg24+Y8TAEbRsySMDPV/8JJqdz/yDfC2qyA9JLt4bZPxBcuP++KraUBqPxL1u6AV7fSbSDTogw5hncGabYOwaOS1yR12Y7V2FAHK+Nrm+j+GPiO5uEWyv00q6kxbzl/KYROQVfapyODnAwfzrl7p9a0PXbGfVprp7WwtryG3jgkMr3MUcRcSsmfmkI2Lg87kJHDV6lRQB5Rp3jHUZZZLWfV7X7Cbm2V9Ujmhm+zRyRzMdzqixg74kQZUgGTq3FZc/i280PwWj2GpAXNvBf3yvcSRJFd7LiXCjKMztx91NuAw+YZFe10UAeeP4qu4/FNtDLfDc2p3FpLpSRoXWCO2mlSQDG8sxjQg52kNgDPNYll401W4t70Q6zYmDyLS5Wea5g8yMSO4ePcEESSYUYVt2CeWORj0waJY/2supMs8l0pLJ5lxI6RsV2kpGWKKcZGVAPJ9TnSoA850LxXLqN7bfbNXk0+IQwPbwzxRCXUSzuG6ZDfdCjyiOobkMorItPG+rTw3jWWoW8yywWs0DTGOZ7dpLlY2SRI1QKQr/AHCzMMfer12igCCyjmitY47qf7RMow8uwJuPrgdKnoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOP8Msug+J9W8PzELDdzSatp7MceYJXLTpk/eZZSzHA4SWOuwrhviTDEdc8AzmNDOmvBEkKjcqta3G4A9QDtXI74HpXc0AFFFFAHKa94surDxIui6V4fvdXuhaLeSmCeGJY0Z2Qf6x1ycqelZPwQ8Oar4Z8JXltrtstrd3OpXN4IhIsm1JGBAJUkZ+lXoP+SyXv/YAt/wD0omrZ13xLp2jSx287yXF/KMxWNqhluJB6hByF/wBo4UdyKANqiuTjsvEWuyJLq1wdE08HP2Cyk3XD/wDXScfd/wB2P/vs11lABTJ4o54ZIZ40kikUo6OoKspGCCD1Bp9Z/iDWtO8PaPdarrd3FZ6fapvlmkPCjoPckkgADJJIAyTQB5zeaNr3wytdQ1PwzdrqfhS2iaZ9Du32NZxKQ7fZ5Oc4BkO18DG0A8Vsab8XfB14kL3GovpaTwLcwPqkD2izxt/FG0gAcf7pNUDp9/8AE3UjLrlpdaf4Hs5v3Gm3MbRTavIh/wBbcI2GSAMPkiYZcjc4A2rXpiqFUKoAUDAA4AFAHL+IPFtjB4T/ALU0W5ttRe8KQaeIpgUuJpGEcahxnALkAnoOa0PBugW/hbwvpui2jtIlpEEaVvvTSHl5G5PLMWY+7GuH+IXhHQNLvvDev6Vo+m2OqQ6/Z7p7eyhVphNMIn3nbk8SEg5yGAOcivUaAIb21hvbOe1uoxLbzxtFJG3RlYYIP1BrmPhPczXfw70SW5cySeSU3H0V2VR+AAFdbXFfDLNuviTT3zF9l1i48q2Py+TAxDR7U/hQ/MRgYPJFAHa0UUUAFFFFAHL/ABPnmtvAWsTQu0caRA3UqMVeO13D7Q6Ech1h8xlxzuAwD0rorOKGC0gitUVLdEVY1UYAUDgAduKreINKg13QdS0i8aRbW/tpbWUxkBgkilWwSDg4JxxWd8PdVn1zwLoGqXixrcXllFNIsYIUMygnAJJx+NAHQUUVi+NtVn0PwjrGpWSRSX1vayNaxSAkTT7SIo8AgsXcqoUHJLADkigDM+HC/arHVtabmTV9SnuBIv3JYUbybeRPVWgihbPQ5yOtdbWf4d0m30DQNN0eyaV7Wwto7WJpSC5VFCgsQAM4HoK0KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOK+KmLXTNF1liWXSNWt7kxAcy791vjPbHn7s8/dx3yO1rl/ifbx3Hw+18ygn7PaPeR84/eQ/vUP03ovHetFNbtbLw3aaprN3BaxPBG8kkjBV3MoOB7k9AOaANeszXdd03QoEl1O5WIyHbFEql5Zm/uoigs59lBNYg1PXvEPGhWx0jTj/zENQizNIPWKA4I/wB6TH+4RWnoXhjTtHne6jWW61KQbZb+7fzbiQem4/dX/ZUBR2FAHms2qXmq/GJLS5uZfCx1HR0SBJQjXVzGk0hIQ8rE3zZwdzYHGDnHqOg6BpuhRSLp1sEklO6ad2Mk0zf3pJGyzn3JNcL4q8M2Hiz4kalpupq6j+wreSGeI7ZbeUXMpWSNuqsCBz+HStz4TavqWs+EvN1iT7TLb3U1pHe+UY/tscbbRNsP3S2DkdMgkcGgDsqK4/4g+I73Tf7O0Xw4LaXxNrEjQ2iTt8kCKpaS4cdSiAdO7FR3qv8A8I340/6H7/yjQf40AdN4i1vT/DmjXOq6zcpbWNuu55G/QAdSSeABySa4jw5ompeM9atvFXjO2e2srZxLouhydLc9rm4HRpyD8o6Rg8fMSRetfAl3ea7Y6l4v1+TX1sPntLVrVIIY5f8AnqyqcOwHAz07c13dABRRRQB5/wDHZL9fhrqF9pDxx3umSwalGz8geRKshOCCCcKeD1r0CuD+Ieo2viP4feN9L8P3EeoanbWM0Etvbne6SNGSqkDufSodP8Qaxr3h7wdaWN3FZavrejjVJ7/yRIsSokG8JGeCzPcIBngLu74oA6bxH4n0/QjHDKZLvUpRmDTrXa9zMOeVQkccH5iQox1rP8GaPqVvq+ua5rHkRXGrmBltIsn7OkaFQrMT8zc8kADPT1rR8PeGNK0HfJZWwa8lJaa8l+eaZiBuZnPOTgE449q26ACiiigAooooAK4j4YztbJrmg3MMlrPpupXHkW7gKotHkZ4DEAf9UEYKMYAKle1dvWF4n8P/ANriG5srt9N1i2BFtfxoHaMHqrKeHU/3TxnBoA3a4LxJrVp4j8SaN4Z0otfRrepe6jc2w3R2i2riVFaT7oczxxIU5baWOF4NTHRvE2v4h1/U20yxhHlvFpj7XvCDnzfM+9Gp4+Qe4Paus0zTrPSrNLTTbaG2t0ACxxKFHAA/E4A5oAt0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVHDPFOCYZUkA4JRgcVJXiHhLT9Z0/RNOfTLO7ju00GK3usaY9pLAytDuVSwHnSFfNwcHBXPG7kA9vorzC5tbu5uNLuGGuto9nrheB2Sc3KQNYyIWKkeaV859uWBOGP8ODUdnc+IbW01SWJNXvZrRoLozMk6G6AmJkiWGRcKxj3AeUSuce2QD1OivMkk8VW1pqcOqpfXhtYreESwCRBK00paSRfLG9hEpVcJyQCBjrUekxa/ex29peT6wLRDqGJVjmtmdQYzBksTIOr43MScYOeRQB6jUV1cQ2lvJcXU0cEEalnkkYKqj1JPAFeYR33iObUtElkh1S3uVawWdTBcOk8bonnMQMQx7SzghgXBTPyjFdzfeGdP1LV11DVBLfGLaYLe4fdBAw/iWPoWzzubJHYigDJl16+8SwyW/hawilsJVKPqeoxkWzKeD5cfDTd/7qH+8axvg94fs28M6ZqOptLf65bK1u73knmPZMrFTEiniIgYBAAb1zXpVcbcQS+DL681G0ie48P3k7XN9CilpbSVvvTpjl4yeWXkr1Xj5QAdlRXIQ/Ebwxca9YaVa6nHcm+ysF5B+8tHl4IhEw+TzSMkJnOB2yuevoA4yD/ksl7/2ALf8A9KJqp6H4T8WaFpqadpnirShZRSSNEJtFZ3Ad2fDMLgAkbsZwOnSrNpNFJ8aNSSORHeLQrdZFVgShM8xAI7cc121AHK+EPCkmj6rq2s6xew6nrupOoe7S3MIjhVFVYUUu+1QQzHB5ZiT0FdVRRQAUUUUAFYnjfS7nWvCmp6fY3EttdTwkRyROUbIIOAwIIzjGc8Zq3rmsWOh2Ju9SlaOLcEURxPLI7HnaiICznAJwoJwCegNUfDfi7RfElxeW+k3btdWZXz7ae3lt5owwypMciq20jo2MH1oAwfA3hq7tbzUNYu7RtG+22UNmmjRypMsCxBiGZxwXLSP0OMHJJJ44LwHql14X8VWNj45nl0yy8P6BFZWclzYrEgjmkVd888U80Uf/AB5Iq72QszsAOBn3muO8E3MWp+KfG1+s0dxJBqEWlpLGwIWGG3jkEfHGVluLjJPzZYgnCgAA6qxu7e/s4buxniubWdBJFNE4dHUjIKkcEH1qeubvPBOhT3c15a2j6ZfzOZJbvS5Xs5JnJzulMZAlwecSBhknjk5uahb6ha+FbmCz1Iy6otsyRXt4EXMuDtZ9ihRzjouPY9KANiivOofEsvh4Xf8AaUeqRvbtaNdxX08c6xwyu0fnRumT94chsYC5CjrUlr44vrm2uY5rOOxv4RBC0TI0xFzJNIoj2grn5EV+SOJFyQM0Aeg0VwFr4s1u9sbBbW1shqk13NZvayKc/upSrykq7BECgE8tyQoJJGakvim5t9aEs108cEcWrRhHBkVnju7WKL5VwSfnIA/2sZ70AelUVwOn+LNavLhNNNra22o/2lJp7yTRnaAtqtwH8tZG5wwG3f75HQZt34w1TWdCjuLIwWAiXTZbnG5pHM8ygqhyNq4BGSDnJHGKAPUKKKKACiiigAooooAKKoa9dzWGlT3VuELxbWO8ZAXI3HG5c8Z7j8ehzvCOvza/FPLJYyWsS7TGzpMhYEngiSNCDgA8Z69u4B0FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQRkYPSiigDzbSvDel3I8SeAtUs0k0mNlv7MAbCiTs7HY3Xekqu28Hjeg4xV4eDvEw0/7GPiDq3liLyhIbO2MuMYzv2Z3f7XXPNXfHw/soWfiuLCnRtzXh/v2LY88evyhVlAAyTEFHWuuoAwPC/hXR/COkyWui2y2wZQ00+N0szAY8x2OSzd+a890nVm0eCZdOlsNUvI7EmTVbG8knAAkjVpLmEkhXwzOPmY/I44Ga9hrlz4005bjxFG0dwF0WIzSPtBEygNv8vnnaylTnHPtzQBi2fiyW3vLb7Rqttc6J/aT2v9qSeWqSp9l8wfOuEyJMrkAA4x1Brn59cv9R025ur7VmhF74VadLXhUnl2z7ygPO4DaTt5xjPFdpb+O9NGlPPeyQQ3y2sl4bNZSW8tVdsksq44RuSAMjqeCdl/EOmJeXFr9oZprcMZdkLsqlV3FdwBXcF5253Y7UAZXg67vf7Rv9Nvbs3aW9tazxyMiqV8xXyvygcDZxnJ55JrqqpaVqlpqkcr2cjkxP5ciSRNE8bYBwyOAwOCDyOhBq7QBxvj+1votQ8O65ZQXF9BpNzI9zYQxLK8iPEyCSNT/wAtFYqAQR8ryeuKyhpni46hqni21tLCPW5oIbO10q5lzGtujlm3SqAfMYsSDghemDXo9VdU1C10rT577UJ0gtYF3ySOeAP6k9AOpJxQBw9/8RYXubTQYLaXT/FWoOYYLPUVKBMAkzbgcOgwcbSCxAHGc12HhzR4NB0W1062ZpPKX95M4G+eQ8vK+OruxLMe5JrmtG8Mx+IbW71TxfYLJd6koCWkuf8AQoRnYqH7yOQdzMNpyQONop50fxD4bG/w5ef2tpy8/wBmag+JEX+7DN7KqqqOMZJLPQB2lR3EMVzBJDcRpLDIpV43UMrA9QQeop4OQCQQT2PaloAzbXQdItLOW0tdKsILSYgyQx26Kj46ZUDB6DrUtzpWnXUdzHdWFpMl0yvOskKsJWUAKXBHzEBVwT0wPSrtFAGO3hbw+wh3aFpR8nPl5tI/kycnHHGTzx3q1Jo+myiQS6dZuJFkRw0CncshDSA8chiqlvUgZzir1FAFCy0XS7HZ9i02yttkhlXyYFTa5TYWGB12gLn0GOlRyaBo0jW7SaTp7NbKEhLWyHylByAvHygHnA71p0UAFFFFABRRRQAUUUUAZPitYG0G5W8RpLclN6q23jevfB47n2zWJ8Pv7FMuot4eieC1IjHlbV28F/mDAknPPX0FanjhtvhTUCWkXKqv7sgFssBtySAM9Mk45rF+GcMUEd+lr9oSBfLHlXMSJIj/ADbhlFVCOgBUnp2zQB29FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBFeW0N5aTW13FHNbzIY5I5FDK6kYIIPBBHauf8AAdxONOvdHvJpLi60O6OnPcSMXaZBGkkLsx5ZzDLFvOBmTfgYwT0jHAJwTjsK5X4Zf6R4Th1R+bnVppdRn3cvG0jkrC56lok2Q89PKAwMYAB1Z9q4Nfh3FFYKkOpXAvJbO6tbueQySJMbgEyOsZfbH+9w+B7jvmu8ooA5XUvCP22x8RW323Z/a+lrpu7ys+VtSRd+N3zf6zOOOnXmkuPC9+bbVrKy1gW1jfySzALbnzopJOTiQOPl3EnG0HBxuHBHV0UAc74Q8N/8I+2pv5loxvplmKWtr9njQiNU4Xc2c7ckk9TXRUUUARXNxDaW0txdSxw28KGSSWRgqooGSxJ4AAGcmuQisZPGmoWup6jHPb+H7YlrSykLob0nGJZ48gbOAUjYZ/ibBO0OtVHjTU5Lqdt/hqxnAtIl/wBXqEqgEzsf4o0fKov3SyF/m/dleyoAKKKKAOa+Id59g8OxXJuPsyJqWneZLv2BUN7CHyey7SQe2M5rm/FvjG6XVQmhappUVkLQTW9zNdRrBdT72DRFyGyFCplUIb94DmvSaKAPMbnxdqdtqmu24vI7meETNGtuIpobWNZ0Tc4GJUdUYkq+VYq20gDFI2uXk+raUR4hzpMWrPbLqSmMR3Sm03hXIwjESFlBAAyMY3LXp9FAHklhrWsaLpIe0uTcpcR6rMkLxBhC0V1gOMfM2A7EqTzgAY79v4N1OXUH1SMagmqWVvMqW9+gTEuUVmXKYVipPUAdcdQTXSUUAFFFFABRRRQAUUUUAFFFFAGT4qvf7P0G7nFvBc5Aj8q4fZE24hcOdrYXnng1V8LCO1a40waTY6ZJaJGoSxKmExnO0LhVIxzwVAGeCeateK5reDw7fPeX7adbeXiS6VEfylJAJw6sp69wa5P4KNHJ4ZaVbOws5i5WSO2042bZVmALg4DZXaQVAHJoA9CooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuL8N39noOu+IdBvrqC2VLr+07RZZAuYLkl2OT1P2gXXHZdvbFdpWTrHhvQtanSfWdF0zUJkXYsl1axysq5zgFgcDJNAEv9uaT/ANBSw/8AAhP8aoav4z8N6PFFLqWuafAkrbEJmB3NjOABnsKj/wCEC8H/APQqeH//AAXQ/wDxNWtL8KeHdJu1utK0HSbK6UECa2s443APUblANAGN/wALR8E/9DHYf99H/Cj/AIWj4J/6GOw/76P+FdnRQBxX/CctqjAeDdIuddjH3rpXEFsO3Ej8OQeqryKhHhXXtfu0uPGGsCK1SMxHStIkdLaYEgkyswDPkAqV6YPua7uigBsUaQxJHEipGgCqijAUDoAOwp1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAY/jAzDwzqBtmnWUR/KYLUXL9RwIj976Vk/Dy0ltLe+EseqR73VgLx2MZyMkxK3zIvPIPeuuooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Although the \"yellow fever endemic zones\" are no longer included in the International Health Regulation, a number of countries (most of them being not bound by the Regulations) consider these zones as infected areas and require an International Certificate of Vaccination against yellow fever from travelers arriving from these locations. The above map is based upon information from the World Health Organization (WHO) and is included in travel information issued by the Centers for Disease Control and Prevention (CDC).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     file://www.cdc.gov/travel/yellowbk/figyfaf.htm",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_14_11496=[""].join("\n");
var outline_f11_14_11496=null;
var title_f11_14_11497="Papular sarcoidosis - face";
var content_f11_14_11497=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78691%7EDERM%2F69405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78691%7EDERM%2F69405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Papular sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFFAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDkGg3MoVju65jHJHuP8KjuIgwYPIXKcHavC++7+lWohvUEfL15i59j17/SmxhkZj5pyQQOgI9unFcdj1TOEG0IeWzwV6H9acxZDtIADA8luRV2dlliwqk55zncCO+T+FIsUfkoF2SDk7lwct2A7iocexopvqPguAkeAxCk9cenb6H1rU0O9hjnK3DD7pBJz09B9fWsaAgKwePco+UruC/TnHY0eWJZisTDcf7rbhn+n0pWaKUu50r6iEO/dswMLgcgdh71D/azxw3GY4JnlPzOynOPUGufVZCoyJPvY6cVNOJZEUudoACnJ5Y/0qbyuaPlZJdzR3RhjCpEsbAEp3/xq6+nRbsJ5zjO0GMHaayZYAsIZVJJPBLDA49u9W7PVLm2sxayFzFncB1BNVp1Ie+hoGNUBREZXz8rSZyRjkelSWklvdJCCJsjIdRwGPbGePwrMkJdzvBRgQxxV63GNjYOw5OWJIOOv9KTAtuWWTAVImOF2gdv85qeDdIWIR/LxjbgDcfWo4mhkCiN3DR5yBxn/CmRNJBvQsBgnLA/MQe3NIZpQKEV1Rg6N1yxYg+mepqZPLjiDNNs2n5VVQScVXnL2kieXGrBwDvBA24749aczRRy7ZcoXzhiTz+Qqr2EtSK8MzASeWigjfuzzjpz7+1ULgKGbcCxb16H2IrTlikJO7cyuN3zH8sVTlBSAuWB/eD5mx/Koepotiuo85m3Rl5FUYIJzmo9+wmModoOSM9frUrS5ZfLZX2jGVBHJ6g0Hbgh1wpAIQDIzWZaFO2VTLJKisowAgwCfSpFdPPWOR2D8YEYJBFSII4XQoxRiBhOoJ9/anhwCMg4HBKngGn6isP+ZgsEjlVZ8jdwOnoeaci7pBGVBROBTI45GyxlRgcKc8fSlKTBVc8EHkYBBqxDp2kMkflxI8TNt6AMMVHcMyA+ZBJljgOpBCD2pyAySb8LtUbipfp+VTykFTb/AHuhV8H5R1x70yGZzH5hkFGxhmC5IPr6Cs6dn3eZADuGSGU8nPv3NaV0z42qz4bqv97mq8wXYd0wjZAWdx1x6UWEc7OueA7YU8gnnJ71SZBFNtLq+0ZyvI+laMgEqMQrnBOSBgD2FLPNcQ2ZgCBY5Fy0eBj8RTUb6mcmU7dFEpVgxjOGHlcgD15HStCGWOFFaN5nlxkMpIwfQdz61lh7jG1CqKFzw2OO3/6qjmkjUgF3dxyzg8fl/Wq2JN631J0ZlkJJDEqWj2sxPc1oWA82NppkBbGQCML+Fck8xdQZZSw4ILNkkGtC2vJIV2eX5kTD5fmIx9KTbZULI1ZW81CT8qt8wK9CfQ1USLzk8qMJJI4PAHv71X+0OyLGDjsF25/DP9aRJR5iBxj2xjA75px3Cb6I044iy7laRIxhVUnagzkYBP0qdROzhXSNDKNgGQDtHUknn/Gs37aoLc7wF2iMnEa+6g96k8u5nRF2EQkgL82Dnt9f/r1pdLYhLuaN1cWkaoqEPIQMN/Eg6YA6Z/Wo5bizaeS2sVmnkZhHBIflOO/Hr19Kii0+2/1azTb87SCgAX1/z1qS7h+yxKG2tEeQxjCgewI60mm9SlYeVvZ4mLQbUVTuZnAU44BAPfiqiGV5BszHhcks3Ue/tWsfKS3EsVpvRcAf6GdrH0znrVW9E8zzmLTiiqMYx8yDGTmk15lJkMtpcvaJcPcRMjsSF8wE5+lZ4WRFbPmHcecc8e1aEEKySxiK3lyy4JYbt577elQXSqX+UbAB8yJkAH1561DXUpMiiikVv3MZDFSfm649s01BIqH92pSNvUcn39qeqBl3D5mUZO5s5NTHbPOZZoUIPOxDsCn2A/lUPzKGrNM6GIsqxdGCOFGPr1xUllApcLB5AlPC+b8wPPUHoPxq3FGJESOaCJPLBCBchznux7gVKoDXBACvN90Ang8dOasloQ6ZlZyJbW8Kk5xcgMp/2R0bNWL/AO0fZIgl/FcRWybIwcBlJ/hBHU+5pDY3NtbjBhSKRRvgMmcgH+LuvXOKjhtHuFlSGS3RxGZWyUG5ScYBHf261XyJtYoyi4jBe5WSRPKCiQQgJwcEf/XFU7+JIMXNusKxOxQRP8xQgeh5xz1q+ZopLYW+0NDErCSKTIUP2I5yT6DpUByINiyRRRrDhEmHmOxzyAAPlJ96l2CzMo7EwibRCygPg7jnuRnvUcyndHDEsTyRkj5OWfvknp7VZ1CJ4GSKWNEDAMgX5jg/1qjKJG+ZscdMcNzUhYvrOBE8LuUHDBpBkDHIxjkVAjkxq5AWNzgN1IxzwK1JltIlZNwJI3Hcv3qpyL5+0iFvLQAHZ1xWl2LlRVkl+UZWRwoznoPypj3HmbfKVgBxhgOfcVo3Vk/2ZZoSV25+Q9j7etUFjchWOAQcHfkD8D/Si4uUkMm8BJGyAOXkPWoGuPmPzZGMHCgZx06VJ9lhMcrCeJZF4SNgcsc9vSqq7Mhn8tsDBUDB60m2F+5ZE2MEggNxy2SKeFMZEis3AwQ3HX0qG2EYkJAUHOdqrkgfjUokZlAUF9v8O3t3FCXcGzY0/S0vbaRlmRPLG5tx6j2x1NWf7NjVJFWZXlBAUZG0fX3rn4TMkhmtFOV/1kYOCOOw9Ks22pPNK7xQM0zAfKO3vzTvboNO48M8beXMrAglTuHAP+FWoF2RpEkkgO47QSCD71Ua7eeKOOdQkiE7nU5JJPU1JbuYpImkZggPK55I71MvIcDTZ5IQPMdt8pwQo5Yexqa5PmRIqZLDK7pF5I7VBuQWrsikOzbhnsB2obb9oG/5BjtSL3JElJYx+cE2n5UHrVvzZJ0+cs6H5RvBHNZgaFZ5Ds+RuBtwT+Jq/CEd4+QVUYJYj9BQmBekhgZh5qYkHQ9gveq8lm+CIVJX76AEHgdat2EVrM85kuSDgLhck8nA56CrHkRq6vH8yEcr0z+PrQ1cuO5hrFtl8xQoH3vT8KVYg2clSGB4BxtPvWpa2MmoXLR20MqFT82FLEe+BTL7SpYFBVH8s55ddpx+NZcrNtNjOjeNEIAXA5Y55oQxeWVDEdSAD1ohSAbmyrYHC9DWnPYW1qgbzA6MARsBzk+ue1CTew3a5WO51VVRCuAOvzf/AF6AqyxriGTnGSSccck+/wCNT3tnH9njlgJx6dDj60llLL9njWQZiB7dSRxVrfUzaW42NCJHZgoXALHAx7GmFj5+d6oJB8zL044qrcM0WER9pIK8r+lVJblGx5qDg5B2dDTuZtMuXQkAT5lKgYGFwfqfasyX5ooQ+ME4yo4FWjOZVYs0YH3SzKST6fSql48phwCBk/dHReOuKbJKd26KCAAUDcMvINRFYmfyzDNLvUkCIc7scU1wyfKCCRyOcj602O7+zSpIsSTSAMATngnjIqoW6mMyheRG3kPmxSQ56bhwPoepqoeRuDYJ64P3q1755mLTzq5d15Jfd7c9hWPFa3UYSRULlQXABBOB3ApuN3oTe25JbQys2URGAAO7HIFaNuHkSQkx/NzjkFs91x3qxbzLqFrKEuc3FvGSoOS0uPT+6OTxVnRYo3jSWWZUuC+0BifunvjsKrla2EnzGY0TRq23zEI58vqB+NTta7HQPKWC/f2rwo9B71c1dWjkkSEAyA5IHUY/pVWWBoWRrhwjOQTt6Yxxn0pDY6S6gMTpDFtLcDcMt+GOAKupcOytIs2xo14QL0+XnrUmnWf2+xuEtIWZ1G8gDhFHfNU2inCMxByWAGehoUmNpJFq3aS4ClT8xIJD4HynHOO1TzxyG3ZCUOCWJMxCqD2Cjr9ariQJIS8uT9zHcjvSreo0dx5KOpbaoJOCBjscenandAaMdzdytFDJdSGJwrjaTtGO5+gqvPxcFVeTqGkVTjdnJHPbHXmqplcjdCwAB2hiSB60+OKWaEy+e6xhtrs/Pv0ocmykrF2HKWj/ACuYVb5T5uQFI5XaevPJNVpREpUJtKEhyGPX8B0FNhtF3jadzA/OhboMZqR7ZBuZHSRcAhVX17daiTZoiBpYhGwCsWB6KuB/+qmxyKRGqrIHHDbRk1dRUcOjYaQ8HL4A9cDvUESLvHzPHk7diJj8SfrWbLQsCvNlI5GVM/LuQ5P41PJaXBAldJt5O4S7uWHqM0khUyyA4YKMZ39D659KfZkXZKFZWjA5VSxBP1/kKLCbJo4rd4hvlZZkk3qW25I9z2bP6VRuPNuJ0RWikJbkhdu854JOefrxVtY4mmaO3hWOPGWLuHYDv1wM1Wu7i3uI5IUaOJoCFiV1zJIfQsOM/Wr6EXGj/VzQmUQR5zGqJv3OO2eo6nr1rPeQwSPIJkExXAUJuwD/AF/lUu+SwntbqCREmJyPKlG9D/nqajv22TpHJcW77gHYYyYyTyGPc96m3ULkEUXk+ZI0UUjfcRi5wCehyO4qoSr5bAJPr1z61Yu7uJ4GtlS3YhiROFIYjPQDsKpEkAZ+VjwxNAjTYtMzSOVaU8soG0cen+FW7EzblMMZIzyODke/tVExOiBwzLggtkZP+PIqyupJbRsoSRNwwhTkH2rXYm9y9NqEdmWikYscZVGGNufb+lVLO6+0XCNexjyo8sRjAY9s1nW1pNOrTMrOwHzZ6j2zWhafaDIg3Nuyu1WXjI7H6U9QutkU9TtU+2FBuY9fl42+1JFZGRCqxhl/ibGNp+tWb25dLmSSVI5JAdgwABgnrxWja7oo4pANrSZAXHfsTQkmS3qZ32e2to8NJ5rjhY0xzn1NJc26GAPHLAs6EAxg9R7f1qwxihupZekqkpvyGQN7Cqc8VqtmWM2blSHZT95snsOnFOwm7FQyPFKA3BU/dxkUDyXjnIfa5PCt656in6fCuparsmYR/LncBkIOvSrmo6dbxWlrPbyGR5H5XgDHcGp2GveKTyyPMWlQbsc7cAfU1pWj7Ilcb8HgqBwfeqKrEZTiNQrcBQeh9BU0W4kOPmLcEg8/Ss2zSCL8cn78+SpORzg4JpkjTzujkhsHkMcip9OjjZ181gmDySelWN6KzooATPfuAetSzeKRWjt2OSWJJPKqvWrkdqoTKgq/QoW4x71NbTTROWs0MjkbTlgD1q1FESTJIVRSCNpIOKk1ihLZAICxiRBn5n2g/lWrazeTI3lGIg8hmHQeucc1Qsiqo4BiMfCkEdT2x3FTsVaP5goIbO4PwPbb6+9NOwmrm3ZX91a3HnQ3CW8zkOZYugPT5hVPVNUa9N3Fq++W6k+VZ8/cwf4QODWTI0m1GfcMcLz2PNVpyWZXBG0c7CScGm6jtYlU1e7JVk8kSMQrjspT07g1Dc3Mt4qxxpJgttChskH3psiytDtb75OAuOg9B6VokRwQoUBzgNwMA54OT2/rUp3LtYk0+2nWEwxoWJUh2V+QPoeOvWortliiTy1ZGTOTHjDH60kRYsV5z1wD8q96dICpMhQuSMY38k/4VV9BWKUVu8oLMdwPzbmOSfeqt3FK5LOuYcZCgZA+prUtJ/KjaOXhTlgcZqeO7tlaTzkMsLIQY+CN2PlJ9qVlLUTutjjHTEpC/Lz69falulMUiqjnH3gH5zXWCCx1D/VrFZvs2qqk4Y47k9M1W1G0tPsETKm2ZflYkcf/AFvr3p2b2YptbHHzkMXZQEXA4U8ZqqJQHyxZFI5wOT9KvXMWw5bkN0I7Csy7jEe7a24nvTTOeUTY0VI72KRbo/u++0cj+lVb63jsZRGpEsDHbvIx+XpxUOnXR05mDBvNZgQjKCBj+Ie9S31tN9mSRTuG7fknnNbJqxk43M7ULaS0Yy2bl5do3benPb64q1p98hjXz/MKKoGR0z6HuKrahqCpa+dPJH9plcAohwcD1A6VDpdw1zGVYDYMgAYHPv603ZkJ2OjQr9qaaPLqFVvmB5Ppn0rPvbuSbG6MhS4Llj6d+auadq0ENq8E7FFJBzjuB0H0qve2kM2nvcQyM87DKhjkY/xqVZmjbRoWWsQaXcNHG37uVADg7dp9v/r1WuJjcXISNyE4ZmPOwVg4nAjRELc89MjPTFWYLmSD7ybiTzvPp2qW2tBqSZuLbxRAMbg57qeGx6cVFK4jdI0Rtq8HcOAT/wDWqF9QLK5jjRRnAYD5V9/rUInc3Jd5PMbIy2c4JH5U07ibJ3kXznZIMoh5yCFJ7AelXrG4tyuY2ZZAcbW5ycYBx3NZ8c0hQrvkR5fl2sD+BHY8D9asxahJ5EcUUamCMBZFdRljnJ5/ShbjT0Lq3LKkbFUIQkKSmOvJOeKbFdKTJvKoCRlljOGA7A+9VpZUQgFsIcM2BjB9B9KVpwzucJgrlOoBHqfU0mWmWvtaqVfJR15VlPIPoO1QK/LHaXkbJ2kng+vvUYmUh2SRIyOAFTlunr0pUkAnDiZjIp+YRrz/APXqC0WUnEce0tnd95QMAjr+JpzXUtjGojuZAlwgkI2lcA9gP0zTLUwtJMW8jzecHYWAx3x2+tTxXMha2kvGedEBFu6Shf8AgRJHGKLeYmUJnV8qzyMp+4s0bfMT1OfQVFuhNusbGCGKLITy4yxmIPJJ/rWpLq9xdq9pLeSX0swMbSuhYxxjnCD+tZV35l5IZIbbAuWCwuZBxgfMNo4A4qrW2IbK93dvNDOWjiSaQggopB2AYwMcAcUxLr/QGs99uId3mnMfz5A4G/rTru4T7Ssks39oFx+9G4rz0AJ9vaql5JJHGbSWVdit5mUOVyffFAiBnjljxtZZQxO7PGOwHv703zw0YwreYvGSQVI9MetSRkKNoMYjOA8m3fj+v5VG95GICAW83djIUADHQiklcTdi5JLB1dJTKCMnJwR6ZpY1t3UNcSsjAnKseqmoYnhkafe+xAS6mRyPw475xRl5XBMzAlcnC8kdc/8A1q6LM5+ZFlL4rIYrEDYB82Rw3pWrYalJCEllmUSFyXjZchh3z9fQVzzxgS4DSoScccduRn2qBwyRsizR5fjdnLD3xU2Zop9De1ZzdTNNGn7sAZfhQO449Koz6xJKqN5h3A8L2FY5mkLC3gkeedyFCgZLE8AAepqpfLd2lw9vJH+/H314O0+hx0I9KnVlOcUbbXcxgCnIQjnjjGepFWbaBZtqtgRqDz0Le5/wrOEtvc3OnJp8ewJbqt05LfPLznIPHp04raeVS4jjGY+hYDk0NWCD5tSrKqpIFgIJ7gDp9aqyeZ5q7mwM/rWg0TrIQp2qT1oez2qS4OSc57isnI3UNBqIYZUCuG2ngD/Gr9odifc2np1/rUUFviQ8nAA2gdM1ptCpCKFDAH59h71LZUYWGwxhVVolwOvPar0aAtEJMuucvjqvsDUEMDbCuV4/5Z5yauLCWkGGOR93nKr7UrmlgW0YSBY496u2FIb+VXzbvGquzK8YPzRrkk47ZqGLzHJAYn07YpyeazAhmDngMTTuirsuZEdvKsSBvm3L36euP61C0YuI97MDjkdufSmbAoZG2/8AfWCT60m/BIwSRyrDnik2MYqOdqLkKvJ35P1pzKsrYCunGc0sp3BWG7DDOOTn1xQxQlJFBA4G088+tSxiqNqFFICt3Y5xQqqXcJ5jLgfOeBxQ8krR+WzMqHLAAcH1JpmXxtfITG4Kc4b/AOvSuBMrxoEWQIMfN/tGoriUll80rnp15x7gUvIVQAME7gMfMuOxpqqhyyrtlz8oZRtPqadxDQAFBcBFI4BGSeeB7VLDdxxhceT5gbKuT90j/PSmQKch2AJXkZ4LEdvpUTQM0hn2osTH5kVc/r9apPQRcW4gWINIg81mIEwGMnrzVbXpwyiGLARsGQI2Qx7c/wCRTYw0TKEYEkZCFdw57YqCaDYhVti8ZBC5wf8ACqcr6Ct3Ofudy5BQ/K2GH+e1VbtFLBAu1cDIwM/TNb86hST5Y+YYy3JHvWZLbn5tqHaDjcD+dQnYmUbmRtjWWRSGx2Oeh+veuusbOzutKchjLcImTIuQQQM4weo965a5T5iFwOR81RrPNAzSq20t8ucdK2hJdTnlFrUxNd07dqDOD+8c/MD0/wAmqaXDae7AZ8ns55/Ctia4VpzJdK0oIy2DgkfXtUE7w3+mpCsAVkbIfoTnqD61tG0lqcsrxYyKeG9JXftUgHk8E9/pV60nZUMSk8Nhc8ketYsemrNvaKVovLO0471Eb64s540nd2VBhcdQO3FHKgVRnRElDcEErCsYClwSxAPfjjmpDN5ZdYwQyDbGVPUn/CqGn6qgjUPKJImwHAY8AHv6+tWHnjnkyrAAEAEjjOTz+NDCLZdMUm1ZGXC8bivOTRcQyBhndhT5hyvb3xWxLJ9piW2hdI48ghd+7HHJz/Ss8zo7fZ3QF9uzKZGfY1KRo3YredIGJV1IAAXLHI9v1qcHaWYvBhiU2ZyCe5HemQ2lzIzrbpNtdcsxXOMdc+wquoflXaJ4w+M4wTSBSLkhST5XYFydo+UkACld3DA+fFJuAJRmwBjoKrBmyihiiA7tqndznrjvVgxtLJ+8aRweXKKAPYDP8qlo1UkTKXCbgEMeBuUAcA+hp+51SJ2j2W+SBIhy2R61lyyIGwwc59Fxj+lIpWSVFEucjncMAe2agtSuaAuLd1C/vlP8RZAR7cetSLDJM5S2dJAR1f5AvfHNRY3Syxx3Vvuj52hCyOvru/xqJ5Y1SJZoIWGPmaGbBc/yFO1hOQ+6bOXzL5owuEPCrj2qNbdGUhrWWSWbgOitujI7BenPFQO0HlKOY2GBhWHPP+eatQ/MpiO9ZAyhAJeVHcfjVJakNli1s33tvuIYZvuGKUjIwOhGODzTb2yeBBI1z5ghUNErcgZPIAPXB6ilkaztULC2dLrcSGZyzY9ffvWRf6s0i7IS4IYEbsGrskiL3G6yn2STc+7e4D8YA55zgVn73cs0gAz6jkj1q3sM6K10wiiUgggFnYZ9P1qK53ZZm3MzHhm/u9uB0pW6ibsX2wkalojE8Y6lT8w+o6VmXt4FkfCvsbq7E5bnP6Vz2oa/d3QXGWQcITxtFVSLmbe0sgIA3A/wnPpW3K+pzKaNmbU02t5bsccFVIPPpis2S7ubhjsVt3HvVrTrKOXymiTlyQQeqkdT9D2rtNO8MeZC08uYYlXIY4AY9Km+tki0m9bnL2WmyXaQGO2uVljUec+/hnz94f3eOMVqssWnlopER9owyqTwT9Op9asaklrZI5t5ZZpN21Ax6+hApLayfYGmjBYYx7H/AD3NKUrFxhzbDNKtZGwqKqyyElv9n610mnac+2N2Xcu7aW7VRsIVjvFZjhejH3+ldNaarmxiSdRJ5WRHI3G0E5xgdayunudMYtLQne3gsI3Ty3MUoO/egJHpism5hDnczYOeB/E3tirdxdT3ZBcusBBIXOAffFII9iIWk2gHCkLyfWs5yT2N4prcS2t9siqwypGNrcGntbnEghVV/v4z8vPb1q3GkbYxzkZ5BBP51I0YGWUFnA6jgioNCsInRMy8Y4CY79Mn1p7R7ovmLR9PvDt3/GpliY4LsjKoJwzdD/jUpQD5o2YYXJ46n0zRYTZD5Q81QA7rnkZ/h7VYTLDAVcJ/Bu5J/wDrVWYSNIwJZGI6Y6/TvSxJhnYK25uGYkkjPSi4E0e1SCeGXk55Jp6XksTCRGK7iemBj1qKFxFgYYlW+71qK5cxrljlQT3xg4/nS9CkLLLhnCnJJwOwpouG8w7mGSME4BFZ01wnByCMdAc4+tMa5BBK8YPapNFA1t/mKo3gLjLMOo9jT9ylQokwh6H19KyY5ZQA3bFWorvfHsPycjBxz9BRcTiXhErPuByNxznr+FS4hSPdtdvmBOfuBfr1qCJ3J3RrufpnP3akkWSWDnGAduTjA96pMke0u6RSI9pYcdx9c+1AkwR+8kkfJZjjIPvilCsYgYI2wqjdITyRT+TIAZGKquenQfh2ouKxHJF5sbeZ0Xrk5Ofb29qrhQUPmMxK8KD0/WrchMjqGcKvVhGMfl74qIrGoQooUHILMD+tMdik0SsMOrF89c9c1WmtD1Q8BeVrTuGAJMqA/wBzH3RSlY9nnJCV54Zm4GOvHrQhWOUvLUFiB9/tgcVnSQkMcg/Vq6+9tY5MMGO1uSrDBUfyNY1zAvKjdnHzKx/l7U7WE4pnMTwvIPlHrjjoO9R27eXPvKIW6EgdR7Vq3Ftvz5jFTjg9M/jWebcBNrsdrDotVGVjlq02IkPk2st5BMA8Y/eKFBVlPqfWqjxpq1lOukWQWKMASzscke49f6U27RbSKVVhjkDqFcsdxx3IHrVBLxrG5zblUhlGVK/dVvTH9K6Yu+qOKSs7GBqEL2kxiiLllAZiOOKfb6pqFvtG4Mic4b3/AK12WkaNHrwllE4jaCEysZH5mkzz7n6Vz93p+yIpIpMiBrmQLyTzgD8K19UZNddi3oPiTZexzMWiKsADjjntXWanqHmbJDCEIAAbHLe9eXfZJhCWmjZdy+Yo7tnv9KkS9ukRoY7iRkyPLVjkD1PtUunfYtVX1PRYbyeZIyT5akY+R8A89Tz1qyLcy7EB3E578gjkn8q84i1C7g2iRsrkkleCQf6V1Oga/DFdqJf3bD5vzGOankaKVRSN4IHuRubc/QLjpXQQy25tk+0R7ZlJY9wffFYFxr0CxSRRwrG7EYcEHdxWe+oNIiuGBIOODk49Knm5TRWe51Emmx3MixxPsEgHylsBTz82Tyfese+t55kcyGNWT5TldoHOOcevUGq39qXQXbE8oDfp+NN829lh8qR2VTxju3pmpcoy6FrTqVzOwkKwoYmK7SsZPI7/AJ03crRgJD+9JwWPTH0q0liSV8pWLY6L1P40wxqo+aHDA4J3Hn3xUWsNSRDkStGzogKjJwAM/TFa1lNbKEYQhEUY3F87m7HnkVRiheQLtQsoB+UL1/8ArVKbaIBd00gODkBcgfSnFu4O3UTVr9ZrYrEpVmblupz0/L2qnaoDIpeNQGHyojcnA6f4mpjFDCmd0hcn5QT09/amC8t7NZCAHLLs3k5IHfH1qld7kNpbGpbafcNFmSTYkuHKR8kjsP5fSqOpxR28jplSSxYkVlzeINknmkghuFUNyPQEdqw9V1m4vJDFCnlv03Ect7Cr5WzNzSM+O3zCpAfd5gw2Mjk/yrobqDyPLjmPyKMFR1xwQfx6VGqwxSKiFiIzujXPTn+L6c4q0yRmaaW6nM0gH+rxjgdCe1U3czUUiujvDC7cLHuGAvPTp+VakWsO9nyXEY6j+E1mXkst2qtMEt7ReI4wMb/pWzo9rcYOIEhV1KAbckL3IPqe9TKy1ZrC70ig8O6bLqGqK7Dk58mM9D7+1dpd6Y1gpgLQlhhmcSbs8ZHI4J+nSs+ytng2NDjcv8Kdfxq5KMqWYlGxkj+8D/IfSsXJdTrjCxRKB3+RV3DPK8/jVxYDwcxiV+QE6LUUEBbgbioONqr3rSt4o+ATtY5GcYJPpWDbOhRBIbgBcszYGzYSPlFTRrHDGWZhz7biKnWNVAD+b8pwAwGB+NTQREszIhIx90rwfc0alCWwfgh5CrEbRtyCaldGQMsvmKf7wGMj0qaOLCnb5W4D++VB9/amEuxSMNhAdw28hfeqERqyrG8eCXJ57Ae1JcMzr8yhFIxk02dFLsAHwD26/X3psuxgsduGBBAJLZwDTJKpUEkBnDA4JQHA9qkVlCoFVyD/ALWBSws4iaOVsQt8wA6Z9SajleMkAqQ3crnBqdirXG3FwIwdpCuHJAxggf4Vn7Wu2L5+Qepxn3qzMrOCOSB0rQ8P6PLfXLKgYgANk+hOOB3yaSTk7I1WiuzDQLvVR+7buNuQafDbyBuihOuT2Nbl/pi2h27nJ3AEuMEj0HrSQWkT3EUMsixozYLdSB70+Vrcvm7GY0NwioWjdfNXKgdGHt7VY8nFqGZHXcAV5HzCtwaTBbwyo91GY9wGdu7APOQfX2pLXTIGkeA/Z54whZpVc4X0bb1z2wOKr2YnJWOdty8b42h9pzjPSr8Q3E738vBwRjkUkcEaTFJHMf8AdIwTgelTCOKFiVcBDgZPynr1brzUWsQ2CsAwOXYseMMACPbFSEM0S7sFlGRtGc/j1pEkmlXCqrj7ueDinYXLbgVCjhQc4Pqc0JCK0kk0cb7V+Zudsh9D6VBNcSEkc8nJPrU8kZKDaHT3kPBqsy5BLL1446UWNEkNhuFbCEyYByeaWRcgszFeeCT2qq6mN8Hp14708T7lQSfNjgAHkChO25fKOllxKCPu7snHBOKo3Mz7n3qx7fMTke3NXlZSfLaTyUY85XdjjvmmvAY513sWGM8/55o9CG0jCYoCfkJwcnvUUsSO2NpA6nd39q07qATSAhc8HG3IrPlDQPggmMkc+lBlJKRm3MKlDH8rcjB/iH0rl9U02QbvL5B+8nY+9d23lSIAMZPTcOB+PrVS6tN20vglflTHGf8A61aRm46o5KlFSRxVjdyWqqjhiq8A45Ue4q6b5jFNLaklmZEJUZJUHP4Vc1nSQ0jBF2uv93/PWspbeaLBcH5PuyJ1HuR3roi4yOOUZR0FumS6jbyiQ6Kw3EZyD1BqvZ6YrWLzqQWK5UL1z6Ve85PLX7Qq7XOFuYxjPsRS29tLHMZIJEeMjgjgir1iZ6MwTC08yAFshduDwF44H86q3CSRytCQQyKqYx15/wDr10csKSebHJ+6nUkjPBJ9fes+9Wbz1kkjAmUbW4yHHXj3q4yuS49TK3yJho5WRk7Mep7mrNpf3MERcSN+PrV2SyikhZoic78qpX7y+xqm5Hz2/A2I+0EHJ5zTTTJaaL1r4ikiOJ42YdgDnpWnb+KFE25PlCr09f8A69c7fWsdvDBIvzFkBHpnv+lV4APNUo21kIKn6HilyRepXPJHe2PjE2oEokG9wTkrnBPBqlJ4khifcVEhIxyDgZ6VyIkLPOSo3K24uBypPUfSnyKqoYXVgSA3zDlfUUvZp7sXtJHTx+J1/wBWWI3cFyuR+FVrzxDM8sZy535GTx06DFYnlR280LMjsrdFOV5HXB/z1q3m6uJnlSN5Hj+ZhtyAP/1Uezih+0myW41K8lOR8pYkA+mPX0qtNBc3dojHIl3ED58bvqKcVYea0aOUKKzYbC4z6e/6YqSyYRqzYEiuRtVhnnvz2OKqyWyJu3uxdJiRrqMXaYE7GIv0y3Qc+tWNT04wTFUAYKcPg8OB1256MKQq/lyr5Rkil4eMjPToR6N9Kfa3zfZTEN0si9HI+ZQOzD+tZuXVGij0ZclUIDGgKMygeUnLH6ntTZYSpQTgMW5SFOc/7xqwFYSCG0j2huWlY9cjrnua1dI0kJJltzue7DJP/wBaplNRRpCm5si0rSWmkE938xAwsbHIT6V08EZjjBjC4xj1H1qVLKNIgHDE44AOcH/ParNyVDR+RCyHaOW7H6elc0puTuzup01FWRAqSbfvOu4AhVX7/wBKkijXcPMLyAHO3HJ/+tUxDm53ShpZNv3gfve5qykAjJMqbJScBeoFR6GyjYjhzvHl/KhPQ9T61dihTevy5AbljlsL606BenyYX0bnFXYbcbpCHRhgfKCefaixQx1wFUNuQklcgYI9TUiSPInkuuFAztDYB+nv9atCTbEpjj8kOMKFbOT+PrQ4aNMSR4BHTj+YosBRkLmIorMvHGRkfr1qC4kUFgoZwx4UjH1OPXtk1eeSEq7M7cDgg8g+mPT3rOYxSbTtYDbnryQO5p2sAiJ5hzgjjIUnAI9ajaJXHGcZ+UH5entUqhH+Ve3LOeie9ROcSs0b7gOnfPrzR0J6iDczhIkXGegHX8KaqM8oBcKF5+bt7UGQ4QKVLfw84496EOI3DtjOAQKh7lom4dysMUhAAPzjg+4rR0y81CHalmUieJSQQeTk8jPc+npWYWlRflOzPC4bGPaoxIB03AqOCvOfempcruitGrM19Q1E3DAyrEJI+AVHQZzxWe14pUrtGeo479KR0XagZHEjHqOcj6UsUJ3oFi++cKm7JJobbZouVF+TU7ea1tUMSwyRrsxEmFxnnPc5qK4uzdKsk8jggfIeny+nH86t6pDpsUKRQ20wnXiRy3fv+RrG86MKm1wvJBCryB7mqk2tyLroPMqeUMRbh0bHbn1qFA0h+Yrkr/EcfQD3pgKbW5STPAPOR6YHejzPK2jI6ZJAzz6kGovcktBChi3RgA8FN2C3vmrSS+UNsa7cMfvEHn0rNglAdjt+fkqScrVpHJPzhc9eQDz/AFFWhXLTFnwZDkr2zwPy7VNIkcMZDQRvI5AjJbhTnnp1zxUEIYMWhjUhhyxbP1xUd0kjsgV22AEhT1A9AKtFRkrlw+GLy5JZrbyCU80IxChh6Lnv7elY1tYiS4ZYGPmpkEAdM8c10Vs8sNzZLeyTMnymMufu8gE49h0qr4gt003XS9rPuSZig4xuQnqf89qbgrXEpyvZmbqeiXNikJuY2VpRuXPIYf41RgYRj9+N2BhGXsff1rrNNvYI7W4XUgtzI4/dmZ8mM9yPbHSszUNPnezS7MHlRvkRDGC/c/hScFvErmurSMprVpInQAMSf3OTj6Z7Zqpdaa01ldTCHyjaSKkqlxkZ4yB35HbpWvcKEWKeBAkT4ygyNjAfoeOlZ97ctqLRvIi70BA4wV/KlJpGajLoYMUQ81g25lx24q01pu8x8DymGwp0f64q6lqWVpJF2rwCy09I12SFGkVwVKhU+Vvoeo49KhXCSMya0hMUKF1xjr3XHqPWufv7IKZWXBUHgY612M8NtL+8FukcZALAMc/hnv61SltoWwLcCTJJw3JA9fShStsYyp3R5lqcbWcoYozRFsuM5H4VYiETOfsEhjV+kUhz+Ga6nVdNaRMsIyjEgAMOCK5Sa0NrITGGPXIJ4NdUKikrHBUouDuWhK4j8q6gZVIx++XOT7N2qWfTYjHj95FxuDA7l/Dn3pkF0zxLtLXDBfmQ9x6EHvUtqIWy1vOYzgcHkH147H2q9jMqxWF2kfmW7pMqHkHGDx6etVbqBriZJHhEbIwBJH88dq2o45k/eyQicc8oDjHrxz+dSRqsoQYjlJ7BsN7A1N2iuW5zm2BZSxRodrkgY3KhPbHp71TubdfPBiVOU49FI6YrtVs4VBEizxYBAO3IHsfWm/YYpW2vbq2/j5B+gzTVSwOlc4eGCH7bMjrtiljwvz4Ab1+lXrK1t3x5rzblUD7wGHB4P0rpD4esmiC5kSVZMKJFClR9TwasQ6BZkMwSaXAAbC5wOlN1Lkqk7nGyxyGZQ87p5YwC3JAx0Hr7VZitowxZrsIxHG1DnPue3Wu1j0C0kjYGJhGowu4gHPpSW2hxQOjoqtDtJPmyAMPypOpoV7KxxKac+5pQJWy23BG0Y96c+jyTKBArI7dgeD9a9LgsYI5Y5VZGwR8pbcB34WrMaW3mSYCmNW4V+Bz1P19qXPIpUkef2Oh3e4faEyNudyP0/A8n6V09j4fDJvGFcAgEKPmI5ArYM9ognVo3Z5FA+UcKB/U+pNWVaa4aN4oFWTbhSMKWH+znr7mpbTNIxsc7Y2AOFVBk8EEVt28Q2EyEBRnjpg9vwqSGLODG6kjk7f1FWWtznKgnjIUNnC/41zN31O2MUiKGKRTGI3wS2R8vRvarEUErK5+XcCPlJHJJohZwVVFMnU7cjj1NTspJaORTI7DORnIA9PSkjTQZbq0jKDveRVIAIyW9vp7VcWM7whPlowAcFcY9s0tsrzKZfIJCnA2vtAUDt7+9XYQqoB5jFCeEI/rTAgMCFCmeucsBzj2zU8VsI1jRkdEYHYeBuA781Z8mNXG5Y8f3ixOB2HuKuxKpRlaAHOIwxHK9wc+nrT5bibsUVWSONiylUzlSMZP+H4VXUFyoYsSxyYw33qsySlCwlUHHy7Qflz6+9Uy2EUDkYzljyuPSmkK5XvioR1i3OuMkEfdGfWq8mzykLAD5eMDp7U+eQICG+ZRz1zn6VQlnk89uenGCc0bCuSzS7oyd/lxpjAAySagi3yOULAn7wGOg9KhU+Y+AQQOff8KemYy3z7+M5DdDUMCXepGY1y7HGVPSkkYRyHKgELgKG5Bqu8paVWLBcnk9B9cU91BikRGVucsxGMn2peZdx9xcNIqeY4fPOBxtoJiDOA2cgY+v9KgaUKTGpR8dWHQio4yvLFc4/KpbKReVlx8kgWTIAJyPrzU6XXklNkwWQHPHOD2IqjFI0ZJX5twwBweO9LNI7bl2qq5zjNFyiy88sm4xljgfNj5jj1+tV2aeUIpJKjhSRk49KjjljVHHIJHykHHPvU0MgIU44UevXNNajvYryI0bZUsMdBjmhJ3jU8BgQCSefx9q17uGybSluUlc3O/bsA4C/h/WsIgbiFwc8gZ+97Cm42JbT2J0dmbepU46jPUetTwS7zhOGHQg4496oFwePljb0z2+tL5mwZDHpx34ppkGxbysqNuzgchW/pV2G4lkYBSc42qcDj6fnXP/AG4lTgkjspPWrkFykweR2Oc8Y45+lXF9CXc3VubXyY0MRVoWAeTH3znOMZ9Kqa1vvtQZ4I5GgD5R9uc1UVYpQ+NwHDHLcdevvSW5kU7hOVCjgDIOaqTb0HCSL1jAPNjBMpCMfNRVBZeM8ZrsJrmK70tlQxpEygSGb5mOBk+w571zIMJkiWGQSspwXMeB0/M1ailbAgkUGLONrABSff19jTg+UqT5iKOFEWSNpwEODuQEkehHepTZWk13EY1gRSpDKDnae317U50VYldJN/OzZgkKB79/rTbd/N85Ejjyg3FmbDZHTafX2o8gfcoarECskluoWIAB/m+UsOAQaoXLyNbQ28UMibCAjb8qCf7v1rS+yTsweJ3MmSzZRlAH97nr+VVZZ2iMkZYSOF2oBypHGMDtUsSKSo0UX75fMwQVdTkIfTPTmq8lmWQTMi4J6g8hvTHpWz5kckKLLsD5DFQx+Y+noCPpWfNvuJz5hbcz9/8AAdahpBa5mXNkWJ8yMh887h+S/wD16wNR05nlZViBIJJX26mujv0kjba5YlDjHr9PSs6eCYvkHGDkcZP40r21FKCkrHF3lpsDlEXLc7x/Q9RVISSxyD7Unn7jt8xOH/8Ar11V1bsM7uc/xY5rJuLXYDjOfXPSt41O5xVKDWxXt714sNby5jzt+bhl/wB4f1q9DeW8xzeRAO2R93YV9CCKyrmJiVDKFAOc7cZ9j6ipEMYVIi7sHwWHUf8AAfQVrdPY57NPU3kR0Cm1nkmi/ii6N9R6+9WLa5ba0L3KwB/vCSM4YZ9P8KxLdZopSttOkkY4wcggVqxatMoEN2BLGDlCy7gCPQ+ntU21NEyzcOwmKw30N1H/AHmU7T+dCQO83ln7NJ2G07V/pUcVzDKp2W8KNnqDwf6/gKtQxwsQDZSSFDkhXyPbg1LRaFitbmNsCNiQcKAVP4/SpkhupIi0mBEG+bGwEMe5yelRSQRrGQsFzA+MN33exFNJjcr+6nZRgAbOc+9K1h3L09tImxrkXALfNu6jHpx2q0NMEUaStYSuh5UuxyQR1x6VnR3ccblEa5CNjK4Ap6zQlXSS5uAAeBnP50r2KSNiKTYkUVrCpWUiNUAwcg9OQfrSX06WpMZGSFCNuXayN1KqPT3pBJZ39jYpFrUdrJbKQ8M7lcHJO9SBySO/tVbWb62nv1khle7JSNCyjBmKjlvXJNDk7aDjHXU0xukjZQN0ackKQOvX61ALR2+f5vky2BwSPT+lXoGh3ojx+WE5yPvEU5440J8wM+8YyxPy+/FYnXYZFMGiQmBo2x8spHI+vrT1fPliVFzghD5ZB+vvU1pG8rAHYr8FOTtJ+n9Kt71dkjAwRwV6kn2I/lVIBiLslHk/fAySuAufYenerknlvGQWJkwCcfKWz1pY1QNLEv3nO5l28AjsfSmRKvmmcybWyEOBjj61ViepLbRkKyyNuC4AZOc57UrXQ34ifknZnHX3NVmmjjkKCdmVm+ZTn05xUUkgVB5bABPUcqc0IGwnZthLbQhfGByRxyaoSSxxozgAFiAvOQKe9wpWRduJAA3H3Tg//XrNv7krJsXIYcNgZHNMzuNuJiQdxyAMgDoATVF5C2FU7Q3PPOKikuNw+bJwCAajLjlmBVlqGx3LEj7UwC23PGR29ahkkb5R1A7DvVd2ZnIBbA5/+tT490jqoJ3dh71BRKxypbnhuuO9L1YtK5kJHr0PuahYlfcjkH2+lO3jaOD7rjHNLqWidXAkw2Sg4OO9PG1hmPO7PTviolwUXbGFPIB65+vvTsrvAXHzCktBokVgAowEx1IOS3+FPcqoY7TtPTmoypeLeVwinDHPPtUbOWC9cA4x1FAx5bgKFHXO7PIp4mLn94/HXOOelQyfKDxg+oOKjfDRhiCO3HrRqFycXOM7GKg49qgkcbVwyjIySTwT7VGI2Vgc/ifWmxQmVmJXKD0Hf2poQwzK0mMblAwOe9SQqJJApDA/d+pqSBFMhaOMgg8eYPzNV5SUfenTOV5/WmItvahE7lk68YA/rTIZXgJCk8jDdutMn1GSYlpm3MABnHJpjSJLubABB4AOMVXoRfuaFvcAA+YVGBjGa1IZmtztKx+aThXLYxx/gfyrAR8Y2YAbjIqxby7Gdi2CoBHfJ6c+1UmQzpLyaa2kEVwVMkPyja24HuNh9P6VZtphJAzsEd0IO1+CM/SsYK8sWbeJN+4cKMge4z0oiu3t3DYVZkbKuOpbsfaqatqOMrqxvxvEYrhyxTaw+RycOfTPrRaySxSMsE5RScsr4+Xis2G6Se+MUIZlkfeVbDbj7n61Kshd5kKKFHO1myRgjIzSuaJl25vWuoH8yYo+1SpOcDHY4/zzVdGkjgEskcTPs2GMjDD3z61GzszqVP1Dryx7Y9aVgwbdMx+aTaR1YYHAx2FG4h06nZh1Cu42g5DZz9eRUE6iNXXLbmITdxgD3x3qae2dpVadFdt7fMoOF4+7VZwiyBVR4hnl15LH3/xqWUiK4jZJQEDyoOCwT7/0z0qtcQGZA4j2HHBHUVqJujWRZiF2ncADxn0z1qu1y0JfzEJLDanGCOOh9qNOoNPoYE2nOY2ZMuMnJ7D3rFe1BYxttyDjNd/pbXKyRmMr+8GGTK4ft39j+lY+u6WtjqBCxnaTkjIx17Y7UWVroW7szibizO4lyApPJ9aozWWEBXg47AnArurqyRVfapwTxx+f0rOktmh5woAXAA701NownRRytpO0VxGLlDsVduYztYitU3PmCHbLDtAKhHQArz0J7n3ovLFSxckBz2JwMVS+z4j3BeNxHTj6+9ac5h7Oxa3RHAMaLz821sj60KIQ2AGBz95WOfyNVdrR5YMQfu8cVJFJcq2fKMn+9S5hqLNGOZlBKysvOOSalimlXJ82Q/3iDWd9okVWeSFfw6H8KQXZkfkbUB5CdB6UuYq3c1WK9wynuSASaWB7VWZ5xK4Awu1cfjzVGNxgcYHVmbgEexq5bXcaPEXiEoD5MTN8hHoe9S9S1odRbyX39mae+jR2cMTIfNWRo97PuPJ3e2KxNaa6bUidQK/aQi7zHtwo7crx0qb+17Lhl0WxZsYOd2FH51QuSLu7LQww2dvgbY0yV4/i59aJPQIJp6ndfZ1K7zv3YG31P171JbiCKdViQrA2cIx3FPXNTrYeXO+4nzNoJLH+Q9KbsZnWRXjiCg/Pg8kf40jqEktR5vmQsxQHKvGcqCOxpSYwY5WUhlYEuigH8amQohL7V3NwwGcdOv1qNlARQyl32Hcu37q54JP407IQsrxtKSokLBTjHp6H3qI3A8tjKnzZwQT/AEps1yEkJj3GJW+7gDOBzVC9vNkR4CHB2/3vy6CmQ2Ti4dpQ0YyYgQHGMfj6/SqclyQwBl+bHBwME9xVOTUoYIwsmZIymcN1ZiOv4VmR3LSRyTIiqpbC5zj6imiJPQ0by4RxJ5ahWJ3YB6CsyacsMlvn6E5qOVyD97BPb0qvJIIlbpuzgc5xRJ3IQrOAAp477s9B6UCTfklj/s+596idnfC/dAGcH1p8MRLMXPTqSenpWbLWpNCELbpJNuQT070sZxzg5xmmjZhhjORgE9j7Ui/Jg9R7nipLsWI42JY7ucE465oYAR9eT6VPApEDKAw28t0GD7+1Jg5UEDPsOQfWpZoiNCwjIKgDPHGfzqxZIC7MVLKoJG3AIPY/SowCpwCoJ5PPen4GD8p6Zznj8qBjWGArMXPJJ44zmo35wQSx7DNTOAqg7wM+n+FQgO0e7aME5yWHSj0AcJsMcsGLDG9hmo3bLths9iR0z7UpyxDAhmPNGwFcHBYe/QUCEBeQKoIGB1YcZq1p8sSSgSAsG4wMLj/61VsMq7cEr0oKkKdy5OOue1Fwtc07qa1FvIBFulboU7fU9zWFKHG7I5J/StC2MazL50ZaL03Ypt95CxfJjJPPzdP8au9xNWZjtknl9p6dMmnh5Y1bcYpBj5cdQe3NFxgsHKgqD0x9/HXkVNbtvz5ACE8sCfuj2qkRJFazumjk2yLk5+7jH5GtAujgbCfLJzjOSPrVK8s5XXETYVGyWHX8aSB5I3KyYZQPTBH1p9NSLm1a3Nwkojt2ffINpxjJ47Z9q0dTCzrbyQhmtwg3DHLkfwgD096wRIQrhDkMPmPfFPhmaE7GMhhbh1U9R/Q/zqoy0syGmndFqC7MTLtfG3JDAnkHp+VWbS6ztDBC7DzA3QkdNufese6YrGzFArMAFypHmLj73t2qGG5KyRu+GRXBKg44HYGoasaxdzppLgNcoHchNoLKwPynnGf05qwlwsa28kjFHkRssBjaBwCT3J5rBkumlEzyOGcMNuW5IGOD69auNcfuiDg7ANxQZBPYt68cU76jN+ORnMsu9MhPMUNnJHYk56/40yz/AHrRCRinUuykcjtVSK8KLOrjcxRQN56DHAxUgmxdCJcAMqgnAOcjoMcelDY0TyNEzsiylgcku4wMepqtt3lBGNzeijDcdOtaBCCSNWh3mNR8sjY2nPOfWny3ccAZUVXJJYFRnHvk1NtS0ypFZvI0Mio0YZc7vvbh/eHv6inrYpDexteSrPAc42Ehk9Mj0qzFeMIBsAdQCwR1JwO7Z6/lUDPPMItiqIgCEZm/r7UXSHYrXNvHIPOlkzL/ABDOBj+6P0rNvLOSCKNxFyfmwwyBn/63rV55ZpZGMqOQnymUDAzRLBcKxyxd8jkN7d/wobJcTnJYVAPmlWZ+c4zt56VTurcROfJY7Ox/oK6OeHyY83GGEmQAmOD2NUpFWHbsffEADtKZ5I560kyHExHsYxMoWQSqRuJIxz6Vd+wJ02sdwydvHPpUvloQWIXOM4PGOelWbWe4EsYJQxoc57Af1qk0S1YittFkmgGxCGUgYKkHnmsO90/ypGUqQ5bG3pg16D9vhDQncSC3zZAwB7Vja59huJPNgddxI3KTg5/HjHFW4JLRkXvo0clGjRv84BAwPn55/wAKl2uWJCq5JySFxj6Vo+XGy8x7GbncSANvtUDIzkBHLqp+Uqvyj3rO5VhkYeVY4reKWSVmwAi5DH09zVm5jh+6IriB0wJUkIHzY5wMZHPrXRWE0MelRTQySrLBA1skSof3bu3zTZHqD9azdYmS61EGAvKsMaRGWVSDIyjBYg9PxptWQot3sdzsEkI3blk5DM3R19qjDFtkK7XBPJC8j0980yK5DSKjnCrxyM5HbFQhiiO8RO/occfUCi5uJGzO8XyhFiz84ACn3PqfaqtxcczfOyLgK+B98Z7+3tTridYof3iOFcbkRWwp44JrH1G78llUso9TjJY0hXH3l6kUISIPtVSS2/GcnqBWZdXeX25DEqMAHgnHes+8uy+AFCFsknPWs9mcxmUsdq8E+hoV7kyaSuXrUie6COVIwTgZHf1qxcSCNRDs/wBWTjnOR71WiHkQBmbcWwTkY2/Som3ucjg5rX4VY57uch8zgjCn5z3JpmCCegyOeM1LbW/mOqDueavSaeY1HQk/w8ZHtWdzZU7FJFLPv3Nycg989qn2P94kHHFKyiMBGB55yei//Xo/fAswJwTg5HX6VJaQ/BYq0hyPUnpjtipYVJQR7FDMep5xTreJsbiGUN14598CliXO0oSGHQgdaRVhpAGSpLYOPlXNSIu8D5srn7vPWnYKsd271JB6exqWENuHyhTn73UioGOKAuZNoAPULx+Qp58vAI3Mep3Cmzq6ZxgYIHzenrQkTsVLBQrDIfPFOwyCRVYM0cbjjk4zj3qe10nzLRJppUQzKWUs2P8A9VLsYE8/O4wQeBipi7xpsnOWjHygqCR759KcbdRO/QzYLdzIVIAOeC3Xjtipbi1aNwXdQGGcqM5qwAzjzi/HOApz3qSNFlZAWVcfw4P6e9D7DSM1UZicAsB+AFNUKzYw2/61vxWXnsEjjkdfQD5qorbZuWih5BOSSvT0J9qfKwbXQp+Xhhh2I57A1FDbiUSbmVExsJxmr7RHnzccDGQOaqOwX7kRiQgjj+L3oEUrm2kgtyZDkfwkcYH07VSEirMpDE8jPb6itBonuXAuGO7HAPIOOgqBLSKSQIwk3Y+YFfun2q7WI3NOwv7eCFnd1LnpEy528+v9aq6nNA0yvaDkggqVwAf61Tltk8ySPaVYfdB4zU0dwkNm1uLf98WB80HBI7cVTlzaMhRsQIyhCAxLdSCOlPWT76now59aZcSnzf3i7exwKajgnkZB7+tShNaFyW8drcRPuLhPLEzZfCdkA7EetZcTNGik7s47HPB6Z981rWFzLaB3t7h7ebgCRQDwetYUrYu513fIGLMeh/8A11T1RnGVnY0BKptBGhfzC3P/AOurlrdSGO8YyFzLGB8o+6M859qxUcn5lYsoJ5zjr6VchlGACMADbhDgnjqai5sdBaT+c0m9vMkC7zI/OVAHb1FWraRkl3iTAJORjtjisKF5YZjjDiFfm2nKhT24+taQmCXGY0LB496Bxn5TwTx70DRso8jSyeWm13Ybgo4z9Ks29vuLrjzPN+Ulh2/pVO0kXcZ5XQBSp2LnLn0x6Y71bnYMcxhVYncyR9Rk8fWmWn0FEiRlTIGdiQArnI2joCOwqdZjIrOPL25+9F8u3/AfSoX8szMJgUUKAV53D2FXMmVIftDF0TACp8oXjpkDg1JRXk8yRWaGSOXblmd/vYPXjufrVKB3QOxON+ADIu7dj0zV69lVLjylmVwq43qmO/X61A0RIVFnaUA5CEEBRSbGkQrdBpGPkhpf48DBPpx0xmqD77WWRnDweYpGdoPXtj3q+I1W4JlVHVyBvK5YD1A605IEjAk32+3llWY5GOxA65HpT3RLRheUuQREZFI3bM84oFuWiEsMhjCtwuQCPYCr7RhULJchnYHegQjvxz6VHc2nzIImjeVzuZomx26EHvSTE4mdcRmOQwREyqxz85wfcZqs7zNkYTIbIGQefTHetEWW5l+0yiLOec8/l2quIFDsG3Mi/KCD1+lF2LlKThpPmYMoPHzDGfXA7VKkDlN24xxHjJ5/SrCM89yJLgiRw2QGyelEqJLKZUCqewU8e9BJvWKzXGjeTb3UccLWjRtEziMmbfndz1yO9ZuuNDcX67blpmEaJNIuCsjAYZh/jWm8cken6YV0y2vvMQhpWg807s/dIHTHrU2sWNkbe5ZrSC2eDyhuhXHzt96I+pHXPatWm1YyVk7j5CsUg81tvBJO3j6DFUUmj/eFmJjRC2ScZPYCmz3StO67m3kFiw7D0rFu5Q7ARgKm75QeQB71mdDJLi6bYA+NwGUJbgD6VjXN8RJlyR1yTzz7Ut3dRiZgpHHGQOtZkpaR2wM54Hc/hTsQ5ENxIc5Y5zn8aWNpJwIwTtBBI7cVdtbYpHiVF3vjGRkgf0qx5IRAEA64FVaxFucSJDIx5CgHoBwPpVhIvMbCZIHGSMZNMtoWXDHgHitvTPs0Lj7QHznII7etJu7NYx5dipZWcgTzFypB7VKRydwLEccnNaouImD+QCqH7q5+761Xkiad1PzKW+6SOtD02LvcpNAs83l/OM4wD1rem0yK306NmkTzy21oyMMPceorPWOSMDawV14G0btx9jVmZw5yzuJyOSxHy/Q+lEbLcyk23oZtxBIu5mBQZwC46mlBEDgo7GMqOM81Yk3TBlMgBwOQvX/61PjjJVcReYx6Pjr7c1Ml2LT7kEZDOizMdhOd4Xk0vlYJfLEHgg1MVdNpBXL5wAMkfSnpDG74dZcgYfce9SURtnC7sAY6Hn34p2QzEtySc424H+AqeGNmT7OrINp3Aseh/wAKmAc2Sq3IPJ2jkH0NVYRSVHc5BaJWyMFSSaq3CKJdtuzSoB/rNpGfwrWjhMuI7mR2I4RT8vHvUtg8Vuk6xsPtBJRd3cVUYJ6MOaxzYnkhYMxEgz09PetOycPEz7oguN2VGW/H0NTaPpVrfPOL6YxsCdoQAlj6Ad6bBpksE06RSIY4/vtkDk9ue9HK1qDkmaUat9mcQxozAqoLMQSPXH61X1aXzXAgihT+8ynaDj39KbE0khIZ3MaD5g7Fd3YdKh8uMyIDhY0A3bP4icnqf1NNu5L7laIo67HVV28lhyX/AB/pUiKjMBJKyhB8oUZA/wD11I9q4jEcW53ZshdgI+q06304SuZJC8cacuM8/wD66izvoNWaM64WSISbUL7uR8vIBNWtMeN5limtdokICsFxgeuP61sPFbG2uHVtwVVRATyM9896yXkvUCvAy7Y1OCTzk+tar3XdmbXNsV/FOnJZ3dxGHRxEwG5H3An2NYi+UZ0MrNhQGO3uP8a3ItPeWJZb2dY41yRjqzY6Cmw6ZHcXYCkIvYsOM1End6FRVlZhqt3a3Wn21u0MKGFjiUJ+8ZT2Yjg4rCurR3eR7ZNsI4T09avXVgbeUIWZ1JJJYbeadDetbnDxLJCOgPrRzXeouTTQxEbD5JI/u+mai1OAMizh/nYsGjA5GBwc+9XLn/SZGaMKhOWIX7tVlkl8v907JyCeefz7U0ZVI9UZdu5RFkyy54Rh61oW8qo7eSTtzkce1YofFzt+XcCcAfdOP6VdtXy4JXEZPJ9KTVhxlc12l8yWQrtAYBgAc4NXYbhVWJFG0seSG4A7Z/GsSPekoeJiCrd/4fSriOv33B+UnJHU5qWaROj0+4K3GZPLcQ565Kn6+9XYpFD7o3IOeGPaudtJmdWRiVVsfQ+5ratLhg0EQiJOQwA6MTyCc+lC1LvY128ueV3/AHcScERqScn+ncnNW3mkkSKDzGJQlQccDnPA6/jWbAEON5O8NuZccGtNIUO55AQ7Dcu9cn65oLRLLDE7LLbRvbxABd7vuYtjrg+vNRSOiRLu3rHu+Xd1c455FSJC91AJCyho84Bbkfh6U5YY0T984z5gx8uQO/FA/IrJbziWSclUL4x5rgY44Cjrz61SltHmkEKOElLdWHGfrWwsp+0SlVhRH6mQcAegPrVOQAMIyEkD/MNhwqk9qlgUpFjjQRbCr5++/XPfkdvaqk0TgE2zlhu546epzW1d2p6XDkOx3feBUD8O/tVSaGaXja3krjOw9FHbjkU7C2MyVUG5JUAkHRjwahZEO0qzMR1YDgfhWtPLChSJYCCRuYuQ7kentVS4DTFvLcbcZIHy/gfWgkqPKWYkhlb+JgoBH0FRRT/uWjAHlZzkjmp1jmiBZHQtnbhTkj8KrSIVH3gMHJOcZ/OgLI6HT47WK1Qyfa2mltmuyYpzGGAPKgD0Hc1natAguUt9LjkEM0aSLG7ZHzD7xJ7/AEq3bhLKzsXnu73cwaaJoFVkUEkEDPXOORVS9unur0yQtcEYA8yVNrenAHAHYVpfQxSd7mZfXbKCSMORgqOOKxpp2y7AkDgK2cY/CpLibhw5JbGeKzbiYs7BQCAPx+tZltiSMfmK5Ynr7VXtXzfQjJC7wNx4zUcjsV46Z61Y0iATXm9jlE5PoT2q0mZvV2N9slsnue9Io+cqvPvUs2N2GJCgYGeppYI2mRzGNwQZyBg4obuaxjYSKPIIKMxzgYOMe9XLayupbeSRI2aGNss45C57VLZSeTOJiFkdR8oYZFbtnrhi0uSyUBYXJY4GQD3/AJURinuXd30RkpbrHKA7hweRsPH5HpVxzFsXGTkABV9exqLKmTd8vmc896lTAUBsZGcAjGaAkwZUGN4VJRwcdR9KYGVQA7koT06kGmKwaXlXQgZOWyB+NTW6KyhZhGqnJGeSfbrxmqRgxsciO7QuJducbYxhTz/eqSYeU4zHIikkBvT69jVm2Sa5gMKQtHCmXAyCVIHYHqKtWJkuB++cPEoLup4p2voUmZywr5QMyoQPm3ocEjtTGtZjA0yqHj7nPzZHtWtqemtYpBE80MjSNuYHoo7c+tQRy+a6SJ8siserDGO5z6+1TydzRS7FeJW2IhXA4YYOc+9WIUKLulWQr2IbHPamMyiQbthLdQDjGDirU8iPMqwYCbRwXz8w75NNIGyndqkcqMVZm2guD2JPao9QCzW0AghbzxnJ6cDpj+taMlsbuaV0Bc7flyA2fp7VTjjuTIwcALGQpOMsufSjVC3Ma3MkcjsrMmBnngrWhHYXMVit2PmSWTG7IOCOvFSzLCzESL8vXBHU+v1qKOQMhCcKzY2ntiklYT3Le9XjkEzKWm/eHAAOR2BH8qgggTzvPuI90LxswDtjvgfX6d6cIoxE53GORMFAnKn1yahSVYojDIrphwU4GM9z+tP1JLV5OkFxDNGWG4BlC8lcdhVJx5jESuixE797cFv6052eQrsYLtUjcCMqc8Z/wqORyWVW2yMBlufmOe9FrhzWH/ZWDZhhE/POG/WlieSIBGKCJTkLj+L396SKV4HZ4JHhY8fKOvt/9eo43yPn3EdSpbPPfnvRbsNPoSXAEk3z5xyc/wB714/pVE3EkDkxZAHIOMgDNXLjYsKlmzJkYj253D1qfTtWmtJpfsscbJKmxt6A7fWoaV9WadNjMnnu9Rk2MDJKg4zjgd6rXNh5nkqCGLfL8wHHNaF7P9vwlvCvmDrIx5AHb6VVtL02rul2iyIfTt6EVSsndid7aFbXNDk0qYJNG1u4G5SD196xDC28sgLIeD9a6/Vby41WyZrqVboR48ufA3IP7p9fxrl1QRLwDnJyCOR6Vc7J6GFm9GcrqsXkXzJjAPIpyyAvHuVV4wcDr7/WtDxBb70SVQSV4+hrGiJKhuDt6iovdGaXK7GwjDaAxHz85zn8KtRglhjPHHFZcLktuccnoKvwHMp5Zj1H5VJqmadu0T+YZCVyMqQeFb3rXtP+PfcoJdCFYk8BT0/Wufi+5jOAeRn+KtuzJMUsdsCP7yMeWAHcdMA80jU2YnQNEN7I6rtY5J3N65rSKHMKnKPja6ls7vrWNaEquGywUYBbkj6Vr6f5MzsJTI0eQXYLyoovqUiypJjfzVdpWBRD0APbHpiksS6/JdfKOj45wM9akjDu6KoLfMQoznn+X5VKXgaEJFCBMp+dz06/w/1pblhJII2KKokAJAY45Hbjt9ai2FFkaVggC5KNzuHtjpUssiBPMWJSmCocpyfeo2dJVC5AEmBt3cv7EdQtA7AWLKJwipgZG8Etyary3LTSMDJIsoHORtqS4uHkleERkL0WNTwp9eaLiVZEMpWQuPlLDnGOOtP0FYzZ4Ebb5cAVQeGVizA+/tmk2B1Qxn5h6KAM98ntVuVHgDB1ZJDjjaDgepPY1T8oKJAGO0Z69zmiyJepTl/dqpK7VJJJ3cgVCZLbzonRC2w5Idsh+ePwqV5JHiZG2nnJXGNx7dKLQiOZJbjZJGp+4SQMfh2oJ0R0EV3crp1r/Y8tlCMMzxO6fKSeuG/lWRqV1O9xt1K8HmEDLRKCme2COP61Ol1aKBJ/ZFuq8HKzNyPaqGoJa3B3ww+VuAzErEgY6nJ61bk7GUYq+xxpkX5j1Prk1QlJVmbox5zT5X+UDcCvTHeqswwSwIz6dhUhJkMrlVJ5/wBoD+ldJoMQWy3gcv8AMOO3aua2kuicEtxkmuztVEUKArkd+w6UyYau5OkrEb3yzkYz1Ix/SpLRHEM0gwqKOTnGee3rSW/NwEAU7sDcegqeRF8siNCSGyR0xnpTS0OiOiKokLyBUBbJ4HfntWu2k3USxsVJVwcY4HHWrXhWJEuBcxqfOhDSK23KqR65q5ZXu4TSSHzCyM7b+duecAdqqMFbUTm72RQtI2iKvtUKVO4dTgd6tyESRZFt99eC54z6/U1BJexbFaVCeDjjG49iRVIakFx8q7sAKCeG5o0XUzm2zQlijA2yYwxHAPBP+FWLOWK13mQpIHxgMm7YQeDk1mC53qQrPkn5tygAH0qaADcis0oRj8rL2I7fSqXdGLkabTP9ozIhRFQn2bPQqO39akPlXKPtwpj28YzuYDnJFVlcBl3lGZc7mYZwvbkfpToNkztHGGIIw3Yj8KbZUWU7y/u7lXRdqQFty8ZJI4zmm+a0kQEkZ8yM5JA61Kt48dkbCWIohfcW24Y+gq3IftNnHGsey4QFTEowSD0Jz1rOzepvpYppIAA5XPoAODzzxTyDtDJIuwk4bODx9aSS2aGJWuH2EsQRzlSPaqkSo7t++DEcKOimpbezHo9i7FeyRFJYX/eZwgDYA9SaguNRMtwzKz/MfmGckn3qGYjPJjIA5KnOPrUDxB2wADnrxzik5PYaaNQxSNZPcxx5jXAdwOhPY+9TSRSWcUToMXEq5CtggqeM/Wsj7VLAwRdxiBBCknGcdcetOJebLuypu56HOPr6VSlqQ1fUnjkVwsU2OF+U9MnPTHf1prsF+9tJ7Ac7ffNSCEvGWKhH28nAIHvVdsxSxwybXlJwDjj6g0NEsuQ58pFLIpXnOPvDv+tViFa4AUKX+6xAxx6g02Ofyw8Z81PVQmfm/pUypuUPFy78kl/6etUtiWtbiSROqbo2ZtvYHjPvUEaR7t0vC5BJXt9ane7aMKgI3DlVYjjPv3/Gsu7vz5jIofGeWJwSfQdsUNpArmnORId6vu2YXjg4+vemvHFEwLNwDghT0NQW89uYkVpljfaeEXkHtz71Xu79p9paTeyqFzjHTscd/ep03Nld7FrUBa2l68iEGPAwDg8kDOPaknvrC9vWlSFUijjxhORI3rn0rFvA0kO13IV/+BVXCLCB5RaPtx3oVXyG4K1yzcO9rdFLcrHFJ0yeDzVQKS5LY3E5JXoafLMk7BpWMkm3CkDhRQjDevqT0Hb61LdxWtuZ+qIDbyZGSBmuYhypwP5da7C/AeORegKkHFcbDu6fNlc9BnJqlsc1T4i8hB5HTPrVyF/3mQOvHBqiqlNo/vckDr9atQHJI6nvipZUdzSsm2zKQN20fKCMgn6VtWIJGAAT3PrWBZk+b8pIrodPwBmRCQe69RSTNUa1tuwqxsd5556n6itq1laO18vy4OM5OOeex+lULSzCoLhQDHkAhgTjPbj86v7RHCWjkzMA25ccYzwefrRaxaHwzFioMwRkbpz/AJFTOha4jMTRv5hAIJ2g8c8mqxhJUSYVDIMngjpx+NTQuFiALLvl+8GT5lIPBz70jRIe0bSyHzMxRcjbjdt+tSWwjVvKg3CRTvZiQOF9T1/AVBgtOQf3rsxJYPyPx75psTRRTo2N6KuGTcRz6+v4UbDFuZvPKFFOH+XLDGT6mq87utyLdQzRIcqqtnqO570sf+jNvYsoALBSccexqDzgyBcgBhkAc/U0XBohknlbaEYFxkjBOB9Qazb242J80m5w3PvVjUbo7inb72GXrXN6hOzOQJGII4yMYFNEPQmutQk3ERSBE9zyfrUdreRiaNrpGlReqBtpI+tZY3OSTg7VyQScH/69VnmMRIQZwPXof89qrlMHUR6PYww3sC3Fro11JAejG6Cg+uMioNUdba8aMWf2Y7QNjSCTqP0NYunalHPbWBm+0Kklu9g+2MsqnOVZcdTkjIqfUdQjl1FNgYtBGsTSPGVaR1GCWHUf/WpyWgoSvKxxDNjgHcccVEyEAEElj1zUo2K2/wBD24/Kmsr+WxbOOoyOppJESeommgSajH/dQ7q6qPcQoJ6nODXMaIM37Dq20kAdK6ZGICgD5faky6excRvLySu9WOMDjHrzV6aN0gVHC7ZQCpPXA6D6Vn2zIyuWZsgcKB15rdl0+ZLO2urkMIZ1JiYjrjp+FaRi2i3JIp6d5sE8kazCNHTBbBAz6ZqbUJobceTDI0gTGWxgEgcjP1xWXcebZq06fOo6hjwfpWa10ZoiwG0t8pB4zRdpE3u7lqe9V8lslfr0rJvb8BjuK/TGKWUhlwWCgdGJ46enrXL+I5BCgZJSVYZAJ5qVDmdmZVaiSOttNWZFxDKwEn3s8iul0S6EyFTJ5b9iDyrD+leHWOvSwTYPzDsG7V3+ka5Dc20LxEbscocZB961dOVPVnNGqpno8Ehnd5cxqqg8kk7j2+vPSrC2xS8SK5HlSBfm4x+fvXP6JqEcsmJnBYfdBbAJx0Fby7Z5zJIZEV2O6ZzuJ+pPJxQ9VdHTDclvCkce5ykxSQBwnD7R1x6D3qf+2jBro1PyY5ivMcbngJjAH4Vl3DYgGw8hiPQ7T0GO/rWZPK8tukLKFdc7pAclh2+mKznUcdEdEad9y9NfC5mllcEyMxIwDz/n1qnlcsCMqG4x97NQspjxknAHJJqS2AkmSE5yxzhjjis03JlNKKAmRn4K4DZKdP8A9dNMvl7tgyTnucVcmtlYSRs4XH8RPAA9qyPOPMbOSq8L6AetOUWib3LkMmJCyqwQjJIGefxrVCpkrGXdEGfnGAOOvr1rBViu1WyW+6Rk8GrQuWhjBVwHI4xyR25PtihNLcNzSuAY3IR0JI+YA/KR3rLnKFlE25lUfJnGcdvrTbm68wEMTuzxzn9aoyMUwyljlu4obuFjXiuFEIbcu4HufmIPaprWZFkw8MasGDbg+GPt/wDXrmJrwNIAx+YdGH9amW+VRlMFRgY9fqaalYjc09cheykw5b5huG7uPWufmu/L54zgnk/ypNc1SMwiSaYoir1Y/wAq4C98TZbbHF3yGJq403N3ijGpWVNWbPQoLxZkGCNw4+tWorjcoDEAY9K890vxGGk2yxk+6n9cV1VlfJcxhlIK9TUTpOO5VLEKS0Nx2VlypwcevBqNwQh9xyp5qKMs8JZU+VOGYD7pPTNICc9Qc9cf0rM61K4hVCw2IEGBnJznip44zliAT9O9VpDkEndjGBUq3s6wtEr+WpIxj+LHrTJbuRSkbGJU5Pr2rllj8u6YSloskncQcj8vWunmyVOSWbBJOeCa5/VEEd9KikEKTuOc54HetY7XOSo9UQqSUzt6f+O1btgCxBznsarBSm3co24649au28Y3BeuRkYbpUMuJe09MMoOOeuK6m0iLhFZWYZwR1J/xrH0uEmUEKD6E11WnqwjUMhDr1HQ/hQjcvwRyxmWMB4poyB0H5Y6CrOySYbMhg3zZ9wec0oBkDLhl2jJJIGST14p0gTEu5VcnABY7T+ApspCeUyyZmlVeRkZwccYxj+lLcWx855G8x89WYf49qYu8SDfwSNoO3HHY/SnLgKHHlHc2CDknp19qhlpjcjLKy5YPjaAePx/wpDDuG2UjzO+04x9R3pbi7kCmMkqhIZe+DTtobaZHQHIIDdvf2oHcrCEncU3svJ5HT2x2qtcAlMNjuQQMBj/hVkSBJDLGG2tncB0HPJ/GqdzcAcNhjnH4elCsGtzHuyhY7CeBhivBz7VmSw+YHVFDM3AJ61uYSV9kaJGw6OAQWqCSEI21k+ZRhiFwQff3qorsZy13MK3s44yZbi4VE6BMcsf6fWjUNZkuE8q0060t4Avl5VAWHb8WrXtNKS4uZDKzJbxxtLNLt3hR0GfqeKw7B/suqG4gV4po2DZwM/XHTPb1rS8kjkkk35nRWH2O/sdOgur4WsltEU8l1ZVZsk+Yu31zz34qpr+y41Jfs0jyGKNI3mYYMzAfePv+tbEN4be1tpf7XubeOVMpbx2oYp8x5yOcE+tR67BNFKb17tbuVDG0sTRbMo33W91PT1pyV1ZE03aR5nBIFdS6lsEk4PJrama3l0xIefP++XAGP936Vhbghyy8c4G7BqWK7MaBTyuOf8KmLshy11JtLHl6iQoGSMDFdEvGFB5xXMWcjx6nC4BJLg7RXSMzNuCdT3Pf/wCvUyXU0pscGxIskgZo0HRDzV64167lMAu5ZJLeBBHHGDxGvoKzGdcjK84wN38xUkYgC5RyS4Az6GhOXQcnHqQXGo+faSwyDbGDlSzcD/GqdpPHGGWWV0DDkqoP0606+hQhgFBPYnkA1nxRBZQ0yk46xqcYq07mTlbYjvS7u7iTCnqMcZrk/EFyHxGq7R09Sa6q+ZSON3zHA9APf1NcVrqRxXjLHnavr1zW9JanJWloZBzvA6kVe0+4e3ZpBkSL0GefwqhubcSOPpSo7IwZc57+9dbSe5xXseweE7t38tiA5TG/b0yR/OvULxY7TRgzFHO0Iu1txDdSfp2xXz34E1V7e+MDudkhyhJ/i9D+Feprqct3bKhGNhxnHU+g964p/u24nq4eXNFM1LeZiiKSpI+4PeonykgZsBSeQo498VKqrb2kf7wm6fkocAKB0+lU3vFCA53joBj8655Ra3O6MuwXEqnLFSAOFVeKqpK4zKqgBf7p5FI82/cxDlSNo5wfrVNgHk+UgY7E9TUocti0t08jgySscgj1NJvBRQ24Ekf/AKzVcZRD+7w5OCR3Hp7Cgy/ON5yw647fX6UMx5rltG4/vY7HjAq4m0o2wMCeg7fhVGIRLFuZgW7Ajqc1bt2YpwvygZ+lHLcaZBO5EjbiCcdT7VnXl0VwuTjI69varN+6qWA6jHzA5rFv2UpIxOeOOOvvVRiyZysjO1jVFs1OW3kZ+X2rI/4SxBFxC4bPTPGKxtdneS6kk2sqlduD6VisSNw6g12woxtqeVPET5tDR1PVZtSnHm52fwLn7tZoyTjvSxoz9vxq7bQAvlhyetbaRVkY6yd2aehWnmkKMF24BNd7YacLJWt5UZZ1AO0n7p9//rVzPhyJZHWCVggzycZrvhpc9lrEMV1KkkagE7PvFT2zXNN3uztpxtYrIkqIRtdCTnngH8KldiFJZQvbPrSXtzI88jSJIm5vkVh0HaoGLsPnYN7GuKb1O+GxYtYmuX2J+GeB+NMuIwk5RG3KpwSOhNMWaYK8Y2hWG0+uKfHHtGRjbwKRVxs52wP64+mTWBLtlMjqCAfUc1u3UiR8yoWRfmKjqQOawo4/Pl8xF2qxLbc8AVqtjCWsh8CkHEhJ/p6Vr2VqG29s8A+9RQWUigEgnJxhhg/nXTaXYTBclBtH+1nilY0jYs6TZONjygqM7eRgZrqLS1YGDzV8uMOcyZ5qjZRMVaJSpViOo4/OtllXyUZdmACj7ScH2wf500i9xIHS38u3ljDxuxZc9QPx/Oq7jY8ZVBKZBnbkk89McdsU+PbJCzOApBCgMeR9PUYpLgs5gjJIEI4ZOoH+FFy0iJQS+FJClQGPLH8PSiMiB1aMlAPzYmp1wsLR7SCWwoPXbVbzI48HAcKMAHqPpUFoRmEcbh1UYGMevekkDy7VYHyiQeTzjvj1qQzo0CREJgEkFh1piuNhG9iwccMowOO9BS0JVQPIIo5VK87Xddv0zUWsaYrWy3EGWmCBnjVcbe4578UwybWCvgMD8+xsjrkYx/KnXBkmZkQoMc4XsCOcdv61Sa6iafQraHbW00sb3swhUZ2hj1PYGs6/DxsyNEu8MwJB646k+v1rRSR7Pz4JgNk6j76Y2/3WFU7gFmZw5fOeQwIJ9M/rxTT00Ja11KljeS25uU4ZLiPyJFxxjt196qW+lGOU28/G/c3A3Z59O5rTuraB7d7iEsoTCyL1wSOv51ShnByz7lnXlXHfiqv3MHC+qR2UWlQ2GnWupXxsHtIFEam5Dow5yEITqAeea5PV725k1K7S4t4RJcsrM6HKlAP3ar22Y5q7PfQajpaW+px3zMv3XicDfzxkHv70t3bu8gSW2MWIEEMIOWEYX19ccmtJS5laJjGm1K7PIdy7iBnpxn1p0WfOBK5O4HpkflSSKGyvO7HAA5JqQK/mK5CxnGR2B+lYoJDEjIkLAbSDuGK3423Qoc/eGeKL0r9i0+zxbAwJxIse1nDnPzt0O3oD71B5bReXHH5rOBvkXgrnPG0jtj1onG+gQlbVi32RExVipY4J681Vjv50hEcjArycYHX1H1q1LuZmQjgfeBHQ1QuLUqxw26IDKtjOB6U4u2jHLXVD/tBLx7MBiOT6mluXjdsA4PHNVZOY1d8xg9Cen4UW94kcqyJGAAfvEZyfpVX1FJKwl/E8cDM52E/LjPJ/wrhNSx556/THSuxv7kzSsHBUKCTk8tXJ6gvmOWHXNdFPc4aq0MrBpCPzqyYiRkdKYEJk2jrXRc5mkWdEJTU7VgobEgwGbAz9a9cVtjKr8bhxgdxXnOg2BedS6YBPBNdyheJEiZmZY+c+3tXLWtJnZh7w36m4x3BSrbFbjGME+4quzCJSVBcZ2knms9ZoSwDbmwcjZ1JPrV23Id9xkjiRckeYcZ/D1rma7nfCYNISABxzjIoDomTg5xkn+7Q10HgyY1KE43bcH3oW5jdD8ka+lCVtSnK4+eTfHyyFlUEIhOW9vwqLLXCtI5IeQkucYoH2JUCgTLIxJMhI2+1SsApWOKQSnH8AIwfQ+9Ek9yE+wsr7U3AgfLjkY5qQ6i6QCPKqMYYjgmmrGm1ll+U8EjH8qrSPG8mCAOerDp7Ukmi211IrqZSqtgEknAU5J+tYtzL58wjAYIOfc1r38iqWEe0ccbRWWYZxbtd7WESuBv6YNaR7nPVld2Oa163DvuTDDH41itZbAjZPJ5HpXV3Q3sWEe7cMllGc/T1qr9lAuE2j5CMdK3U2lqcjp8zM62tPNAH8KjjJ/wA81p2mlFyGO1lI42kde1adtp6faG+4YwoJ+taT6fFby/LKkqYHzhT19MH0qXUZqqZRtrYxFCRjHDGt+C9MESsJCOOCTyKhjjSUZOQ2OO9H2YEH3HIHQisXM3hDuXZNUuJxuuShHQ8AnIFVly2Tz/TFRrCA2ewHHtVhAFwAxBNZN8zuzoXkSKu0bccjPPrSg7OeCBz6ClYn5dvQnBqvJKWG1VJYnACjJoirkyaRDdEkysBuAUhcdOf/ANdO0i0LquckJgk4J2jOOakW3NygCMGjXkDGCea6LRopLMhkhyQpQseVYH1Fa2V7Gcdm+pNdRRTXQFq3+jpgRqRjgDnPvWrZxDyAyjgHkA/eplrCuM7BlcjGcVctoUcoJHYjqTH/AA+3pTerNIovIgji3KjozAADP3RzningKHIIJQ4JyeT+Heot4QAonAXCj1qQXCqkiqfvqFYgcqfYHt71nc1RLC22R3WIYUfMwJyB3xn8qgdiyFnjKkEANyeAehP0pZTI8cCJEyHBZumfc59PpUbxZTaFIaP/AFkjNjj1x3/CmmUiObE0b73XfnOeueemaeyFMxIFwBguAefQ0MGa+G2IuCMlRwW4/qKQgRyRt53DDkq+cA9AfT0qbFWIpw+3JfDA9cYDD+tRearzDY8oyoAORj8R3qcxlkkKy5hRuQCeR6gH0qGPyVIZZW81SQuFO7/gNKxRLu/0eMq7Sw4LMD/CehwPSnYjMMihWd2wVdjtCDvToFkQANudwSIwJB355qFXYShmTeD8zEnk0wuRyZYhnxIr8f3uB3+oqoINwk2gyQdQR1zj71W1PkzxMu6ORzuXPBHofcZqS0dmnl89kWPBVmQHj6emaCW2UmhkuoI0uV2vCuyNgOGXr+P1NQvpYjvI0eQx2zAEqpyy5HTkDvWlFaokxR2iZWiJO5jy2O3+FX4Y5Zhb228ykthFdc4yOmT/AJFUlfcjbYzhounxsyz3d+z5HAjX5ePrVrUTDcT7LaNyqqqI0hOQQuCAf61bMVk10wN9FLnIZWjcrkd8j0qG6sRauC211KgiRWJ7ZG0981aVkZ6N3ueNTWbW9x1OR1JPPTnkflSJCxiZyVVVAjBPG7npmt2WzZCVKnnnpxj1zUarJFa7YwyowywByG7dKzvYnkuyneQ+RLAIJ/OESjDYGB32++PyqsrShhNE5SVG3b1OGDe1bSCbTw0NzCux0wVkX5gOox71Z8ix1PfwLSVEyhxjec9MD2prXYrltujm5L2e81Ey3LBpJCFdggH44FPYFoieBkZAzyBnGKmvdNngmZRGVIOAw7H1zVZklk8t2dtycBj/AAj/ADmne694xlCz90qTqSD5mcDlQR/WqUo8xSqjHGCDW9mWchpc5C4YnHzelVY4hNlNoEnZc44/GmiJX6mH9mY4jRcsRwAMGsi/iAcqACR1rrJI0O0yKTn5QORnHoe9Zd3ZLMzfZygJONqjJJ9K1i2nqYySZy0sbAnnd7DtV6w08B4iBveQFj6D2NXYtNaadUVWPO0nbyK62508W03kokcLxgHCv5nOOuauVSyM40bsj8P2tvEhM7BduDhVq9dFhM1xsCoxGEJ6CobaeVI2jKR7v4QR1z61euCkskZMqrtjCkOCMYHUmsuZNaHS6bRljNvJuk+Td91s4H0NKAxILuHyMkE5JqBoS0rLKwaNuRzkH8amSEx5D4k4wpzkAVLFBu9iVVOTmVFGTkg9PwpY0QuV8wqpzzg00KBh0PzDnaRTZXMYXbjJ7DmpsjW7IpZirqUUMVO4bucntVqzuJJW3g7GyflHc+pquhV7VbkZ3PJsRNuAMdTT5FFqfMjYlurEfzpaAm0aYLsrF1BJ469Kq3GIzhySM8gdvxqOGea63eXHK6rzuC8Zp8cVxd3QtljLOw3DIwRjrzTSG5Iz5ZPmHX5vlXvmr+pW0ltaC1abzFABKqeFJ7Yq9FoF48RmjtjLtUn5ASoweSf8aqxqJDMLicrtIWRhgAMenvjGa0Wm5jNXK1hpTXzyLENzqPl+b+RqCLTyWdZVYrGcFye3pitfTjDaT7DIxiUhsqCM+/NRooW9luWBbksisMhwe59KLaAl2Ky2Xykx7c4yoHBpqBs5ccDpz3ro/s0E9tEGYkpkhl4yfpVa804szFiCEUZYYOSfQCk432KWm5kxFfMBLZPtVxY8qSR171HLpl1bXACCPbgMHPQipTFdQyKhULn+In5fqKzcGaKaGPhSgc4A7momnVWz/MUrxXLBmIT0yW4NSWuneaxNzKNvPTgfnQoic+xTa65V4huJHygCtPTdPZl3TKSz9QOgHt/Wrlvp0AQEIQi8YFa1mckLje2Mso6D61WwcrluV7a2SFM/LjoSByf6VopE3kgr+IJwAKiEcrndsJBOEJ+6f8atxBFXZMuMDp6mlc0ULaksAZdpC9Bg5PWrEKtFIzhiGJwV46elVCysyqQ4y3U8VYRFjkw2dx+YZBwKC0Xn2llRP3TYyPf0FMlkKB2iDBsBSrDP8+lQn5gCn+rPGQcjHtSyed+7YuGBGOuT/kVJaLnnNLK2W+UoQMYyR6D3qF5F8vKkqQpBZcHeO2femrI74DNvC8bgMfj7U6BvMfaYv3QHJIB/H2oGhhwIhIryR3P3m5BJHt75pDG8tuWjQ7l4lOQBg9wOtMmRQYVDIMEhpOue+P8A69OceXO0Uq7ZXPCngj9eKXXUpEeSBtEiPjIy6kY54x70ts8cjqsTMC5+ZVYDH4mnKquoTIJVSTg4IPfJpBbpGrncAzL8o27j19+nFCC4+MqqH94YypI+X73P8zilSMSBIVeNcBgMt2759/So57WWHesL4L4Yp1HT9KRZGiURjDE4Y/N1/GjqAqFigIeNjGCHaTk7fb6UiK6EukoUbNwVhu3KfXtmlnkzCqnYyKmAGXBH0x1H1qQySzIzOgARVxwFzjjH5d6BDydzRyM+8MmN0pyeOo+tT288q+RdR4Z9xJAOTkeo7ZFQIjosTBcMzEhSc7s9qYGmjBuGZkdHzuQc7scH6UxPUv8Am2Ns8EklmxZnD7VlYoM8c5FTXclvMCrhEVkAQdFAB6f07dasXNzqEvlSCO4QAAkoM7uMnHqPY1lsbiWX99N5o6ncMMR/THpitbmMVc4+S2eKSRXLTbV6DlW9Pwp8NvJdzgW0LOy5Koo/hFauoxv58sRWJplAAEbbQDjp7/1NQ2M13by/arCYpeBNrKgyceox0qeVXsx36lPUNOVoIbmWfzJJPvHk/TrVC3i2KS0UcvP3iCSvv7CujnlaXTzeRqiu7ndE4zg47e1UYrZhK/mSLECu9wp5JPbApTSvoVG9tTMiWO41ELdSgxTNl/lOB7//AFqrtp8085hiRpI0banlpw2T1x15rXnt7VgpIdYycvID90dgfXNTp5jSTNYARxoCCW5aQeme4pW01J2ehy8tiq53HgHAyCCT3qncWIdclQQP5+ldhqFhGiRtIvkNty2Rndz1+n0qpdQRO0qxRpnACttK59wtJxaehTszk3WRUyGRQvylCuQo/H+lVFmkQvHyYRgDAC5AOccDPWtq8t5Le5JdzFMDkDGNvocVTupJJY43eTJQEAeXtAH+FUpPuc84K5USLfINq7Dndt6gmtkacXV5J5IxMACec4FZFqEWcOmSw5JAOK1Su4rvGeMbRjn0xQ5X3CEbbDrnT2trqdbiNVdABtH97sPxGKqPHNBG1tIi7x8zk8n021p20vl3cZnfzArZKyHAJA70kg35ZQShyc9GJ+lDa6GsU9mV7bSN1oszxOiNldygAbh3yf5VSvNOuLRjt2yIMEFOQc/1r0f7RpsXh2C1i2SygmRwq8/iT1/+tXOzm3ZgqxnJ+Y4PAPaqlFRWjIUeZ7HHLDOY9wjkZMYJB6U1IpnUeWpKg9SRnmuskToPKQSH7z+2e+eKS1jh+0urpvl5Ysg/TjgVKRMotGGmnyRohuWdVVsrGgyDVlXAjCxwQxqflcheR+dbF3arFKWfG1+fvbj9B7UtxpqQRM+6L7u4DIz7g+5ptIFEx7dfNyIflODtyevv9ansbJfMX55GmY/K2cDGeQakkhWO3UQIPN3AvnsfTH6UpuMQqkhLPCpwqgDeSfX2oQnGxJcX17HDNDDPJHBIdjKp6qPb0qhYw2007tMJI4oxliR1Pel1W4JljUbTI4wASTk4HU9hVOV55B5RIboSsYx07U79yZdkafiCbT3vEaxEpg2gHectkd+KXSLSO8gy83zBuAVwGP19R6VhbHebcSyDblV7E/0q5bTsGjgMjhGwR5Y/r2pt63CLNrVFsg0R0qWYgqFl81cZfvtx2pZF8xY98jsY+NyDGGxx9RUSCKZWaNSDEu3Yo5P1Pc0qKIiqLgbs7ivOKV7bGvLcnQM77nYqy9Qv8R9c+tIVjMjBC7H+IAY4/HvRb6e0kLSxqzIrY3YI+lJPDJA5RlKTDoj9jUc7LVJWHXSw4HUbQdvHf3qVbNX2l9h4HyjnrQzPJsXhmAwdo/xqVbeTIkkBUZ475/KhyBRFVEhcgSLjGGqeBFUZVWJPABHUelDIkQ3IFJ6ltuRTWG59zHaQOAeCcdqVykkWobyRF2rvxv3gDsakvLlJbnIURuTllUcfX2rMGM5L7QDzjvStgggkH5sbc5GPWp5iuUviRTxywAAOSOnepY+qhS5HTaTkfhWXC0gZgzBo88KemK0Y3YlwzhW9CeQfSri7g9CxuAhIVWznAAycU5DtkwZCXP3lAGfrUH9wZyOD8zcj8O9TrGu3eoyx4XK4OM8mhoEKvzCTJUYOCA+M/WppSJDGBMz7iR8ozz0/lUcijymVgApYAYJp+wrvDBdyjcSrdh2pFEMJWS4MKKV3EL84z07n3qWUKzsRsVkA7fePQk571H58aXRLL5hxtAXkbv72O9MfzGi3Ki5zllHYg+9IaQuQwAijkErMMDjZj/a9TmnXjeW/+kbn8zgu3DZ9gDzimshMySOogbdnaAVAx/PmlmVpxIxfe/dpVx+ANJ67DGR8Iixu0jgZZNpGB9aWaTCoVijwMcFiw/8A105IwJQJZkkzH5g2nCqcdKhbcrbxt55G0ADimAgmbCGPCknGMdPp61ctlEy+S6bZyxJOMnB6ADtVePzFhlRXGx/mYphhgemelTwHYwDKPXcj5I70xEke9mEKKcAfxHoB3yB61c026jNyJZo/lRsAouMn1OTjAqvNMDeRjllxhsnZu46HFJp5h+2QpdqDEG+bJyqqT3oW5Eti4LPJONWhYOd24s+7r1xRfyiS8Xyg0pEYVWYDc5xgs3fmr10Unh+z3svl3IJVWEYXYccAkdV6VQ1RBDe/Jt81YYxIi8AgL+VaPRGcX72pyMtw3mO9o6EJuYFzg8+vv71c8OXDhHidNwfcxKABh6kn0ApYoJUWKGOUpF5Zky0alsjkYqKx1C2WBYLpGDySZkmQDdj2/GpV07tlaW0G3jETpFEFaJR8qbuh9aSN0vtsYhAuD3z1/wAKglRJHSOBi7Fj8zDgDtx3NX7aCO0hQxOI2/jfaSW/w+lLlcncbkkhkUUtuksMzh0BKspPHH8WP73pSmO0jQ5VUjIzu5yD2Gen1qAqPPMsTuZpCSyq2AT/APq60kao6EPkqMlVHzBR3/KqtbREb7kl3eC48sNMW2KE5PAHoAaz724lYusTrujGNxXBX2qO/KlFfzAueB8uG/wqlqIS2RF+0JcbkDNtB6+hz19KltsG0ireXDyMA8iySL8wJ6/X+tUXj8xS0igPjACk4Gal4G9tihyee3B7U0rLGhdieScBf89KSM2ySxt9kqhAvHOff0x3rbvEbPn3EKQvvGVVcEZHoOlYlo/leX99pXBwCfzP4VNPfl2dmmZyxC7lOV+pNUtATJZFeCQHAkDLkZIzt9PrWlpZXcFbKu/QnjC96xbT/WlJBKWbLAY6GtS0nRpjtZQVHGMlTQXGR0FvbxKjzRopSIeYzFsBQOxz1/Cq1+IzMxSMKuNysF+Xnpg+lVWuJpZTlUZC24RtgIT3PHel8yeV5FCuISwfZHkLnscn9KHJGkdXcbcW4W1PmROwcDHHU+mKjEQKHzEAULyFb+dXFlUKDNAGfqQH3KB/jVo3FtALjfEuJF+QHjHpg1PzG1cyGhOMogjQjaowf59+arsN83loH+7ueRueQemavSymVwDtMWM7EPEYA7nuarySzYRU2yjgqgHJPuPQUyGiPyVVYRECzhsszDkHqSD+lZ13LMGlJVkIyoBGWq/cHzJy2Du64C4U/wCFRyLcNFuxGAvzFmP8h/U0JkSRhxmdpBKUyc4+5yTnpV0Q7owPIYPn5z/d+v0qRmBgbBVcZLv1LY5+X3oha4uvk3RooACs56DtkVRkokc0EqohiVoolYrnABP/ANenRxbC/nqyw53KF53fj1FSywMJFkd5GYR/e3Db9akhkDWimQSTyYxyMKvo3vRcpKxNAskqxywMvl5PL8MPSlhSXY/m85yMlcDP0oCSxFnZAiouQgPX8u9Og8y4tAUcxFPmOep596k0RoWd20Vq8Um5+BtIO3a39ajvYlkZZXkdpGAZi3PP9OlMjWWXYyRqRkc4+ZiPSnokkysZ5mkI4CFcD6DHSp30NEGMwhg4dBwSgI685yetT27HJxIRn5dwBxipYSihVJyi8LtOdp9hVWVmeQBhtwTkFsZPsKWwFyB5IDsG0u4I3FsgZ70ksbq5GAdmOnIPtUbBY+Y25IztBycf4U5pV2kHaTn+EnJP+e1MZNHp7PAJkjDDOGGen0HpTm03ZEZXPlmNgGT0zTImZoiUkfa/AXhc49D1qQeSu0ZaRweVcjII6k+o9KLIpyexd0/UFtJJxDaxShwBl1yFHcVVfBctGp8tSRheeDUaFDMTIpaM5+7xu9R/9ekWRlmXy0/dk8DHOPTPfFWtiGWclWV28zC46AfkKkMyNKOip3j9PaqaNsclhuP3gQ2M81ZHz87VHGVyePx96GCLMZ8xmEbc9nc4GPT61DIXSMBXy24/dbnr1HtTUUCVV2kjOFYMOvTg+lPA2MOA5zgNIMZ9OKhlIdLGsnlfusdGZiMFh7fzpXV0JbcnlZB2nGcZ4OOvvS+WY3I27iuD94c8dBVaR90bSO4jVWHygj88d6LlE0u2RgPu7hypc+vr+uKiR40Uhon3ZyCGwqg9M0x3llV0B4ZtxwMAn1pwZTIXZpZCfnb5iM/QUdRiRPukBSIkNj5gcdM9qR1AbOWbsSvAUdKjHCSrypQEhCwyPcU6ABgzDbKQp+Zj+WaSEySTCblQOSCAGONqj1qwY2kUNiMOcL8v8z+VQSIViaQopkyFwFJJ4zkH19qjHmMYwWwr5JDHlR3x/hVCuXDK0rozqA2PLHAXIUdfrSDypiqoS0gbaM8Bs9iO/wBMVWuGXesixocEZdc4z7Z6VbsJ447q38xiULFlYjIUsOD68HFD3E32LkyBgbd7m18wHiNicg4wQWxj8Kqtc7blomtJAFXy3ViMl/UnpVw+VFcxNc3PlyIqJ9l2E5BGGXGOST/FnvRfAm6yCJBAixuQw4YDpnp0xz7Vduxmnd2MOxgmYtdrcMgXK+WqjGAT3/Cpr3ToJQkhUCSZVkdsc9MkD0ooq4JNakN2aKnlQ2thJcJGd7SFVwfujFVJ5Z0nV1mIVkG1MZCgj3/nRRUvRIb+Ib5Qa42N9wALgcZ4/nUUsaoVRQQOeAeOlFFSK+pkzysYRuJPzAcHA9aqPI5ibJHAG3jkDPSiikglsV2bG1VVRnuRkinRZnAyduTtOB14zn2oopIzYqIAyorMOGIIPTj+tV0fdFCNqjYew+8fU0UU1sS9zTlUlFyc+YpJ46AdqfDGXcW6u0ZJUbl45JxnFFFDKialvaxmMxtuYK5U5Y/N7mnbEAIiBRnGwtnJx+NFFJnQjQjs/OslmjkMSROUCAZHCbqykkLyMZArHcAOMYHpRRSe40yExtdHBcry2RjII9MUkDXgvFV7lCh64iCt07EGiijoS9y3Gi3GIlGxVDOT1LY7ZqS40+OK1aVOPlB24yPSiiqjsKRWjgRbmNyqssY2hSvYVlLfNeX7vHGluhcgpGOoB6fSiiqexn1ZNNGqXBdixVjkoCAOP5UwoUgQmSVleQqF3cAUUVPQRasXLXEUTbSM4DEZIPrVhfMkRA8hKqSMYFFFMtbkNpdySSXBG1VX5QPTjrn1q/bt5qxK27aHAI3daKKlldCW6gjhmUBc78g/XrmpRF9m+b5HAXoV9qKKfUroLEqtEflUStyHA6AHpj8amjXYnlthkBzjFFFIQRLuulB2jGGO1QPbj0ph/coGQDMm7rzjHFFFCKFumIlhjJzyeT9OaiVi/GAEz0oop9QexaQZcKoVVbJxjOPantlLUOCcEEYJ7560UVTEJHKGVfkO1Yvulic1Zs3Zn8pGZAxOe46UUVCLGOxYA4RdhEY2rjPzYyfU0s4zI1s4VlXgHaARRRSe41sRhhHLHGo+Z1JZj/Qdqr/aGFwybVyrH5sentRRQthj9QZVk80xRklsgBcYNCTYChlDE85NFFD3ESBR9oDRZjOSMqTn61BKfJcBFUEnGce1FFAFqNysBKqm3eHKsNwz7elMW4ZQQQGcDbuPPB7Y9qKKp7CLc+oXslmR9qkVEG0IuAMdcU6TBBwMx+WEKNzkAZ6+tFFCYNJbH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Papular sarcoidosis. Multiple round papules are present on the eyelids and central face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc. Original photo provided by NYU (Tisch) Department of Dermatology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Papular sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small papules are present on the nose and cheeks of this patient with cutaneous sarcoidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc. Original photo provided by NYU (Tisch) Department of Dermatology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_14_11497=[""].join("\n");
var outline_f11_14_11497=null;
var title_f11_14_11498="Blood donor medical history";
var content_f11_14_11498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Blood donor medical history",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/14/11498/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/14/11498/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/14/11498/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/14/11498/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/14/11498/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/14/11498/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/14/11498/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major goal of transfusion medicine practice has been to reduce the risk of transfusion-transmitted infection to as low a level as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/1\">",
"     1",
"    </a>",
"    ]. This discussion will provide a general overview of the blood donor medical history as a means for screening donors in the United States for the possibility that their blood products might transmit such infections. Issues related to the actual procedures involved in blood donor screening and the laboratory testing of donated blood are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=see_link\">",
"     \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donor screening and laboratory testing of donated blood prior to transfusion are intended to ensure that recipients receive the safest possible blood products. As of 2009, such testing consists of determining the ABO blood group and Rh blood type of the donated unit, testing for red cell antibodies, and performing infectious disease screening for the following agents: HIV-1, HIV-2, human T-lymphotropic virus (HTLV)-I, HTLV-II, hepatitis C virus, hepatitis B virus, West Nile Virus (WNV), and T. pallidum (syphilis) (",
"    <a class=\"graphic graphic_table graphicRef69661 \" href=\"UTD.htm?30/59/31676\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, many blood collection agencies screen for antibody to Trypanosoma cruzi, the causative agent of Chagas disease. All infectious disease screening assays must be negative in order to release the blood unit or its components to hospitals for transfusion.",
"   </p>",
"   <p>",
"    Since 1999, standard serological testing of donated blood for the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) has been supplemented by the addition of nucleic acid testing of pools of donations for HIV and HCV RNA, which allows for detection of additional infectious units [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk of viral infection from transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current per unit risk estimate for acquiring HIV from transfusion is one in 1.5 to 2.1 million, and for HCV is one in 1.1 to 1.9 million [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Risks for hepatitis B virus (HBV) are more difficult to determine, since there are more unknowns in the mathematical model; current estimates range from one in 205,000 to one in 355,000, and are lower than the mid-1990s estimate of one in 63,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. The risk for HTLV is estimated to be about one in two million when the older published risk estimate (one in 641,000) is adjusted for the fact that only one-third of potentially infectious units actually transmit HTLV infection, due to loss of viable virus upon blood component storage (",
"    <a class=\"graphic graphic_table graphicRef69661 \" href=\"UTD.htm?30/59/31676\">",
"     table 1",
"    </a>",
"    ) and (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=see_link\">",
"     \"Transfusion transmitted HIV infection and AIDS\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DONOR SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major procedure for screening donors at the donation site is the medical history interview, which contains questions to protect the recipient from acquiring a transfusion transmitted infection and to protect the donor from suffering an adverse reaction after donation.",
"   </p>",
"   <p>",
"    In order to exclude donors who may be bacteremic, viremic, or parasitemic, blood is not collected from persons who are febrile at the time of donation, who state that they do not feel well, or who are taking systemic antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1983, with the recognition of the possible transmission of HIV by transfusion, the health history interview assumed new importance and became more complex and probing than it had previously been. The trend of adding medically sophisticated questions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    socially sensitive behavioral questions to the donor interview has continued to the present day. Donors are asked questions concerning their sexual activities, their injection drug use history, their prior HIV testing history, and their history of selected sexually transmitted diseases. Donors are also queried concerning exposure to or medical history of hepatitis, malaria, CJD, babesiosis, and Chagas disease.",
"   </p>",
"   <p>",
"    A distinct decline was documented in the prevalence of hepatitis C virus and HIV infection in blood donors between the years 1991-1992 and 1996 (",
"    <a class=\"graphic graphic_table graphicRef70772 \" href=\"UTD.htm?23/29/24027\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/9\">",
"     9",
"    </a>",
"    ]. A second study conducted by the American Red Cross gave similar findings, establishing that the prevalence of hepatitis C, hepatitis B, and HIV infection declined in blood donors from 1995 to 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/10\">",
"     10",
"    </a>",
"    ]. A Canadian study extended these HCV findings to 2006 and a US study extended the HBV findings to 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. Although many factors may explain these decreases, possible reasons for this decline include [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effectiveness of behavioral risk factor screening",
"     </li>",
"     <li>",
"      In the past, HCV-positive donations occurred most frequently in donors born between 1945 and 1964; currently, most first-time donors were born after 1964.",
"     </li>",
"     <li>",
"      Approximately two-thirds of HCV-positive Canadians in the general population have already been tested for HCV, and are likely to self-defer from donating blood.",
"     </li>",
"     <li>",
"      Increasing rates of hepatitis B vaccination among younger donors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data from 2007-2008 have shown an unexplained increase in both HIV and HCV incidence. The increased HIV incidence occurred disproportionally in younger donors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medical history questions concerning specific risk factors for infectious disease need to meet the deferral criteria established by the United States Food and Drug Administration (FDA) recommendations. Furthermore, each blood center's medical history standard operating procedure must be approved by the FDA. Variation between blood centers in the exact wording of questions or in the format of interviewing blood donors is permitted.",
"   </p>",
"   <p>",
"    An interagency task force under the auspices of AABB (formerly known as the American Association of Blood Banks) has reworded the donor questions for increased clarity and has validated these newer questions through cognitively based research protocols. This Uniform Donor History Questionnaire (UDHQ) has been approved by the United States Food and Drug Administration (FDA) and is being used by many blood centers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/12\">",
"     12",
"    </a>",
"    ]. It can be administered orally or can be self-administered, with follow-up questioning by a health historian if the donor's responses raise questions about donor eligibility.",
"   </p>",
"   <p>",
"    In addition, several blood centers have implemented a computer-assisted self-interviewing (CASI) process that includes audio, pictorial (visual), and touch screen components. A two-year evaluation at one blood center showed that identification of high risk behaviors among prospective first time donors significantly increased following the use of CASI when compared with results obtained from the previously administered oral questionnaire [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Recent vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;AABB standards for donors who have recently been vaccinated are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No deferral for donors who are asymptomatic after receiving toxoids, synthetic, or killed vaccines",
"     </li>",
"     <li>",
"      A two-week deferral for receipt of certain live or attenuated viral or bacterial vaccines (measles, mumps, oral polio, oral typhoid, yellow fever)",
"     </li>",
"     <li>",
"      A four-week deferral for receipt of rubella or varicella zoster vaccines",
"     </li>",
"     <li>",
"      A one-year deferral for receipt of unlicensed vaccines, unless a shorter timeframe is approved by the facility's medical director",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the possibility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    of segments of the US population arose, additional deferral questions were added to the donor history to address the recent receipt of a smallpox vaccination and skin contact with someone who was recently vaccinated. Positive responses lead to temporary deferrals (minimum of three weeks) to ensure that the potential donor is beyond the period of viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of vaccine-related deferrals was illustrated by the occurrence of transfusion-related transmission of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    virus from donors in whom a proper vaccine history was not obtained. [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HUMAN IMMUNODEFICIENCY VIRUS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Screening issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;In April 1992, the FDA issued a set of recommendations for screening prospective donors for prevention of HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/16\">",
"     16",
"    </a>",
"    ]. These recommendations state that prospective donors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Must receive both oral and written information concerning HIV (AIDS) risk factors and the potential for HIV transmission through donated blood. This information should include informing the donor that, in early HIV infection, a donor may be infectious and capable of transmitting HIV despite having a negative test for HIV antibody.",
"     </li>",
"     <li>",
"      Should be given specific information as to how they can obtain an HIV antibody test at a site other than the donor center.",
"     </li>",
"     <li>",
"      Should be told that all units of donated blood will be tested for HIV antibody and, if positive, the donor will be notified of the test result and",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      name will be placed on a donor deferral registry.",
"     </li>",
"     <li>",
"      Should be advised not to donate if symptoms that may be compatible with HIV infection are present. These symptoms include persistent fevers, night sweats, unexplained weight loss, persistent cough or shortness of breath, persistent diarrhea, swollen lymph nodes that persist for more than one month, presence of whitish oral lesions, or the presence of bluish purple spots on the skin or in the mouth.",
"     </li>",
"     <li>",
"      Should be asked direct health history questions about behaviors that put them at risk for HIV. Preferably these questions should be asked orally.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Donors must sign a consent form that specifically states that they understand that they should not donate blood if they are at risk for HIV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Deferral of donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific information to be obtained from donors during the donor interview that will lead to a",
"    <strong>",
"     permanent deferral",
"    </strong>",
"    as a blood donor includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Have you ever had clinical or laboratory evidence of AIDS or HIV infection?",
"     </li>",
"     <li>",
"      For men: Have you had sex with another man, even once since 1977?",
"     </li>",
"     <li>",
"      Have you ever injected intravenous drugs?",
"     </li>",
"     <li>",
"      Have you engaged in sex in exchange for money or drugs since 1977?",
"     </li>",
"     <li>",
"      Have you received clotting factor concentrates for hemophilia or other clotting disorders?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The donor should also be asked questions regarding behaviors during the previous 12-month interval; a yes answer to any of these questions will lead to a",
"    <strong>",
"     temporary deferral",
"    </strong>",
"    which is removed 12 months after the last potential exposure. The donor should be asked if",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    has had sex in the past 12 months with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A person who has HIV infection or AIDS",
"     </li>",
"     <li>",
"      A prostitute",
"     </li>",
"     <li>",
"      A person who currently or previously used intravenous drugs",
"     </li>",
"     <li>",
"      For women: a man who has had sex with another man",
"     </li>",
"     <li>",
"      A person receiving clotting factor concentrates",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The donor should also be asked if, in the past 12 months,",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    has had or has been treated for syphilis or gonorrhea, received a blood transfusion, experienced an accidental needlestick injury or a blood splash to a mucous membrane or non-intact skin, or received a skin or bone graft or a tissue or organ transplant. The questions about blood or tissue exposures are designed to protect recipients not only against HIV, but also against other transfusion-transmitted agents.",
"   </p>",
"   <p>",
"    Two additional changes to HIV screening procedures have been implemented since these comprehensive recommendations in 1992. In 1995, the FDA recommended that individuals who are inmates of correctional institutions and individuals who have been incarcerated for more than 72 consecutive hours during the previous 12 months be deferred for 12 months from their last date of incarceration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/17\">",
"     17",
"    </a>",
"    ]. In 1996, the FDA recommended that new direct questions on high risk behavior be added in order to exclude donors who are at increased risk for HIV-1 group O infection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These questions relate to birth in Cameroon or surrounding West African countries where HIV-1 group O infection has been identified, to blood transfusion or medical treatment received in those countries, and to sexual contact with anyone who was born in or lived in those countries since 1977. This latter set of questions are only required for those blood centers which have not switched their HIV screening assay to a version of the test that has higher sensitivity for HIV-1 group O strains.",
"   </p>",
"   <p>",
"    A preponderance of data has demonstrated that the theoretical possibility of long-term persistent HIV infection in the absence of detectable HIV antibody, HIV antigen, or clinical symptoms does not exist or is exceedingly rare [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Multiple studies have demonstrated that HIV nucleic acid cannot be detected in HIV antibody-negative individuals from high risk groups who are at risk for latent HIV infection.",
"   </p>",
"   <p>",
"    Other data have shown that seroconversion for HIV is highly likely to occur within six months of HIV exposure; in studies in health care workers exposed to HIV infected blood by needlestick injury, the longest interval from exposure to HIV seroconversion was 213 days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Moreover, since the time of these studies, improvements in HIV screening assays suggest that the interval to seroconversion has been shortened [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, HIV risk behaviors that can be defined as ending at a specific point in time (eg, sex with a particular person who demonstrated HIV risk behaviors, an accidental exposure to blood, a blood transfusion) should only defer a prospective donor until laboratory testing can definitively prove that the individual is free of HIV infection. Although the scientific data indicate that this is only a matter of a few months, given the combination of HIV nucleic acid testing and serologic screening, the deferral period for these risk behaviors has been conservatively set by the United States FDA at 12 months.",
"   </p>",
"   <p>",
"    However, despite this stated rationale, men who have had sex with other men (MSM), even once since 1977, are currently permanently deferred as blood donors in the United States. This requirement, which has been in place since the mid-1980s has been the subject of intense debate; risk modeling studies have been performed to evaluate whether the policy can be altered to no longer defer persons with MSM activity that ceased many years ago [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. However, this policy has not been changed and moreover was reaffirmed by the United States FDA in May 2007 and again in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/27\">",
"     27",
"    </a>",
"    ]. Other countries have deferral periods ranging from 6 months to permanent deferral [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Evaluating donor history questions",
"    </span>",
"    &nbsp;&mdash;&nbsp;An approach to evaluating the potential sensitivity of medical history questions has been made by mailing an anonymous survey questionnaire to recent successful donors for the purpose of determining the percentage of such donors who would admit to behavioral infectious disease risk factors that they had previously denied at the time of their donation. Investigators from the Retrovirus Epidemiology Donor Study (REDS) mailed a 53 question optical scan format questionnaire to 50,162 allogeneic blood donors who successfully donated blood within the previous four to eight weeks at one of five participating REDS blood centers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/30\">",
"     30",
"    </a>",
"    ]. The questionnaire contained items related to demographics, donation history, comprehension of written donation literature, the use of confidential unit exclusion (CUE) or callback procedures, sexual history, injection drug use history, other history related to HIV risk, HIV test seeking, donor's knowledge about AIDS, and donor's knowledge about donor eligibility criteria. Questions pertaining to sexual behavior and injection drug use were preceded by a short statement explaining their purpose, the need for truthful answers, and giving the respondent permission to not answer any objectionable questions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=see_link\">",
"     \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of 50,162 donors sampled, 69 percent responded and 98 percent of the respondents answered all of the risk questions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/30\">",
"     30",
"    </a>",
"    ]. The data were analyzed by using sampling weights to adjust for differential sampling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    response rates among different demographic groups: 1.9 percent of respondents reported at least one behavioral risk that should have resulted in donor deferral. In 0.4 percent, this risk occurred in the prior three months, a time frame compatible with acute seronegative window period infection. The results from this 1993 survey have been corroborated by a similar anonymous survey by the same investigators sent to 92,581 donors in 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data demonstrate a low level of behavioral risk that is not eliminated by donor questioning, laboratory testing, or confidential unit exclusion (CUE) and callback procedures. They support previous interview studies of HIV and HCV seropositive donors which showed that a high percentage of such donors will admit to a history of risky sexual behavior or past intravenous drug use that they had denied prior to donation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. In addition, a study of seven American Red Cross blood donor history questions indicated that there is a continuing need for improving the clarity and comprehension of the screening questions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/35\">",
"     35",
"    </a>",
"    ]. Thus, continued efforts to improve the sensitivity of behavioral screening appear to be warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     VIRAL HEPATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Federal guidelines for preventing transfusion-transmitted hepatitis were established decades ago in the Code of Federal Regulations and subsequently revised [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The current regulations require the following deferral policies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persons with a history of viral hepatitis after age 10 are permanently deferred.",
"     </li>",
"     <li>",
"      Persons currently or previously testing positive for HBsAg are permanently deferred.",
"     </li>",
"     <li>",
"      Persons with a history of close contact with someone who has viral hepatitis are deferred for 12 months following their last potential exposure.",
"     </li>",
"     <li>",
"      Persons who have received a blood transfusion are deferred for 12 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A history of viral hepatitis applies only to clinical disease; deferral is not required when the donor's history is based solely on a positive serologic test result (ie, anti-HBc or anti-HBs) that indicates past exposure to HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/37\">",
"     37",
"    </a>",
"    ]. The lack of deferral for viral hepatitis occurring before the age of 10 is based upon epidemiologic evidence in the United States that clinical viral hepatitis occurring in early childhood is almost exclusively due to infection with the hepatitis A virus, which does not induce a chronic carrier state [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional questions about receiving a tattoo or body piercing within the last 12 months have also been included on the donor questionnaire, due to concerns about hepatitis transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/39\">",
"     39",
"    </a>",
"    ]. However, affirmative answers do not necessarily result in deferral. Some blood centers will accept donors with body piercing, provided that the procedure was performed with sterile, single use equipment. Donors with tattoos or permanent makeup are deferred for 12 months after the exposure unless the application was performed in a state that has a regulatory body that licenses tattoo parlors. In that case, donor deferral is at the discretion of the local blood collection agency.",
"   </p>",
"   <p>",
"    The definition of close contact with a person with viral hepatitis clearly includes sexual contact. However, other aspects of close contact are more problematic to define. The definition used by the UDHQ is living in the same dwelling; this implies the sharing of household, kitchen, or toilet facilities. For hepatitis B virus (HBV), this definition appears reasonable since HBV can rarely be transmitted from an acutely infected patient to a household contact, probably through nonsexual contact with body fluids [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/40\">",
"     40",
"    </a>",
"    ]. Data do not support similar transmission for hepatitis C and deferral is not required for sexual or other close contact with an asymptomatic hepatitis C carrier [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PARASITIC DISEASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion-transmitted malaria is common in some parts of the world but is rare in the United States, occurring at an estimated rate of 0.25 cases per million donated units for 1972-1988 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/42,43\">",
"     42,43",
"    </a>",
"    ] and zero to 0.18 cases per million units transfused from 1993 through 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/44\">",
"     44",
"    </a>",
"    ]. Policies for preventing such transmissions rely on donor questioning during the health history interview.",
"   </p>",
"   <p>",
"    The deferral criteria for malaria risk were revised by the FDA in 1994 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Donors with a history of malaria are deferred for three years after becoming asymptomatic.",
"     </li>",
"     <li>",
"      Travelers to a malaria endemic area are deferred for one year after their return to the United States (provided they have not had malarial symptoms).",
"     </li>",
"     <li>",
"      Immigrants from or residents of malarial endemic countries, defined as living in that country for more than five years, are deferred for three years after their departure from the endemic country based upon the premise that such individuals may have partial tolerance to malarial parasites, thereby resulting in the delay of malarial symptoms beyond one year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These policies represent a compromise between prevention of transmission and acceptable levels of donor deferral in that it is well known that a P. malariae chronic carrier state may persist for decades, resulting in transfusion transmission many years after the resolution of symptoms.",
"   </p>",
"   <p>",
"    However, not all malaria-endemic areas pose equal risks for the development of malaria. In one study, travel to Africa was estimated to present a risk for malaria infection &gt;1000 times that of travel to endemic parts of Mexico [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/46\">",
"     46",
"    </a>",
"    ]. Shortening the deferral period for visitors to Mexico from 12 to 3 months was estimated to increase the risk of collecting a contaminated unit by one unit every 57 years, at an annual gain of more than 56,000 donations.",
"   </p>",
"   <p>",
"    An FDA draft guidance document has proposed a revision of the malarial donor screening criteria for immigrants from or residents of malarial endemic countries. Residents are defined as those living in the region for at least five years. In addition to a three-year deferral after arrival in the United States, these persons would also be deferred for three years after their last visit to a malarial endemic region, due to the possibility that partial acquired immunity to malaria could delay the occurrence of malarial symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/44,47\">",
"     44,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective review of transfusion-transmitted malaria in the United States from 1963 through 1999, there were 93 cases reported to the Centers for Disease Control and Prevention; 10 of the 93 patients died [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/44\">",
"     44",
"    </a>",
"    ]. Among the donors for whom complete information was available, 62 percent would have been excluded from donating according to current guidelines or those in place at the time of donation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Chagas disease and babesiosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chagas disease (American trypanosomiasis, infection with the protozoan parasite Trypanosoma cruzi (T. Cruzi)) has rarely been reported to be transmitted by blood transfusion in North America, with fewer than 10 reported cases. Prior studies have suggested that the rate of transmission of the T. cruzi is 13 to 26 percent per unit of contaminated blood transfused [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/48\">",
"     48",
"    </a>",
"    ]. However, more than 150 cases of transfusion-associated babesiosis have been reported to date in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Currently, donor questioning concerning infection with these agents is restricted to asking donors whether they have ever had either one of these diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. It is not yet clear whether adding questions about country of birth and travel to countries where Chagas disease is endemic will help to identify donors at risk of transmitting T. cruzi [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23880?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology and control of Chagas disease\", section on 'Other modes of transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data on Chagas disease indicate that the risk to transfusion recipients in the United States and elsewhere may have been growing over the last two decades. Transfusion transmission occurs at high rates in endemic countries (eg, Mexico and other Central and South American countries) in the absence of donor laboratory testing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study from Spain, overall donor seroprevalence for T. Cruzi was 0.62 percent, and was 10.2 percent in donors who were born in Bolivia [",
"      <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study among blood donors in five blood banks in the cities of Guadalajara and Tepic, Mexico, where routine screening is not performed, the rate of confirmed T. cruzi antibody was 0.75 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/55\">",
"       55",
"      </a>",
"      ], and may be as high as 2.8 percent in other parts of Mexico [",
"      <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immigration and blood donation patterns indicate that an increasing number of donors with chronic asymptomatic T. cruzi infection are entering the United States blood supply. In a study evaluating donors between 1994 and 1998, donors in two communities with large Hispanic populations (Los Angeles and Miami) were asked if they were born, or had spent more than six months, in countries in which Chagas disease is endemic [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/57\">",
"     57",
"    </a>",
"    ]. Donors responding with a \"yes\" comprised 7 percent in Los Angeles and 14 percent in Miami.",
"   </p>",
"   <p>",
"    The prevalence of confirmed seropositivity for T. cruzi was approximately 1 in 8000 (0.012 percent) for all donors in these two cities. On subsequent evaluation, over one-half of these donors were demonstrated to be intermittently parasitemic and therefore potentially infectious. Furthermore, the targeted donor questioning was not sufficient to identify all of the potentially infectious donors. A later report completed in 2006 found a fourfold higher rate of T. cruzi-positive blood donors (1 in 2000, 0.05 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/58\">",
"     58",
"    </a>",
"    ], while a report from the El Paso, Texas area found a seroprevalence of 0.03 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these considerations, the FDA, in December 2006, approved an ELISA blood donor screening test (ORTHO&reg; T. cruzi ELISA Test System) with 100 percent sensitivity and 99.9 percent specificity. Although not mandated for use by the FDA, this test was implemented in 2007 by the majority of US blood collectors. Data from the American Red Cross indicate that during the first year of testing, approximately 1 in 30,000 US donors tested positive (by both the screening assay and a confirmatory test) for T. cruzi antibody. The highest antibody prevalence was found in California and Florida [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link&amp;anchor=H19#H19\">",
"     \"Laboratory testing of donated blood\", section on 'Chagas disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Leishmaniasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leishmaniasis, a parasitic disease transmitted by the sand fly, is endemic to the subtropical and tropical areas of the Middle East, Mediterranean coast, Asia, Africa, Central and South America. (See",
"    <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cutaneous leishmaniasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/20/42308?source=see_link\">",
"     \"Epidemiology and control of visceral leishmaniasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been at least 10 probable or confirmed cases of transfusion-transmitted leishmaniasis; most cases were reported more than 40 years ago and no such case has been reported in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/61-63\">",
"     61-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Persian Gulf War of 1991, several cases of atypical cutaneous leishmaniasis that featured a visceral component were reported in US military personnel. Further concern about this issue resurfaced with the report of 22 cases of cutaneous leishmaniasis in US military personnel deployed to the Middle East during 2002-2003, primarily to Afghanistan, Iraq, and Kuwait [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/62\">",
"     62",
"    </a>",
"    ]. Therefore, as a precautionary measure against a possible blood-borne phase that might be undetected in the currently reported cases, the AABB and the United States Armed Services Blood Program Office of the Department of Defense (DOD) implemented policies to defer prospective blood donors from donating blood for 12 months after the last date they left one of these countries [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CREUTZFELDT-JAKOB DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creutzfeldt-Jakob disease (CJD) is a rare, fatal, degenerative neurologic disorder with a long asymptomatic latent period; it is thought to be caused by a prion. Sporadic (sCJD), familial (fCJD), iatrogenic (iCJD), and variant forms of CJD (vCJD) are recognized. So-called iatrogenic CJD has been transmitted from human to human by the transplantation of dura mater, by corneal transplantation in a single case, by the injection of pituitary derived human growth hormone, and by the reuse of EEG electrodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=see_link&amp;anchor=H6#H6\">",
"     \"Creutzfeldt-Jakob disease\", section on 'Iatrogenic CJD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While transmission of vCJD by blood transfusion has been documented (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Variant Creutzfeldt-Jakob disease'",
"    </a>",
"    below), there are no reported cases of transmission of iCJD by blood transfusion. Nevertheless, due to the long incubation phase of the disease (as demonstrated from growth hormone transmissions) and the inability of conventional sterilization methods to inactivate the organism, there is a theoretical risk of iCJD transmission from asymptomatic donors to blood transfusion recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidemiologic studies (including a review of mortality data in heavily transfused recipients, neuropathological studies of deceased patients with hemophilia, and lookback studies assessing the health outcome of recipients who received blood components from donors who subsequently developed iCJD) have confirmed earlier studies in failing to establish a link between transfusion and transmission of CJD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. There is an emerging consensus that iCJD is not transmitted by transfusion, or if it is, this occurs very rarely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Variant Creutzfeldt-Jakob disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variant Creutzfeldt-Jakob disease (vCJD) is a fatal, degenerative neurologic disease newly discovered in the United Kingdom in 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/71\">",
"     71",
"    </a>",
"    ]. As of October 2008, 206 definite or probable cases have been reported worldwide, with 167 in the UK, 23 in France, and smaller numbers in many other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/72\">",
"     72",
"    </a>",
"    ]. The etiologic agent of vCJD (probably a prion) is the same agent that causes bovine spongiform encephalopathy (BSE, \"mad cow disease\") [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=see_link\">",
"     \"Variant Creutzfeldt-Jakob disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Soon after the discovery of vCJD, the risk of transfusion transmission of this agent in humans was regarded as theoretically possible, based upon its differing biology from classical CJD and the experimental transmission of BSE by transfusion in animal systems [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/74-79\">",
"     74-79",
"    </a>",
"    ]. In the past several years, several case reports have shown that such transmission appears to have occurred, with four cases of probable transfusion transmission of the vCJD agent reported in the UK. Three cases were clinical and the fourth case was preclinical.",
"   </p>",
"   <p>",
"    These four cases occurred among 66 recipients who were being studied due to having been identified as having received a transfusion from a donor who later developed vCJD. The 4 recipients with vCJD comprise 14 percent of the 29 recipients surviving for greater than 5 years and thus indicate a high rate of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/80\">",
"     80",
"    </a>",
"    ]. In addition, a hemophiliac recipient of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/12/198?source=see_link\">",
"     Factor VIII concentrates",
"    </a>",
"    pre-1996 in the UK had evidence of vCJD prions in his spleen at autopsy, indicating possible subclinical transmission from transfusion of these factor concentrates.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first clinical case, variant CJD was diagnosed in the transfusion recipient 6.5 years after the receipt of a non-leukoreduced red cell unit from a donor who subsequently developed and died from vCJD 40 months after the blood donation [",
"      <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the second clinical case, a transfusion recipient developed vCJD seven years following transfusion of a non-leukoreduced red cell unit from an implicated donor who developed vCJD symptoms approximately 18 months after blood donation.",
"     </li>",
"     <li>",
"      In the third clinical case, a transfusion recipient developed vCJD 8.5 years following transfusion of a non-leukoreduced red cell unit from the same donor as in the second case.",
"     </li>",
"     <li>",
"      The case of probable preclinical transfusion-transmitted vCJD was uncovered by autopsy investigation of a subject who died of a non-neurologic disorder five years after receiving a unit of non-leukoreduced red cells [",
"      <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/82\">",
"       82",
"      </a>",
"      ]. This subject had no neurologic symptoms at the time of death. The blood donor developed symptoms of vCJD 18 months after donation; vCJD was confirmed at autopsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Blood donor deferral",
"    </span>",
"    &nbsp;&mdash;&nbsp;To eliminate possible risk to transfusion recipients of developing CJD, the FDA has recommended that all prospective blood donors who have received human pituitary derived growth hormone, a dura mater transplant, or have a family history of CJD in a blood relative be permanently deferred.",
"   </p>",
"   <p>",
"    In an attempt to balance increased safety against decreased blood availability, the FDA adopted a vCJD deferral policy based on length of time in countries where persons might be exposed to BSE. Since virtually all reported vCJD cases have occurred in the United Kingdom, deferral of donors who have traveled to the United Kingdom during the peak period of exposure to BSE infected cattle (1981 to 1996) was deemed by the FDA in April 2000 to be a means of reducing the hypothetical risk of transmission of vCJD through transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/80,83-85\">",
"     80,83-85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, due to an increased number of BSE cases in other European countries, the FDA subsequently broadened their donor deferral criteria. The current criteria defer prospective donors with one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Have spent &ge;3 cumulative months in the UK from 1980-1996",
"     </li>",
"     <li>",
"      Have spent &ge;5 cumulative years in Europe from 1980-present",
"     </li>",
"     <li>",
"      As current or former US military personnel, civilian military employees and their dependents, have lived for &ge;6 months at US military bases in Northern Europe from 1980-1990 or elsewhere in Europe from 1980-1996",
"     </li>",
"     <li>",
"      Received a blood transfusion in the UK or France between 1980-present",
"     </li>",
"     <li>",
"      Injected bovine insulin sourced from the UK or other countries with BSE",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the UK and France exclude blood donors with a prior transfusion history, the German Federal Minister of Health recommended in April 2006 that persons with a transfusion history not be excluded from donating blood [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     WEST NILE VIRUS INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since 2003, blood banks in the United States have performed nucleic acid testing for WNV as part of their routine screening procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link&amp;anchor=H13#H13\">",
"     \"Laboratory testing of donated blood\", section on 'West Nile virus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on data from transfusion-transmitted WNV cases occurring in 2002 prior to the onset of such testing, it was hypothesized that a question asking about the occurrence of fever and headache in the week prior to donation might provide additional protection against WNV transmission. Such a question was added to the donor history in 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/87\">",
"     87",
"    </a>",
"    ]. A subsequent evaluation of two years of data from donors with laboratory-proven WNV infection failed to find a correlation between these pre-donation symptoms and WNV infection. Consequently, this history question has been dropped from the donor questionnaire [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/88\">",
"     88",
"    </a>",
"    ]. As with other acute viral syndromes, a general donor history question about whether the donor feels well may elicit the presence of non-specific systemic complaints leading to donor deferral.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     BACTERIAL INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial infection is another potential fatal complication of transfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=see_link\">",
"     \"Transfusion transmitted bacterial infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of importance, blood is not collected from persons who are febrile at the time of donation, who state that they do not feel well, or who are taking systemic antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/8\">",
"     8",
"    </a>",
"    ]. These requirements are also applied to candidates for autologous donation, since cases of transfusion-induced sepsis in autologous recipients have occurred due to the ability of Gram negative rods to multiply at refrigerator temperatures and secrete endotoxin into the blood bag [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/89\">",
"     89",
"    </a>",
"    ]. Autologous donors who are taking antibiotics or who give a history of recent or concurrent medical procedures are evaluated for the possibility of bacteremia and deferred accordingly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=see_link\">",
"     \"Preoperative autologous blood donation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OTHER RECIPIENT SAFETY ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     History of malignancy in donor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donors with a history of malignancy pose a theoretical risk to recipients; however, no cases of transfusion-transmitted malignancy have been reported, nor have epidemiological studies found such an association [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/8,90,91\">",
"     8,90,91",
"    </a>",
"    ]. Since many transfusion recipients are immunosuppressed, it may be theoretically possible that malignant cells circulating in a donor's blood could engraft and multiply in a recipient, provided there was a sufficient degree of genetic matching [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/92\">",
"     92",
"    </a>",
"    ]. In order to decrease the possibility of this occurrence, donors are questioned about a history of cancer.",
"   </p>",
"   <p>",
"    In most blood centers, a donor with a history of a solid organ tumor will be deferred and will be eligible to donate only if",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    has been symptom-free and considered to be clinically cured for a defined time period. This period usually ranges from one to five years at different blood centers. Donors with a history of hematologic malignancy are permanently deferred; in comparison, donors with specific malignancies (eg, basal cell cancer of skin, cervical carcinoma in situ) that have been fully excised are not deferred, since the tumor is known to be low grade and not capable of hematogenous spread.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Medications taken by donor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most medications taken by donors pose no known risks to recipients. In most cases, only small quantities of drugs are present in a unit of blood and the drugs will undergo significant dilution in the recipient's plasma volume. However, some drugs may pose a risk due to their demonstrated teratogenic potential at low plasma concentrations. Five such medications (all in FDA pregnancy category X) have been identified by the FDA as potentially dangerous to recipients: these are etretinate (Tegison) used for severe psoriasis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    (Soriatane) also used for severe psoriasis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    (Amnesteem, Claravis, Sotret, formerly called Accutane) used for severe cystic acne,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    (Propecia, Proscar) used for symptomatic benign prostatic hypertrophy and hair regeneration, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    (Avodart) used for benign prostatic hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/93\">",
"     93",
"    </a>",
"    ]. Deferral periods are one month for isotretinoin and finasteride, six months for dutasteride, three years for acitretin, and permanent for etretinate due to its demonstrated presence in plasma several years following cessation of use.",
"   </p>",
"   <p>",
"    In addition, donors are permanently deferred if they have taken bovine insulin (risk of variant CJD transmission) or human growth hormone derived from pituitary glands (risk of iatrogenic CJD). Donors who have received Hepatitis B immunoglobulin (HBIG) or an unlicensed vaccine are deferred for one year. At the discretion of the medical director, most donors are also temporarily deferred if they are taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , or another anticoagulant. This is because of the effects of these medications on the therapeutic efficacy of plasma components as well as the potential for impaired hemostasis in the donor following the collection procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Aspirin and aspirin-containing medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In December 2007, the FDA made recommendations for the collection of platelets by apheresis, stating that collections should not occur from donors who ingested",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , aspirin-containing drugs, or feldene in the previous 48 hours or from donors who ingested",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    in the previous 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/94\">",
"     94",
"    </a>",
"    ]. Although donation centers routinely ask about these medications, which might interfere with platelet function and defer prospective plateletpheresis donors accordingly, there is no routine quality control testing of platelet function for platelet apheresis products [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/95\">",
"     95",
"    </a>",
"    ]. This is due in part to the poor predictive value of in vitro tests for predicting in vivo platelet function.",
"   </p>",
"   <p>",
"    This donation restriction is specific to plateletpheresis donors and does not apply to whole blood donors unless platelets made from that unit of whole blood will be the sole source of platelets for a given patient. This would only apply only to platelet transfusions designated for neonatal and young pediatric recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PROTECTION OF THE DONOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donors are asked questions about their overall state of health as well as specific questions about cardiac and pulmonary problems. In general, donors with coronary artery disease, cardiac valvular disease, arrhythmia, significant cerebrovascular disease, or heart failure are deferred, as are donors with any active pulmonary disease impairing gas exchange.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Donors who have undergone recent surgery in the absence of blood transfusion are deferred until healing is complete and full activity has been resumed.",
"     </li>",
"     <li>",
"      Donors who are pregnant are deferred during pregnancy and for six weeks after delivery.",
"     </li>",
"     <li>",
"      Donors with seizure disorders are acceptable provided that they have had no seizures within the past 12 months with or without medications. This policy appears reasonable since there are no data linking the convulsive activity associated with seizure disorders to the convulsive activity that may occur secondary to ischemia from a post-donation vasovagal reaction [",
"      <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The minimal age for donation is legally established by individual states in the United States and is generally 16 to 18; donors who are legally minors need written consent of a parent or guardian. The upper age for blood donation has changed over the past decade, following studies documenting that individuals over the age of 65 who met all other donation criteria had no greater frequency of severe or life-threatening reactions and had lower rates of post-transfusion reactions than younger donors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/14/11498/abstract/97\">",
"     97",
"    </a>",
"    ]. Most blood centers no longer impose an upper age limit for donor eligibility.",
"   </p>",
"   <p>",
"    Safety issues concerning apheresis procedures and those engaged in frequent donations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=see_link&amp;anchor=H12#H12\">",
"     \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\", section on 'Protection of the donor and deferral criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/52/22338?source=see_link\">",
"       \"Patient information: Blood donation (giving blood) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26820?source=see_link\">",
"       \"Patient information: Blood donation and transfusion (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21040292\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major procedure for screening donors at the donation site is the medical history interview, which contains questions to protect the recipient from acquiring a transfusion transmitted infection and to protect the donor from suffering an adverse reaction after donation. The following issues are covered during this interview:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21040417\">",
"    <span class=\"h2\">",
"     Recipient protection issues",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Donors are asked questions concerning their sexual activities, their injection drug use history, their prior HIV testing history, and their history of selected sexually transmitted diseases. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Deferral of donors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Donors are queried concerning exposure to or medical history of hepatitis, malaria, Creutzfeldt-Jakob disease, babesiosis, and Chagas disease.",
"     </li>",
"     <li>",
"      Donors are asked questions about their travel history (relevant to potential exposure to malaria or vCJD) and whether they have received a blood transfusion in the past 12 months.",
"     </li>",
"     <li>",
"      Donors are asked about recent vaccinations. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Recent vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood is not collected from persons who are febrile at the time of donation, who state that they do not feel well, or who are taking systemic antibiotics. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Donor screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most blood centers, a donor with a history of a solid organ tumor will be deferred and will be eligible to donate only if",
"      <span class=\"nowrap\">",
"       he/she",
"      </span>",
"      has been symptom-free and considered to be clinically cured for a defined time period. Donors with a history of hematologic malignancy are permanently deferred. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'History of malignancy in donor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some drugs may pose a risk due to their demonstrated teratogenic potential at low plasma concentrations. Deferral periods are one month for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      , six months for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"       dutasteride",
"      </a>",
"      , three years for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"       acitretin",
"      </a>",
"      , and permanent for etretinate. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Medications taken by donor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Donors are permanently deferred if they have taken bovine insulin (risk of variant CJD transmission) or human growth hormone derived from pituitary glands (risk of iatrogenic CJD). Donors who have received Hepatitis B immunoglobulin (HBIG) or an unlicensed vaccine are deferred for one year. At the discretion of the medical director, most donors are also temporarily deferred if they are taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , or another anticoagulant.",
"     </li>",
"     <li>",
"      Collections of platelets for pheresis should not occur from donors who ingested",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , aspirin-containing drugs, or feldene in the previous 48 hours or from donors who ingested",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      in the previous 14 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21040425\">",
"    <span class=\"h2\">",
"     Donor protection issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"local\" href=\"#H24\">",
"     'Protection of the donor'",
"    </a>",
"    above)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, donors with coronary artery disease, cardiac valvular disease, arrhythmia, significant cerebrovascular disease, or heart failure are deferred, as are donors with any active pulmonary disease impairing gas exchange.",
"     </li>",
"     <li>",
"      Donors who have undergone recent surgery in the absence of blood transfusion are deferred until healing is complete and full activity has been resumed.",
"     </li>",
"     <li>",
"      Donors who are pregnant are deferred during pregnancy and for six weeks after delivery.",
"     </li>",
"     <li>",
"      Donors with seizure disorders are acceptable provided that they have had no seizures within the past 12 months with or without medications.",
"     </li>",
"     <li>",
"      The minimal age for donation is 16 to 18 depending on state laws. Most blood centers do not impose an upper age limit for donor eligibility.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/1\">",
"      AuBuchon JP, Birkmeyer JD, Busch MP. Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med 1997; 127:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/2\">",
"      Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000; 40:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/3\">",
"      Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/4\">",
"      Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/5\">",
"      Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/6\">",
"      Zou S, Stramer SL, Notari EP, et al. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009; 49:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/7\">",
"      Donegan E, Lee H, Operskalski EA, et al. Transfusion transmission of retroviruses: human T-lymphotropic virus types I and II compared with human immunodeficiency virus type 1. Transfusion 1994; 34:478.",
"     </a>",
"    </li>",
"    <li>",
"     Kleinman S. Donor screening procedures. In: Clinical Practice of Transfusion Medicine, 3rd ed, Petz L, Swisher S, Kleinman S, et al (Eds), Churchill-Livingstone, New York 1996. p.245.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/9\">",
"      Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA 2000; 284:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/10\">",
"      Zou S, Notari EP 4th, Stramer SL, et al. Patterns of age- and sex-specific prevalence of major blood-borne infections in United States blood donors, 1995 to 2002: American Red Cross blood donor study. Transfusion 2004; 44:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/11\">",
"      O'Brien SF, Fan W, Xi G, et al. Declining hepatitis C rates in first-time blood donors: insight from surveillance and case-control risk factor studies. Transfusion 2008; 48:902.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Guidance for Industry: Acceptable full-length donor history questionnaire and accompanying materials for use in screening human donors of blood and blood components. file://www.fda.gov/cber//blood/bldguid.htm (Accessed on October 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/13\">",
"      Katz LM, Cumming PD, Wallace EL, Abrams PS. Audiovisual touch-screen computer-assisted self-interviewing for donor health histories: results from two years experience with the system. Transfusion 2005; 45:171.",
"     </a>",
"    </li>",
"    <li>",
"     Center for Biologics Evaluation and Research, Food and Drug Administration. Guidance for Industry: Recommendations for deferral of donors and quarantine and retrieval of blood and blood products in recent recipients of smallpox vaccine (vaccinia virus) and certain contacts of smallpox vaccine recipients. December 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Transfusion-related transmission of yellow fever vaccine virus--California, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:34.",
"     </a>",
"    </li>",
"    <li>",
"     Director, Center for Biologics Evaluation and Research: Recommendations for the prevention of human immunodeficiency virus (HIV) transmission by blood and blood products. Memorandum to all registered blood establishments. April 23, 1992.",
"    </li>",
"    <li>",
"     Director, Center for Biologics Evaluation and Research, Food and Drug Administration: Recommendations for the deferral of current and recent inmates of correctional institutions as donors of whole blood, blood components, source leukocytes, and source plasma. Memorandum to all registered blood establishments. June 8, 1995.",
"    </li>",
"    <li>",
"     Director, Center for Biologics Evaluation and Research, Food and Drug Administration: Interim recommendations for deferral of donors at increased risk for HIV-1 group O infection. Memorandum to all registered blood and plasma establishments. December 11, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/19\">",
"      Sheppard HW, Dondero D, Arnon J, Winkelstein W Jr. An evaluation of the polymerase chain reaction in HIV-1 seronegative men. J Acquir Immune Defic Syndr 1991; 4:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/20\">",
"      Jackson JB. Human immunodeficiency virus (HIV)-indeterminate western blots and latent HIV infection. Transfusion 1992; 32:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/21\">",
"      Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med 1997; 102:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/22\">",
"      Ridzon R, Gallagher K, Ciesielski C, et al. Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. N Engl J Med 1997; 336:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/23\">",
"      Lindb&auml;ck S, Thorstensson R, Karlsson AC, et al. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. AIDS 2000; 14:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/24\">",
"      Germain M, Remis RS, Delage G. The risks and benefits of accepting men who have had sex with men as blood donors. Transfusion 2003; 43:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/25\">",
"      Soldan K, Sinka K. Evaluation of the de-selection of men who have had sex with men from blood donation in England. Vox Sang 2003; 84:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/26\">",
"      Anderson SA, Yang H, Gallagher LM, et al. Quantitative estimate of the risks and benefits of possible alternative blood donor deferral strategies for men who have had sex with men. Transfusion 2009; 49:1102.",
"     </a>",
"    </li>",
"    <li>",
"     Available on the United States FDA website at: file://www.fda.gov/cber/faq/msmdonor.htm (Accessed on May 24, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/28\">",
"      Seed CR, Kiely P, Law M, Keller AJ. No evidence of a significantly increased risk of transfusion-transmitted human immunodeficiency virus infection in Australia subsequent to implementing a 12-month deferral for men who have had sex with men. Transfusion 2010; 50:2722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/29\">",
"      Hurley R. UK lifts lifetime ban on gay men giving blood. BMJ 2011; 343:d5765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/30\">",
"      Williams AE, Thomson RA, Schreiber GB, et al. Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study. JAMA 1997; 277:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/31\">",
"      Glynn SA, Smith JW, Schreiber GB, et al. Repeat whole-blood and plateletpheresis donors:unreported deferrable risks, reactive screening tests, andresponse to incentive programs. Transfusion 2001; 41:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/32\">",
"      Maclennan S, Barbara JA, Hewitt P, et al. Screening blood donations for HCV. Lancet 1992; 339:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/33\">",
"      Doll LS, Petersen LR, White CR, Ward JW. Human immunodeficiency virus type 1-infected blood donors: behavioral characteristics and reasons for donation. The HIV Blood Donor Study Group. Transfusion 1991; 31:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/34\">",
"      Centers for Disease Control and Prevention (CDC). HIV transmission through transfusion --- Missouri and Colorado, 2008. MMWR Morb Mortal Wkly Rep 2010; 59:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/35\">",
"      Orton SL, Virvos VJ, Williams AE. Validation of selected donor-screening questions: structure, content, and comprehension. Transfusion 2000; 40:1407.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services, Food and Drug Administration. The code of federal regulations, US Government Printing Office, Washington, DC, 1997; (Revised annually).",
"    </li>",
"    <li>",
"     Director, Center for Biologics Evaluation and Research, Food and Drug Administration: Donor suitability related to laboratory testing for viral hepatitis and a history of viral hepatitis. Memorandum to all registered blood establishments. December 22, 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/38\">",
"      Sherertz RJ, Russell BA, Reuman PD. Transmission of hepatitis A by transfusion of blood products. Arch Intern Med 1984; 144:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/39\">",
"      Goldman M, Xi G, Yi QL, et al. Reassessment of deferrals for tattooing and piercing. Transfusion 2009; 49:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/40\">",
"      Perrillo RP, Gelb L, Campbell C, et al. Hepatitis B e antigen, DNA polymerase activity, and infection of household contacts with hepatitis B virus. Gastroenterology 1979; 76:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/41\">",
"      Alter MJ. The detection, transmission, and outcome of hepatitis C virus infection. Infect Agents Dis 1993; 2:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/42\">",
"      Guerrero IC, Weniger BG, Schultz MG. Transfusion malaria in the United States, 1972-1981. Ann Intern Med 1983; 99:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/43\">",
"      Nahlen BL, Lobel HO, Cannon SE, Campbell CC. Reassessment of blood donor selection criteria for United States travelers to malarious areas. Transfusion 1991; 31:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/44\">",
"      Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med 2001; 344:1973.",
"     </a>",
"    </li>",
"    <li>",
"     Director, Center for Biologics Evaluation and Research, Food and Drug Administration: Recommendations for deferral of donors for malaria risk. Memorandum to all registered blood establishments. July 26, 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/46\">",
"      Spencer B, Steele W, Custer B, et al. Risk for malaria in United States donors deferred for travel to malaria-endemic areas. Transfusion 2009; 49:2335.",
"     </a>",
"    </li>",
"    <li>",
"     Center for Biologics Evaluation and Research, Food and Drug Administration: Guidance for Industry. Recommendations for donor questioning regarding possible exposure to malaria. June 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/48\">",
"      Schmunis GA. Prevention of transfusional Trypanosoma cruzi infection in Latin America. Mem Inst Oswaldo Cruz 1999; 94 Suppl 1:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/49\">",
"      Leiby DA. Babesiosis and blood transfusion: flying under the radar. Vox Sang 2006; 90:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/50\">",
"      Herwaldt BL, Linden JV, Bosserman E, et al. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med 2011; 155:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/51\">",
"      Appleman MD, Shulman IA, Saxena S, Kirchhoff LV. Use of a questionnaire to identify potential blood donors at risk for infection with Trypanosoma cruzi. Transfusion 1993; 33:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/52\">",
"      Gerber MA, Shapiro ED, Krause PJ, et al. The risk of acquiring Lyme disease or babesiosis from a blood transfusion. J Infect Dis 1994; 170:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/53\">",
"      O'Brien SF, Chiavetta JA, Fan W, et al. Assessment of a travel question to identify donors with risk of Trypanosoma cruzi: operational validity and field testing. Transfusion 2008; 48:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/54\">",
"      Piron M, Verg&eacute;s M, Mu&ntilde;oz J, et al. Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion 2008; 48:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/55\">",
"      Kirchhoff LV, Paredes P, Lomel&iacute;-Guerrero A, et al. Transfusion-associated Chagas disease (American trypanosomiasis) in Mexico: implications for transfusion medicine in the United States. Transfusion 2006; 46:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/56\">",
"      Guzm&aacute;n Bracho C, Garc&iacute;a Garc&iacute;a L, Floriani Verdugo J, et al. [Risk of transmission of Trypanosoma cruzi by blood transfusion in Mexico]. Rev Panam Salud Publica 1998; 4:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/57\">",
"      Leiby DA, Herron RM Jr, Read EJ, et al. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 2002; 42:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/58\">",
"      Stramer SL, Foster GA, Herron RM, et al. US blood donor screening for Trypanasoma cruzi: Clinical studies and early assessment of prevalence (abstract). Transfusion 2007; 47:1A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/59\">",
"      Tobler LH, Contestable P, Pitina L, et al. Evaluation of a new enzyme-linked immunosorbent assay for detection of Chagas antibody in US blood donors. Transfusion 2007; 47:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/60\">",
"      Stramer SL, Foster G, Townsend R, et al. Trypanasoma Cruzi antibody screening in US blood donors: one year experience at the American Red Cross (abstract). Transfusion 2008; 48:(Suppl)2A.",
"     </a>",
"    </li>",
"    <li>",
"     Dodd RY, Lipton KS. Deferral for risk of leishmaniasis exposure. October 10, 2003. Letter available on the American Association of Blood Banks website at: www.aabb.org (Accessed on October 10, 2003).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/62\">",
"      Centers for Disease Control and Prevention (CDC). Cutaneous leishmaniasis in U.S. military personnel--Southwest/Central Asia, 2002-2003. MMWR Morb Mortal Wkly Rep 2003; 52:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/63\">",
"      Mestra L, Lopez L, Robledo SM, et al. Transfusion-transmitted visceral leishmaniasis caused by Leishmania (Leishmania) mexicana in an immunocompromised patient: a case report. Transfusion 2011; 51:1919.",
"     </a>",
"    </li>",
"    <li>",
"     AABB. Association Bulletin #03-14. Deferral for risk of Leishmaniasis exposure. October 10, 2003 www.aabb.org; members only section (Accessed on October 10, 2003).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/65\">",
"      Cardo LJ. Leishmania: risk to the blood supply. Transfusion 2006; 46:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/66\">",
"      Ricketts MN, Cashman NR, Stratton EE, ElSaadany S. Is Creutzfeldt-Jakob disease transmitted in blood? Emerg Infect Dis 1997; 3:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/67\">",
"      Brown P. Can Creutzfeldt-Jakob disease be transmitted by transfusion? Curr Opin Hematol 1995; 2:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/68\">",
"      Holman RC, Khan AS, Belay ED, Schonberger LB. Creutzfeldt-Jakob disease in the United States, 1979-1994: using national mortality data to assess the possible occurrence of variant cases. Emerg Infect Dis 1996; 2:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/69\">",
"      Evatt B, Austin H, Barnhart E, et al. Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia. Transfusion 1998; 38:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/70\">",
"      Dodd RY, Sullivan MT. Creutzfeldt-Jakob disease and transfusion safety: tilting at icebergs? Transfusion 1998; 38:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/71\">",
"      Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347:921.",
"     </a>",
"    </li>",
"    <li>",
"     UK government Department of Health Web site on CJD/BSE. www.doh.gov.uk/cjd (Accessed on March 08, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/73\">",
"      Hill AF, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. Nature 1997; 389:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/74\">",
"      Murphy MF. New variant Creutzfeldt-Jakob disease (nvCJD): the risk of transmission by blood transfusion and the potential benefit of leukocyte-reduction of blood components. Transfus Med Rev 1999; 13:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/75\">",
"      Hill AF, Butterworth RJ, Joiner S, et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999; 353:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/76\">",
"      Burthem J, Roberts DJ. The pathophysiology of variant Creutzfeldt-Jacob disease: the hypotheses behind concerns for blood components and products. Br J Haematol 2003; 122:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/77\">",
"      Houston F, Foster JD, Chong A, et al. Transmission of BSE by blood transfusion in sheep. Lancet 2000; 356:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/78\">",
"      Houston F, McCutcheon S, Goldmann W, et al. Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 2008; 112:4739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/79\">",
"      Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 2006; 91:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/80\">",
"      Lefr&egrave;re JJ, Hewitt P. From mad cows to sensible blood transfusion: the risk of prion transmission by labile blood components in the United Kingdom and in France. Transfusion 2009; 49:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/81\">",
"      Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/82\">",
"      Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/83\">",
"      Wilson K, Ricketts MN. The success of precaution? Managing the risk of transfusion transmission of variant Creutzfeldt-Jakob disease. Transfusion 2004; 44:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/84\">",
"      Murphy EL, David Connor J, McEvoy P, et al. Estimating blood donor loss due to the variant CJD travel deferral. Transfusion 2004; 44:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/85\">",
"      Millar CM, Makris M. Dealing with the uncertain risk of variant Creutzfeldt-Jakob disease transmission by coagulation replacement products. Br J Haematol 2012; 158:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/86\">",
"      Dietz K, Raddatz G, Wallis J, et al. Blood transfusion and spread of variant Creutzfeldt-Jakob disease. Emerg Infect Dis 2007; 13:89.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Guidance for Industry: Revised recommendations for the assessment of donor suitability and blood and blood product safety in cases of known or suspected West Nile virus infection. May 2003. file://www.fda.gov/cber/guidelines.htm (Accessed on May 01, 2003).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/88\">",
"      Orton SL, Stramer SL, Dodd RY. Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors. Transfusion 2006; 46:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/89\">",
"      Richards C, Kolins J, Trindade CD. Autologous transfusion-transmitted Yersinia enterocolitica. JAMA 1992; 268:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/90\">",
"      Vargas SO, Cannon ME, Benjamin RJ, Longtine JA. Transfusion with blood from a donor with chronic myelogenous leukemia: persistence of the bcr/abl translocation in the recipient. Transfusion 1999; 39:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/91\">",
"      Edgren G, Hjalgrim H, Reilly M, et al. Risk of cancer after blood transfusion from donors with subclinical cancer: a retrospective cohort study. Lancet 2007; 369:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/92\">",
"      Greenwald P, Woodard E, Nasca PC, et al. Morbidity and mortality among recipients of blood from preleukemic and prelymphomatous donors. Cancer 1976; 38:324.",
"     </a>",
"    </li>",
"    <li>",
"     Acting Director, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration: Deferral of blood and plasma donors based on medications. Memorandum to all registered blood establishments. July 28, 1993.",
"    </li>",
"    <li>",
"     Food and Drug Administration. Guidance for industry and FDA review staff: Collection of platelets by automated methods, December 17, 2007. Center for Biologics Evaluation and Research, Rockville MD. Available at: file://www.fda.gov/cber/guidelines.htm (Accessed on April 02, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/95\">",
"      Jilma-Stohlawetz P, Hergovich N, Homoncik M, et al. Impaired platelet function among platelet donors. Thromb Haemost 2001; 86:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/96\">",
"      van der Linden GJ, Siegenbeek van Heukelom LH, Meinardi H. Blood donation, a risk for epileptic patients? Vox Sang 1986; 51:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/14/11498/abstract/97\">",
"      Schmidt PJ. Blood donation by the healthy elderly. Transfusion 1991; 31:681.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7950 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_14_11498=[""].join("\n");
var outline_f11_14_11498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21040292\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk of viral infection from transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DONOR SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Recent vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HUMAN IMMUNODEFICIENCY VIRUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Screening issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Deferral of donors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Evaluating donor history questions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      VIRAL HEPATITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PARASITIC DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Chagas disease and babesiosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CREUTZFELDT-JAKOB DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Variant Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Blood donor deferral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      WEST NILE VIRUS INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      BACTERIAL INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OTHER RECIPIENT SAFETY ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      History of malignancy in donor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Medications taken by donor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Aspirin and aspirin-containing medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PROTECTION OF THE DONOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21040292\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21040417\">",
"      Recipient protection issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21040425\">",
"      Donor protection issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7950\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7950|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/59/31676\" title=\"table 1\">",
"      Infection risk of blood products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/29/24027\" title=\"table 2\">",
"      Blood donor virus infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=related_link\">",
"      Clinical manifestations and diagnosis of cutaneous leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=related_link\">",
"      Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23880?source=related_link\">",
"      Epidemiology and control of Chagas disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/20/42308?source=related_link\">",
"      Epidemiology and control of visceral leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/52/22338?source=related_link\">",
"      Patient information: Blood donation (giving blood) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26820?source=related_link\">",
"      Patient information: Blood donation and transfusion (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=related_link\">",
"      Preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=related_link\">",
"      Procedures used for blood donor screening: Protection of potential blood donors and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=related_link\">",
"      Transfusion transmitted HIV infection and AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=related_link\">",
"      Transfusion transmitted bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=related_link\">",
"      Variant Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_14_11499="Fibrosis markers";
var content_f11_14_11499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Markers of fibrogenesis and fibrinolysis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Matrix deposition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Procollagen I peptide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Procollagen III peptide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type IV collagen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        YKL-40 (Chondrex)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laminin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyaluronic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Matrix degradation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MMP-2, -9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TIMP-1, -2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cytokines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TGF-beta-1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TGF-alpha",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PDGF",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_14_11499=[""].join("\n");
var outline_f11_14_11499=null;
var title_f11_14_11500="Inher syndromes pancreas CA";
var content_f11_14_11500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Inherited cancer syndromes associated with increased risk of pancreatic cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene(s)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lifetime risk of pancreatic cancer, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Locus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary breast/ovarian cancer",
"       </td>",
"       <td>",
"        BRCA2, BRCA1",
"       </td>",
"       <td>",
"        3 to 5",
"       </td>",
"       <td>",
"        13q",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        PALB2",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        16p",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial atypical multiple mole melanoma syndrome",
"       </td>",
"       <td>",
"        CDKN2A",
"       </td>",
"       <td>",
"        10 to 19",
"       </td>",
"       <td>",
"        9p",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peutz-Jeghers syndrome",
"       </td>",
"       <td>",
"        STK 11",
"       </td>",
"       <td>",
"        11 to 36",
"       </td>",
"       <td>",
"        19p",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial adenomatous polyposis",
"       </td>",
"       <td>",
"        APC",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        5q",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary nonpolyposis colon cancer (Lynch II)",
"       </td>",
"       <td>",
"        DNA mismatch repair genes",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2p, 3p, 7p",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary pancreatitis",
"       </td>",
"       <td>",
"        PRSS1, SPINK1",
"       </td>",
"       <td>",
"        25 to 40",
"       </td>",
"       <td>",
"        7q, 5q",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ataxia telangiectasia",
"       </td>",
"       <td>",
"        ATM",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        11q",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Li-Fraumeni syndrome",
"       </td>",
"       <td>",
"        P53",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        17p",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Brentnall TA. Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options Oncol 2005; 6:437. Copyright &copy; 2005 Current Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_14_11500=[""].join("\n");
var outline_f11_14_11500=null;
var title_f11_14_11501="Fat soluble vits CF";
var content_f11_14_11501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fat-soluble vitamins in cystic fibrosis other than vitamin D: Daily intake and monitoring recommendations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vitamin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Intake recommendations for CF patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Monitoring recommendations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Vitamin A*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        1 to 12 months",
"       </td>",
"       <td>",
"        450 &micro;g (1500 IU)",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         Annual measurement of serum retinol",
"         <sup>",
"          [1,2]",
"         </sup>",
"        </p>",
"        In the presence of liver disease, serum retinyl binding protein and retinyl esters should be measured annually in addition to serum retinol",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 3 years",
"       </td>",
"       <td>",
"        1500 &micro;g (5000 IU)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 to 8 years",
"       </td>",
"       <td>",
"        1500 to 3000 &micro;g (5000 to 10,000 IU)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;8 years",
"       </td>",
"       <td>",
"        3000 &micro;g (10,000 IU)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adult",
"       </td>",
"       <td>",
"        3000 &micro;g (10,000 IU)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Vitamin E",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        1 to 12 months",
"       </td>",
"       <td>",
"        40 to 50 mg",
"       </td>",
"       <td rowspan=\"5\">",
"        Annual measurement of serum alpha tocopherol",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 3 years",
"       </td>",
"       <td>",
"        80 to 150 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 to 8 years",
"       </td>",
"       <td>",
"        100 to 200 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9 to 18 years",
"       </td>",
"       <td>",
"        200 to 400 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adult",
"       </td>",
"       <td>",
"        200 to 400 mg",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Vitamin K",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        1 to 12 months",
"       </td>",
"       <td>",
"        0.3 to 0.5 mg",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         Annual measurement of serum prothrombin time and PIVKA II",
"        </p>",
"        <p>",
"         Additional supplementation may be required during antibiotic therapy",
"        </p>",
"        If found to be deficient, repeat measurement one to two months following therapy to confirm normalization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 3 years",
"       </td>",
"       <td>",
"        0.3 to 0.5 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 to 8 years",
"       </td>",
"       <td>",
"        0.3 to 0.5 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9 to 18 years",
"       </td>",
"       <td>",
"        0.3 to 0.5 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adult",
"       </td>",
"       <td>",
"        2.5 to 5 mg/week",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CF: cystic fibrosis; CFF: Cystic Fibrosis Foundation; PIVKA: protein induced by vitamin K absence; IU: International Units.",
"     <br/>",
"     * Vitamin A doses given as retinol activity equivalents (RAE). 1 RAE = 3.33 IU (International Unit) = 1 &micro;g retinol = 12 &micro;g &beta;-carotene.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Vitamin E is measured as alpha-tocopherol; 1 mg alpha tocopherol = 1.47 IU \"natural source\" vitamin E (RRR-alpha tocopherol), or 2.2 IU synthetic vitamin E.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002; 35:246.",
"      </li>",
"      <li>",
"       Yankaskas JR, Marshall BC, Sufian B, et al. Cystic fibrosis adult care: consensus conference report. Chest 2004; 125 (1 Suppl):1S.",
"      </li>",
"     </ol>",
"     <br/>",
"     Modified with permission from: Maqbool A, Stallings VA. Update on fat-soluble vitamins in cystic fibrosis. Curr Opin Pulm Med 2008; 14:574. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_14_11501=[""].join("\n");
var outline_f11_14_11501=null;
var title_f11_14_11502="Age at onset of IBD in children";
var content_f11_14_11502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F88089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F88089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Age at onset of inflammatory bowel disease in children, by type",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 422px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The majority of children presenting prior to six years of age have isolated colonic disease (either ulcerative colitis or Crohn's colitis). Crohn's disease is the predominant form or inflammatory bowel disease in children presenting after eight years of age.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Castro M, Papadatou B, Baldassare M et al. Inflammatory bowel disease in children and adolescents in Italy: Data from the pediatric national IBD register (1996-2003). Inflamm Bowel Dis 2008; 14:1246.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_14_11502=[""].join("\n");
var outline_f11_14_11502=null;
var title_f11_14_11503="mifepristone monodemethyla";
var content_f11_14_11503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F76374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F76374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    The mean concentration of mifepristone and three of its metabolites after oral administration of 100 mg and 600 mg in five subjects",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 443px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The upper panels depict levels of mifepristone (left) and the monodemethylated (RU 42633) metabolite (right). Circulating levels of the didemethylated (RU 42848) and alcoholic nondemethylated (RU 42698) derivatives are shown in the left and right lower panels, respectively. The concentrations of mifepristone were similar after these doses, but the concentrations of metabolites were higher after the 600 mg dose of mifepristone. Concentrations of the monodemethylated metabolites are higher than those of the parent compound at all time points.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Robbins A, Spitz IM. Mifepristone: Clinical Pharmacology. Clin Obstetric Gynecology 1996; 39:436. Copyright &copy; 1996 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_14_11503=[""].join("\n");
var outline_f11_14_11503=null;
